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ABSTRACT OF DISSERTATION

THE CRITICAL ROLE OF MECHANISM-BASED MODELS FOR
UNDERSTANDING AND PREDICTING LIPOSOMAL DRUG LOADING, BINDING
AND RELEASE KINETICS
Liposomal delivery systems hold considerable promise for improvement of cancer
therapy provided that critical formulation design criteria can be met. The main objective
of the current project was to enable quality by design in the formulation of liposomal
delivery systems by developing comprehensive, mechanism-based mathematical models
of drug loading, binding and release kinetics that take into account not only the
therapeutic requirement but the physicochemical properties of the drug, the bilayer
membrane, and the intraliposomal microenvironment.
Membrane binding of the drug affects both drug loading and release from liposomes. The
influence of bilayer composition and phase structure on the partitioning behavior of a
model non-polar drug, dexamethasone, and its water soluble prodrug, dexamethasone
phosphate, was evaluated. Consequently, a quantitative dependence of the partition
coefficient on the free surface area of the bilayer, a property related to acyl chain
ordering, was noted.
The efficacy of liposomal formulations is critically dependent on the drug release rates
from liposomes. However, various formulation efforts to design optimal release rates are
futile without a validated characterization method. The pitfalls of the commonly used
dynamic dialysis method for determination of apparent release kinetics from
nanoparticles were highlighted along with the experimental and mathematical approaches
to overcome them. The value of using mechanism-based models to obtain the actual rate
constant for nanoparticle release was demonstrated.
A novel method to improve liposomal loading of poorly soluble ionizable drugs using
supersaturated drug solutions was developed using the model drug AR-67 (7-tbutyldimethylsilyl-10-hydroxycamptothecin), a poorly soluble camptothecin analogue.
Enhanced loading with a drug to lipid ratio of 0.17 was achieved and the rate and extent
of loading was explained by a mathematical model that took into account the chemical
equilibria inside and outside the vesicles and the transport kinetics of various permeable
species across the lipid bilayer and the dialysis membrane.
Tunable liposomal release kinetics would be highly desirable to meet the varying
therapeutic requirements. A large range of liposome release half-lives from 1 hr to 892 hr
were obtained by modulation of intraliposomal pH and lipid composition using
dexamethasone phosphate as a model ionizable drug. The mathematical models
developed were successful in accounting for the change in apparent permeability with
change in intraliposomal pH and bilayer free surface area. This work demonstrates the
critical role of mechanism-based models in design of liposomal formulations.

KEYWORDS: Liposomes, Membrane Binding, Loading, Release Kinetics, Models,
Dexamethasone
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CHAPTER ONE
Statement of Aims
A major gap in the progress of liposomal delivery systems is that the loading and
release kinetics are generally found empirically without the use of mechanistic models to
guide the liposome design. This conventional approach turns out to be an arduous and
time-consuming process that retards the pace of advancement of the delivery systems into
the clinic. Hence, the ultimate goal in this field should be to develop a global, uniform
mechanistic model that would enable design of nanoparticle delivery systems that have
predictable and reproducible in vitro characteristics that also lead to predictable and
reproducible in vivo performance. This work, in particular, focuses on models to
characterize the in vitro performance (loading, partitioning and release kinetics) in an
attempt to contribute towards the ultimate goal while stimulating further research with
more diverse compounds.
The central hypothesis is that mathematical models that take into account the
thermodynamics

(ionization,

membrane

binding,

complexation),

intraliposomal

microenvironment and permeability of the drug molecule across the bilayer are the keys
for prediction of loading and release kinetics in liposomal formulations. The major
driving force for the transport of a drug across a liposome is typically the activity
gradient of the free unionized species, which is governed by the physicochemical
properties of the drug. Another determining factor, among others, in the partitioning and
transport of drug across liposomes is the bilayer barrier properties which can be described
in terms of order parameter or free surface area. The model compounds explored in this
study represent typical problem drug candidates that are likely encountered repeatedly by
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those trying to develop delivery systems for antitumor agents. Two of the model
compounds,

7-t-butyldimethylsilyl-10-hydroxycamptothecin

(AR-67)

and

dexamethasone (Dex), represent drugs with low aqueous solubility and hydrophobic
nature while the other, dexamethasone phosphate (Dex-P), is an amphipathic, water
soluble molecule. Highly hydrophobic molecules are difficult to retain inside liposomes
leading to premature leakage, while hydrophilic molecules are retained for a very
prolonged period of time, failing to achieve therapeutic concentrations at the site of
action. In addition, high drug loading in liposomes is critical for the maximum usefulness
of its therapeutic potential. The aim with the liposomal delivery of any agent is to
encapsulate the drug to the maximum possible extent and retain the drug inside the
liposomes for long enough while in circulation but release the drug at an optimum rate
once at the site of action. In other words, there is a need for tailored release kinetics to
meet the various therapeutic requirements. The following specific aims have been
explored to understand the various processes (loading, partitioning and release) in
liposomes:
a)

Determine the membrane partitioning behavior of dexamethasone and its 21-

phosphate prodrug as a function of bilayer composition, temperature and pH and
explore the inter-relationship between solute structure, bilayer chain ordering and
membrane binding
The loading and release of a drug from liposomes is profoundly influenced by the nature
and extent of partitioning of the drug in the bilayer. Experimental conditions that
facilitate the accurate determination of the membrane/water partition coefficient of the
drug are important to obtain a true value which will additionally facilitate the
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mathematical modeling of the loading and release processes. The influence of bilayer
composition and phase structure on the partitioning behavior of dexamethasone and its
phosphate prodrug are studied in chapter three. A quantitative relationship between
membrane water partition coefficient of these drugs and the bilayer order parameter (free
surface area) is also developed.
b)

Overcoming the pitfalls of dynamic dialysis, a commonly used method for

determination of release kinetics from nanoparticles
Dynamic dialysis has been widely used, though often uncritically, for the determination
of release kinetics from nanoparticles. The lack of proper understanding of the underlying
principles and inaccurate data interpretation can lead to false conclusions regarding
sustained release behavior. The pitfalls of dynamic dialysis are demonstrated in chapter
four using model lipophilic drug-loaded liposomes varying in lipid composition to
provide variations in bilayer permeability and membrane binding affinities. A
mathematical model is proposed that can aid in deconvoluting the rate constant for drug
release from the apparent kinetics in cases where drug binding effects and/or dialysis
membrane transport may be partially contributing.
c)

Explore the use of supersaturated solutions to enhance active liposomal

loading using AR-67 as a model “problem” drug candidate
Active loading method is the method of choice for loading of ionizable drugs to achieve a
higher encapsulated drug to lipid ratio. The loading is dependent on the trans-bilayer
activity gradient of the drug, its permeability coefficient and the extraliposomal drug
concentration. The low aqueous solubility of AR-67 limits its extraliposomal
concentration for loading resulting in a very low drug to lipid ratio upon encapsulation. A
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novel method of supersaturating the drug for active loading by the pH-gradient method is
proposed in chapter five. A mathematical model taking into account the various intra- and
extra-liposomal ionic and binding equilibria and permeability coefficients was developed
to predict the rate and extent of active drug loading.
d)

Optimize the liposome release kinetics of dexamethasone phosphate based on

pH and lipid composition
Dexamethasone has been shown to act as a chemotherapy adjuvant to increase the uptake
of chemotherapeutic agents. However, its use is limited by the requirement of frequent
high doses owing to the high clearance of the drug and serious side-effects. There is a
need for controlled and tailored release kinetics for extracting the maximum therapeutic
benefits of the drug. Dexamethasone phosphate, the water soluble prodrug of
dexamethasone and an ionizable compound, was used for the formulation development.
Previous studies have shown that the differences in permeability of the free and ionized
forms can be several orders of magnitude. The pH-dependent permeability was explored
for Dex-P to obtain the range of release kinetics possible with a change in intraliposomal
pH and the corresponding change in the neutral, permeable fraction. The permeability as
a function of bilayer order parameter was evaluated by studying the release rate of Dex-P
in liposomes varying in lipid composition and a quantitative relationship was established
between bilayer permeability and free surface area in chapter six.
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CHAPTER TWO
Introduction

Nanotechnology in Cancer
Nanotechnology is an emerging field that can have an enormous positive impact on
human health, especially in cancer treatment (1). The application of nanoparticles in drug
delivery has the incredible potential of revolutionizing cancer therapy. Current cancer
therapy is faced with numerous challenges including non-specific distribution of
antitumor agents, inadequate drug concentrations at the tumor site, multiple drug
resistances and limited ability to monitor therapeutic responses (2-7). Nanoparticles have
come a long way in cancer chemotherapy, radically changing the diagnosis and treatment
of cancers. Tremendous amounts of research being conducted for the development of
nano-based therapies have advanced the field of cancer treatment significantly, with
several nano-based products now on the market (8). The unique physical and chemical
properties of these three dimensional nanostructures allows great flexibility in designing
drug delivery systems. They may be tailored to provide several desired properties such as
the ability to deliver poorly water soluble drugs, overcome biological barriers and carry
the drug selectively to the target site while protecting it from degradation. One of the
greatest

advantages

of

nanotechnology

over

conventional

therapies

is

their

multifunctionality; in diagnosis, imaging, monitoring and therapeutics (9-13).
Nanoparticles are sub-micron sized colloidal particles made of polymer, lipids or metals
with drug either encapsulated within the matrix or conjugated on the surface. The primary
reason for the ideal suitability of nanocarriers for the delivery of chemotherapeutics in
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cancer treatment is their ability to take advantage of the EPR (Enhanced Permeation and
Retention) effect, whereby the nanoparticles preferentially accumulate at the tumor site
owing to the leaky, fenestrated vasculature and are retained there due to the
underdeveloped lymphatic drainage system (14-17). Blood vessels in normal tissues have
tight endothelial junctions preventing the entry of foreign particles while angiogenic
blood vessels in tumor tissues, unlike those in normal tissues, have gaps as large as 600–
800 nm between adjacent endothelial cells. Poorly developed, fenestrated tumor blood
vessels coupled with poor lymphatic drainage induces the EPR effect, which enables
nanoparticles to extravasate through these gaps into extravascular spaces and remain in
tumor tissue (14-17). Nanoparticles have been explored for both passive targeting via the
EPR effect and active targeting. Active targeting involves incorporation of a targeting
ligand on the surface of nanoparticles that specifically binds to a receptor, which is either
unique or overly expressed on tumor cell surfaces (18, 19). Passive or active targeting of
therapeutics to tumor tissues is the main arena of nanoparticle use in cancer therapy, as it
reduces side effects, increases efficacy and reduces systemic drug exposure. Liposomes,
polymer nanospheres, nanorods, carbon nanotubes, solid lipid nanoparticles, fullerenes,
nanocrystals, dendrimers etc. are some of the nanoparticles being widely explored for
delivery of cancer chemotherapeutics.

A more quantitative understanding of the

properties of nanoparticles both in vitro and in vivo will be key to their clinical success.
Liposomal Drug Delivery
Over several decades, liposomes have evolved from simple model membrane systems to
sophisticated drug delivery systems for a large number of therapeutic agents (20-23).
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Figure 2.1 Schematic of a liposome
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Liposomal nanoparticles represent an advanced class of drug delivery systems, with
many formulations on the market and several in clinical trials. Liposomes are
nanoparticles comprising one or more concentric lipid bilayers enclosing an aqueous
interior (Figure 2.1). The typical size range for large unilamellar (consisting of one
bilayer) liposomes is ~50-200 nm. Liposomes are unique in their versatility as they can
incorporate both hydrophobic and hydrophilic agents either in the membrane phase or in
the enclosed aqueous compartment, respectively (24-26). Liposomes composed of natural
lipids are biodegradable, non-immunogenic and they have limited intrinsic toxicity. The
manifold applications of liposomes have been to enhance the drug solubility and stability,
avoid

rapid

degradation,

reduce

drug

toxicity,

and

improve

unfavorable

pharmacokinetics. They can function as controlled release systems as per the therapeutic
requirement. Stealth liposomes are pegylated liposomes, designed to evade recognition
by the immune system and thereby elongate the in vivo circulation half-life (27-29). The
attainment of longer circulation times in vivo (t1/2~24 hrs) by polymer coating has led to
the clinical success of several liposomal products (30-33).
Liposomes are particularly useful in cancer chemotherapy because of their ability to
increase the therapeutic efficacy and reduce the side effects of a given drug by the wellknown EPR effect. The potential benefit from a liposomal carrier depends on the nature
of the drug, the desired pharmacological intervention and the site of application. The
current pharmaceutical preparations of liposome based therapeutic agents mainly result
from our understanding of membrane-drug interactions and liposome disposition kinetics.
Despite the significant advances with liposomes as drug delivery systems, there is a big
gap in the amount of research efforts invested and the clinical successes of the liposomal
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formulations (33). This can be majorly attributed to the lack of quantitative mechanism
based approaches in formulation design (34, 35). Other factors are poor understanding of
the physical and chemical stability of the lipids, mechanisms affecting liposome
clearance in vivo, scale-up issues and cost prohibitiveness of the lipids for large scale
manufacturing of liposome formulations (36-38).
The ability to entrap as much drug as possible, retain the drug inside the liposomes as
long as they are in circulation, and subsequently release the drug content at an optimum
rate once at the tumor site will be preeminent to the clinical success of any liposomal
formulation. Understanding the physicochemical factors affecting the loading and release
of a liposomal drug and developing mechanism-based models for quantifying and
predicting these processes are the principal objectives of this thesis.
Loading Methodologies
One of the major challenges in the advancement of liposomes into clinical products has
been the achievement of a high level of loading of the therapeutic agent in the liposome.
The tiny intraliposomal volume (about 0.002 femtoliter for 150 nm liposome) demands a
very efficient loading method in order to achieve meaningful drug concentrations at the
site of action (39). Inadequate drug loading essentially defies the purpose of a targeted
delivery vehicle and renders it insufficient. The two most common methods of loading
are discussed below.
(i)

Passive Loading

In the passive loading method, drug incorporation takes place while the liposomes are
being formed. It is mainly driven by the water solubility and membrane water partition
coefficient or hydrophobicity of the drug (40-42). For a highly water soluble drug, the
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extent of drug loading will depend on the entrapped aqueous volume while for a highly
hydrophobic drug, about 50% drug will be associated with the intraliposomal leaflet and
the remaining 50% with the extraliposomal leaflet. In either case, only part of the drug
will be encapsulated by the passive loading method. Thus, although it is a simple method,
the drug to lipid ratio achieved by this method is not very high.
(ii)

Active Loading

Active loading is preferred for ionizable drugs, where the loading takes place in response
to a trans-membrane chemical potential gradient (43, 44). Several marketed products
have been launched based on this approach, the most notable being the doxorubicin
formulation, Doxil®. The active loading method adopted for Doxil® is based on an
ammonium sulfate gradient as demonstrated in Figure 2.2 (36, 45). In general, in this
method, a trans-bilayer pH gradient is first established by creating a concentration
gradient of the weak acid or base, which causes the diffusion of the weak acid or base
from inside to outside the liposomes. After development of the pH gradient, the weakly
acidic or basic drug is allowed to diffuse into the liposomes, once again, in response to
the concentration gradient of the drug. Upon encapsulation, the drug ionizes due to the
pH difference and is trapped in the membrane impermeable form, which drives further
loading (46-48). However, the loading is limited by the availability of the extraliposomal
drug, which is a function of its aqueous solubility. Thus, achieving a high drug to lipid
ratio by active loading remains a challenge for poorly water soluble drugs.
Intraliposomal drug precipitates in the form of insoluble salts can significantly prolong
the release half-life. The formulation may exhibit zero order kinetics until the drug
concentration reaches below the saturation solubility of the drug in the aqueous entrapped
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volume (49). However, with active loading methods based on pH-gradient, the
maintenance or the collapse of the pH gradient in vivo can affect the drug release rate.
Therefore, it would be desirable to evaluate the release kinetics of active loaded
liposomes in physiologically relevant media to predict the in vivo performance (50).
Liposome Release Kinetics
Determination of the release kinetics of the encapsulated drug from liposomes is a
critically important aspect of the formulation characterization. The rate of liposomal drug
release will determine the extent of premature drug leakage from the liposomes while
they are in the systemic circulation prior to reaching the target site. Once at the site of
action, the drug needs to be released at an optimal rate as per the therapeutic requirement
because rates that are either too slow or too fast can result in poor efficacy. Thus, the
drug release rate potentially determines the therapeutic efficacy of the formulation. A
bell-shaped curve can be expected between liposomal release rate and therapeutic effect
in tumors (51-53). Profiles describing antitumor efficacy versus release rates are
necessary in order to predict therapeutic outcome for a particular tumor type. Extensive
physicochemical and medical characterization is needed for translation of these
formulations into clinical products.
(i)

Factors Controlling Liposome Release Kinetics

The kinetics of drug release from liposomes depends on the permeability of the solute
and its concentration gradient across the bilayer. The permeability, in turn, is a function
of the membrane-water partition coefficient of the drug, the diffusion coefficient of the
permeable species and the nature of the bilayer (54). The major understanding of the
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Figure 2.2 Schematic depicting the active loading into liposomes based on ammonium
sulfate gradient method for weak bases.
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barrier properties of liposomes comes from studies aimed at exploring the factors
governing the bilayer permeability using liposomes as model membrane systems.
Partitioning and permeability of solutes in lipid bilayers is dependent on the physical and
chemical properties of the solute and the bilayer structure.
(a)

Bilayer Phase Structure

Liposomes are most often made up of phospholipids, the most common being
phosphatidylcholine (PC) molecules. Some of the phospholipids used in this study are
shown in Figure 2.3. Phosphatidylcholines, owing to the double fatty acid chains, differ
from other amphipathic molecules (e.g., detergents, lysolecithin) in having a preference
to form bilayers rather than micellar structures. The structure of the bilayer is influenced
by the phospholipid composition, acyl chain length of the phospholipid, its phase
transition temperature and presence of cholesterol among some of the major factors (5557). Although liquid crystalline bilayers are said to mimic the phase structure of most
physiological membranes, in drug delivery the goal is to optimize the release rate of the
entrapped drug and therefore gel and liquid–crystalline phases, both are explored. Solute
permeability has been observed to be strongly dependent on the phase structure of the
bilayer (58-63). For a long time, the passive transport of small molecules across
membranes was explained by a bulk-phase solubility diffusion model (56, 64). However,
with the increasing research interests and efforts in the field of bilayer permeability, the
role of lipid chain packing in the membranes on the permeability was realized. Owing to
the physical and chemical heterogeneity of lipid bilayers, its treatment as a bulk solvent
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1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC)

1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)
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1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)2000] (ammonium salt) (mPEG-DMPE)

1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)2000] (ammonium salt) (mPEG-DMPE)

1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)2000] (ammonium salt) (mPEG-DMPE)

Figure 2.3 Chemical structures of the phospholipids employed in this study.
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was not sufficient. Dramatic increases in bilayer permeability on transitioning from a gel
to liquid crystalline phase emphasized the more ordered nature of the gel phase due to
tighter lipid chain packing and reduced lateral motions in lipid bilayers. Xiang and
Anderson proposed the barrier-domain model whereby they introduced a permeability
decrement factor to account for the decrease in permeability from that predicted by
solubility diffusion theory owing to chain ordering in lipid bilayers (61, 65).
(b) Solute Size and Structure
Lipid bilayer permeability has been shown to be sensitive to the solute size, attributed to
the effect of lipid chain ordering which cannot be explained by the bulk solubility
diffusion theory. The sensitivity of the permeability coefficient of solutes to bilayer chain
packing was shown to exhibit linear dependence on the minimum cross-sectional area of
the permeants (using seven short-chain monocarboxylic acids) (61). It was suggested that
the permeants prefer to orient with their long principal axis along the bilayer normal and
correlate better with the permeant cross sectional area rather than molecular volume. The
size selectivity for transport across lipid bilayers may be credited to size dependent
effects on both partitioning and diffusion in lipid bilayers.
The preferred site for solute partitioning is dependent on the hydrophobicity of the solute.
Hydrophilic solutes or compounds having polar functional groups may reside
preferentially at the bilayer interface while hydrophobic nonpolar solutes may locate in
the interior of the bilayer upon partitioning. Similarly, amphipathic solutes may orient at
the interface to maximize the interaction of their polar groups with the aqueous region
and the non-polar parts with the hydrocarbon region of the bilayer. The chemical nature
of the solute (i.e., functional groups, number of –CH2 groups, hydrogen bonding
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potential) impacts its release kinetics across the bilayer (61). For example, in the more
ordered gel phase bilayer, the permeability coefficient decreased with increasing chain
length for short-chain monocarboxylic acids from formic acid to propionic acid, followed
by a reversal in the trend at higher chain lengths whereas in liquid crystalline bilayer, an
approximately monotonic increase in permeability coefficient with permeant chain length
was observed. The results suggested the interplay of both the lipophilicity of the
permeant and the chain ordering within the membrane and that the unfavorable steric
interactions associated with the addition of a methylene group may dominate over the
accompanying increase in lipophilicity (61).
The ionization potential of the solute also has an important role in its permeability across
the bilayer. For ionizable solutes, the apparent permeability changes with a change in pH
and the corresponding change in fraction unionized. This is largely based on
experimental evidence accumulated over several years indicating that neutral species are
often orders-of-magnitude more permeable than their ionized counter-parts (60, 61, 6467). The pH dependent permeability of ionizable compounds has been used successfully
in the active loading of several weak bases and few acids in the liposomes to achieve high
drug to lipid ratios. In this work, the use of intravesicular pH to modulate the release
kinetics of an ionizable drug, dexamethasone phosphate (Dex-P) was demonstrated.
(ii)

Methods Used to Assess Liposome Release Kinetics

There are several methods used for the determination of drug release rates from
nanoparticles. Each method has its own advantages and disadvantages. One of the
methods is to dilute the nanoparticles with buffer and then separate the carrier from drug
at different time points. For separation by ultrafiltration, the issue is that some
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nanoparticles (e.g. liposomes) being non-solid flexible structures may pass through the
filter membranes. Separations using ultracentrifugation may alter release rates due to the
high centrifugal force (68). The reverse dialysis method, (69) where the nanoparticle
formulation is diluted in the large volume to maintain sink conditions and free drug is
sampled from the dialysis tubes immersed in the sink solution, requires a highly sensitive
analytical method for quantitative determination of the drug. In dynamic dialysis, one of
the most commonly used methods, the nanocarrier dispersion is suspended inside a
dialysis tube/cassette of semipermeable membrane having a particular molecular weight
cut off and dialyzed in a large volume of sink medium (70). During the kinetic study, the
free drug is separated from the carrier by the dialysis membrane and does not require a
separate separation step at each time point. Unfortunately, there exists an inadequate
understanding of the dynamic dialysis method leading in some cases to a false notion of
sustained release behavior from nanoparticles. Owing to the popularity of nanoparticle
drug delivery systems, there is a critical need to understand the processes underlying the
dynamic dialysis method and use the method appropriately to obtain reliable estimates of
nanoparticle release rates.
Camptothecins
Camptothecin and its related analogues constitute an important class of drugs that gained
considerable interest for their anti-tumor activity and unique mechanism of action (71,
72). Camptothecins form non-covalent complexes with the topoisomerase I-DNA cleaved
complex and thereby interfere with the DNA unwinding step of DNA replication.
Prolonged exposure of replicating cells to camptothecins results in double strand breaks
and consequently cell death (73, 74). One of the characteristics of this class is the pH
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dependent chemical hydrolysis of the α-hydroxy δ-lactone ring (E-ring) moiety to form a
ring-opened camptothecin carboxylate. The lactone moiety is thought to be the
therapeutically active form and therefore, ring opening to form the carboxylate leads to
diminished in vivo activity (73).
Two compounds of this class, topotecan (Hycamptin®) and irinotecan (Camptosar®)
have received FDA approval. In addition, several analogues are in clinical trial. One such
analogue is AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin), which was
synthesized in an attempt to improve its lactone stability in blood by promoting the
binding of the lactone form to red blood cell membranes (75-78). The substitution of
nonpolar groups imparted hydrophobicity to the compound resulting in a very low water
solubility. Liposomal delivery of AR-67 was pursued to increase the solubility and
stability of the compound along with the targeting potential of the nanosized liposomes to
enhance the overall efficacy of the drug and reduce its systemic toxicity (79, 80).
Besides, a prolonged schedule of camptothecin administration given continuously at low
doses or frequently fractionated appeared to be more effective clinically (81-83).
However, owing to the high lipophilicity, AR-67 has a high permeation rate across the
liposome bilayer and therefore rapidly leaks from vesicles. In addition, the low aqueous
solubility poses a challenge in achieving high encapsulation of the drug by the active
loading method. Consequently, a novel strategy to enhance the encapsulated drug to lipid
ratio of this and other poorly water soluble compounds by the active loading method was
proposed and evaluated in this thesis.
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Glucocorticoids
Glucocorticoids are a class of steroidal agents that bind to glucocorticoid receptors and
are mainly known for their anti-inflammatory and immunosuppressive responses (84, 85).
Dexamethasone is a prominent member of the synthetic group of this class and one of the
most widely used. In addition to its anti-inflammatory action, it has been used as an
adjuvant in chemotherapy. In some of the recent pre-clinical and clinical trials, pretreatment with dexamethasone was shown to reduce the toxicity associated with
chemotherapeutic agents and even increase the efficacy (86-89). This is potentially
attributed to the down-regulation of pro-inflammatory cytokines (e.g., vascular
endothelial growth factor (VEGF), interleukin 1β (IL-1β)) by dexamethasone and as a
consequence, a reduction in the interstitial fluid pressure within tumors. Reduced
intratumoral pressure facilitates the uptake and diffusion of chemotherapeutic agents (9092). Despite the beneficial effects of dexamethasone, its use is limited by substantial side
effects. In addition, due to its rapid clearance from the body, frequent high doses are
required to achieve efficacy which in turn causes serious side effects (84). To better
exploit the therapeutic potential of dexamethasone, targeted delivery systems with
tailored release kinetics are desirable (86, 87, 93).
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CHAPTER THREE
Bilayer Composition, Temperature and Speciation Effects on Partitioning of
Dexamethasone and its 21-phosphate: The Role of Bilayer Chain Ordering
INTRODUCTION
The partitioning of drugs into lipid bilayers and biological membranes is a significant
factor governing their tissue distribution and bioaccumulation (94-97). These properties,
in turn, directly influence efficacy or toxicity when the mode of drug action involves
interaction with membrane components (98, 99) and may also affect efficacy and toxicity
indirectly through their role in modulating drug delivery, pharmacokinetics, metabolism
and clearance (100, 101). As drug candidates have become more lipophilic and less water
soluble there is a greater need for rapid and reliable screening methods and/or
computational approaches to allow pharmaceutical scientists to select lead candidates
based on their developability, as indicated by properties such as their potential to exhibit
good oral bioavailability (102, 103). Guided by the perception originating in Overton’s
rule and the solubility-diffusion model that the equilibrium membrane-water partition
coefficient should correlate with permeability across biomembranes (102, 104, 105)
numerous researchers have attempted to devise experimental systems and computational
models that link drug permeation to membrane affinity. As yet, however, there are no
models that can quantitatively predict either biomembrane partitioning or transport solely
from a knowledge of the structure of the drug and composition of the membrane.
For decades, it has been a common practice to predict membrane-water partitioning of
drugs and also in vivo absorption based on various bulk solvent-water partition
coefficients (103, 106, 107). Although different bulk solvents have been used to
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determine the partition coefficient, octanol has been the most referenced system (106).
However, with time, deficiencies of bulk solvents as models for membranes have become
more widely appreciated. Conceptually, these deficiencies mainly reflect the fact that
bulk solvents are homogeneous and isotropic while lipid bilayer membranes are
anisotropic interfacial phases with properties that vary as a function of internal distance
from the bilayer-water interface (57, 108-110). One striking experimental discrepancy
noted in several recent publications is that linear free energy relationships based on bulk
solvent/water partitioning fail to predict lipid bilayer/water partitioning. This has been
particularly apparent in the lack of correlation between octanol/water partition
coefficients and membrane water partition coefficients for drugs containing ionizable
substituents (102, 111-113). Ionized solutes may have higher affinity for lipid bilayer
membranes than octanol due to the anisotropy of lipid bilayers, their high surface area-tovolume ratios, and electrostatic interactions of ionized solutes with charged moieties in
the bilayer headgroups (111, 112, 114-116). Within the anisotropic microenvironment of
the bilayer interface, solutes preferentially adopt conformations and orientations that
maximize hydrophobic and van der Waals interactions between non-polar regions of the
solute and acyl chains within the bilayer interior while retaining electrostatic interactions
with the polar head groups and water molecules (117-120). The complexity of factors
leading to that preferred solute conformation, orientation, and position within the bilayer
that constitutes a minimum in free energy appears to have no close correlate in bulk
solvent/water partitioning.
Another discrepancy between lipid bilayer/water versus bulk solvent/water partitioning is
the well-known dependence of lipid bilayer/water partition coefficients on bilayer phase
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behavior and chain ordering. For example, decreasing the temperature below the phase
transition temperature, inclusion of cholesterol in the bilayer, or elongating the
phospholipid chain length, cause significant decreases in partition coefficient values (55,
121, 122) that are not easily rationalized using only bulk solvent models for the
partitioning process.
In addition to their importance in drug delivery, liposomes are widely used as model
membrane systems for studying the partitioning behavior of drugs (57, 98, 123-125).
Determination of the liposome/water partition coefficient is essential for characterizing
drug loading and the driving force governing release kinetics from liposomal delivery
systems (126-128). More generally, such information can contribute to an understanding
of several biological phenomena including passive transport and biodistribution (103,
129).
A unified quantitative mathematical model that could predict the membrane-water
partition coefficient as a function of drug structure, membrane composition, and the local
aqueous microenvironment would be valuable both from a practical standpoint in
assessing drug developability and for understanding drug biodistribution, clearance,
efficacy, and toxicity. Such a model would need to take into account the concentrations
of the various neutral and ionized drug species that may exist as a function of the pH of
the aqueous microenvironment; the hydrophobic regions of the solute, the nature and
location of various polar functional groups in the solute molecule and its conformational
flexibility; and the surface charge, chain ordering and phase behavior, and other
properties of the bilayer that in turn depend on lipid composition and the temperature, pH
and ionic strength of the solution.
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In the present study, the influence of bilayer composition and phase structure on the
partitioning behavior of the anti-inflammatory steroid dexamethasone (Dex) was
explored. These studies demonstrate a quantitative dependence of the partition coefficient
of dexamethasone on the free surface area of the bilayer, a property related to acyl chain
ordering that is modulated by changes in bilayer composition and temperature.
Comparison of the present results to previous literature studies of drug partitioning into
lipid bilayers suggests that this concept may have general applicability, as it has been
previously shown for drug permeability across lipid bilayer membranes (122, 130, 131).
Phosphorylation of dexamethasone to produce the water soluble prodrug dexamethasone
21-phosphate (Dex-P) complicates its membrane binding behavior. The dependence of
the apparent partition coefficient of Dex-P, as a function of pH after correction for drug
concentration effects, was determined in order to generate species-specific partition
coefficients. Comparison of these species-specific partition coefficients for Dex-P to that
for Dex in bilayers varying in lipid composition suggests that the influence of chain
ordering as quantified by free surface area on partitioning behavior affects both nonpolar
and polar solutes similarly.
MATERIALS AND METHODS
Phospholipids including DSPC (1,2-distearoyl-sn-glycero-3-phosphatidylcholine, >99%
purity), DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine, >99% purity), DMPC (1,2dimyristoyl-sn-glycero-3-phosphocholine, >99% purity), m-PEG DSPE (1,2-distearoylsn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000]), m-PEG
DPPE

(1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene

glycol)-2000]) and m-PEG DMPE (1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-
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N-[methoxy(polyethylene glycol)-2000]) were purchased as powders from Avanti Polar
Lipids (Alabaster, AL). Dexamethasone (Dex) (≥98%, powder) was purchased from
Sigma-Aldrich Co., St. Louis, MO. Dexamethasone sodium phosphate (Dex-P), USP,
was from Spectrum Chemical Mfg. Corp., New Brunswick, NJ. Dialysis flat sheets
(Spectra/Por® RC Membrane, MWCO: 3.5 kD) were purchased from Spectrum
Laboratories (Rancho Dominguez, CA). HPLC grade solvents and other chemicals were
purchased from Fisher Scientific (Florence, KY). Deionized water was used for all
experiments.
Liposome Preparation
Blank liposomes were prepared based on a previously reported method (127). Briefly,
DMPC: mPEG DMPE, DPPC: mPEG DPPE and DSPC: mPEG-DSPE (95:5 mol%, 120
mg) were separately dissolved in 2 mL of chloroform. The solvent was evaporated under
a stream of nitrogen while rotating the container and the resulting film was dried
overnight in a vacuum oven. For determination of partition coefficient of Dex in different
lipid systems, the lipid film was hydrated with 2 mL of phosphate buffered saline (PBS)
(pH 7.4) and for Dex-P; 20 mM acetate buffer (pH 4) was used. For pH-dependent
partition coefficient of Dex-P in DMPC liposomes, several buffers at different pH were
used (20 mM KCl-HCl buffer, pH 1.5; 20 mM glycine buffer, pH 2; 20 mM acetate
buffer, pH 4 and 5; 20 mM MES buffer, pH 6; 20 mM phosphate buffer, pH 8). To
uniformly suspend the lipid, the suspension was alternately vortexed and heated in a
water bath at a temperature above the phase transition temperature of the respective
lipids. The lipid suspension was then extruded 10 times through two stacked 100 nm
polycarbonate membranes (GE Water and Process Technologies, Trevose, PA) using an
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extrusion device (Liposofast®, Avestin, Canada) at 30, 50 and 60 °C for DMPC, DPPC
and DSPC, respectively, to obtain unilamellar liposomes. Liposomes were allowed to
cool to room temperature for 3 hr and stored at 4 °C until further use. Particle sizes of
blank liposomes were measured at 25 °C by dynamic light scattering (DLS) using a
Delsa™ Nano submicron particle size analyzer (Beckman Coulter Inc., Brea, CA). The
liposomes were diluted in the same buffer as that used in their preparation.
Lipid Analysis
Lipid concentrations in the liposomal suspensions were determined by high performance
liquid chromatography (HPLC) using an evaporative light scattering detector (ELSD) as
reported previously for DSPC liposomes (132). Briefly, separation was achieved using an
Allsphere™ Silica Column (Grace Davison Discovery Sciences, Deerfield, IL) (5 µ, 4.6 x
150 mm) with a guard column (Allsphere silica, 5 µ, 7.5 x 4.6 mm). A linear gradient
method was employed starting with 100% (v/v) mobile phase A (80% chloroform:19.5%
methanol:0.5% (v/v) ammonium hydroxide solution (30%) and changing to 80% mobile
phase A:20% mobile phase B (80% methanol:19.5% water:0.5% (v/v) ammonium
hydroxide solution (30%)) over 3 min. This composition was maintained from 3- 7 min
followed by a return to 100% mobile phase A by 14 min. The total run time was 15 min
at a flow rate of 1 mL/min with the ELSD setting at a gain of 8, pressure of 3.4 bar, and
temperature of 40 °C. The sample compartment temperature was set at 4 °C and the
column was at ambient temperature. Standards of DSPC, DPPC and DMPC were
prepared in mobile phase A and linearity was observed between log concentration and
log peak area.
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Aliquots of liposomal suspension (10 µL) were dried under nitrogen and reconstituted in
mobile phase A for lipid analysis before the start of each experiment. Since 95% of the
phospholipid content in the liposomes was non-pegylated and the chain lengths for the
pegylated and non-pegylated components were same, the liposomes were assumed to
contain 100% DMPC, DPPC or DSPC, respectively, for the determination of lipid
content. Lipid stability was assessed under two representative conditions (Dex-P, pH 1.5
and 6, DMPC liposomes). Stability samples were withdrawn at different time points
during dialysis for lipid analysis.
Determination of Membrane-Water Partition Coefficients
Equilibrium Dialysis Method
Membrane-water partition coefficients of Dex and Dex-P (Figure 3.1) were determined at
25 °C and varying lipid concentrations in three different liposomal systems (DMPC,
DPPC and DSPC) by equilibrium dialysis using one mL Teflon® cells (Equilibrium
Dialyzer (Spectrum Labs)). A liposome stock suspension of 60 mg/ml was diluted to
varying concentrations and mixed with a drug solution having a fixed concentration. One
ml of this mixture was introduced into one compartment (donor) of the equilibrium
dialyzer and one ml of the corresponding blank buffer was added to the other
compartment (receiver). The dialyzer, which consists of five pairs of one mL cells, was
then placed in an incubator at 25 °C and allowed to equilibrate. Aliquots (100-150 µL)
were withdrawn at 24, 48 and 72 hours from each compartment, diluted in 900 µL
methanol and analyzed by HPLC. Equilibrium was considered to have been established
when two subsequent time points yielded constant values. Partition coefficients of Dex
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were also determined in DPPC liposomes at 37 °C and 45 °C following the same
procedure.
Equilibrium Solubility Method
Partition coefficients of Dex in DMPC, DPPC and DSPC liposomes were also
determined by the equilibrium solubility method. Excess solid (Dex) was equilibrated
with blank liposomes at different lipid concentrations at 25 °C. After equilibration,
samples were filtered through 0.45 µ PVDF filters and the filtrates were analyzed for
drug concentration by HPLC after a 10-fold dilution in methanol. Errors due to filter
adsorption were eliminated by analyzing successive aliquots of the filtrate to attain
constant values. Aliquots of filtrate (10 µL) were dried under nitrogen and reconstituted
in mobile phase for lipid analysis.
Simultaneous Determination of Dex and Dex-P by HPLC
A new isocratic HPLC method was developed and validated for the simultaneous
determination of Dex and Dex-P with UV detection at 240 nm. Four independent
standards for Dex-P (100-800 µM) in water and Dex (100-800 µM) in methanol were
prepared. A Waters Alliance 2695 Separations Module coupled to a UV detector (Waters
996, Photodiode Array Detector) at 240 nm was employed. A Waters Symmetry® C18
column (5 µm, 3.9 x 150 mm) and guard column (3.9 x 20 mm) were used at an injection
volume of 10 µL with a mobile phase composition of 32% acetonitrile and 68% (v/v) pH
5.5 triethylamine acetate (2%) buffer. The retention times for Dex-P and Dex at a flow
rate of 1 mL/min were 2.5 and 6.4 min, respectively. The stability of Dex-P during
equilibrium dialysis was monitored using this method as it allowed the simultaneous
determination of Dex and Dex-P. The HPLC response was linear within the range of

28

Figure 3.1 Structures of Dex and Dex-P with different ionization states of the 21phosphate.
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100-800 µM for both Dex and Dex-P. The response factor for both analytes yielded a
coefficient of variation less than 3% intraday and interday.
THEORY
Membrane-Water Partition Coefficient
At equilibrium, the total mass of drug in the donor (liposomal) compartment is the sum of
the masses in the bilayer membrane and the aqueous phase:
𝐶𝑑 𝑉𝑑 = 𝐶𝑤 𝑉𝑤 + 𝐶𝑚 𝑉𝑚

𝐸𝑞 3.1

where 𝐶𝑑 is the total drug concentration in the donor compartment, 𝐶𝑚 and 𝐶𝑤 are the

drug concentrations in the lipid and aqueous phases, respectively, and 𝑉𝑑 , 𝑉𝑚 , 𝑉𝑤 are the

respective volumes. The aqueous concentration in the donor compartment (𝐶𝑤 ) should
equal the aqueous concentration in the receiver compartment (𝐶𝑟 ) at equilibrium.
The volume based partition coefficient can then be defined by
𝐾𝑝 =

𝐶𝑚 𝐶𝑑 𝑉𝑑 − 𝐶𝑤 𝑉𝑤 𝐶𝑑 𝑉𝑑 − 𝐶𝑟 𝑉𝑤
=
=
𝐶𝑤
𝐶𝑤 𝑉𝑚
𝐶𝑟 𝑉𝑚

𝐸𝑞 3.2

Saturable Binding Correction for Neutral Dex-P

The concentrations of membrane bound Dex divided by the lipid concentration were
proportional to the free drug concentration in solutions approaching infinite dilution.
However, deviations from linearity were observed for Dex-P partitioning at pH 1.5 and 2,
necessitating a correction for membrane saturation. At pH 1.5 and 2, membrane bound
Dex-P exists predominantly as the neutral species (the reported first pKa of Dex-P in
aqueous solution is 1.9 (133)). Therefore, the following equation was employed to fit the,
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the ratios of bound drug to lipid concentration (𝐵) as a function of the free drug
concentration (𝐶𝑢 ):

𝐾𝑝𝑎𝑝𝑝 𝐶𝑢
𝐵=
1 + 𝐶𝑜𝑛𝑠𝑡. 𝐶𝑢

𝐸𝑞 3.3

where 𝐾𝑝𝑎𝑝𝑝 is the partition coefficient at infinite dilution at the solution pH specified.
Gouy-Chapman Correction for the Partition Coefficient of Bound Monoanion

For membrane binding of ionized molecules, the partition coefficient decreases with the
adsorbed concentration and needs to be adjusted to infinite dilution using Gouy-Chapman
theory (134-139). At pH 4 - 6 in this study, the membrane bound drug was assumed to be
predominantly monoanionic. Monoanion binding contributes to the development of a
charge on the membrane surface, which in turn changes the surface potential as given by
Gouy-Chapman equation:
−𝑍𝑖 𝐹Φ0
𝜎 2 = 2000𝜖0 𝜖𝑟 𝑅𝑇 � 𝐶𝑖 �exp �
� − 1�
𝑅𝑇

𝐸𝑞 3.4

where 𝜎 is the surface charge density, 𝜖0 is the permittivity of vacuum, 𝜖𝑟 is the relative
permittivity of water, R is the gas constant, 𝐶𝑖 is the molar concentration of the ith

electrolyte in the bulk solution, 𝑍𝑖 is the signed charge number of that electrolyte, 𝐹 is the
Faraday constant and Φ0 is the surface potential in volts.

Based on the number of moles bound per mole of lipid and the surface area of the
phospholipids, 𝜎 was calculated and then using eq. 3.4 the surface potential, Φ0 , was

calculated. The apparent partition coefficient at infinite dilution 𝐾𝑝𝑎𝑝𝑝 𝑤𝑎s calculated
from observed 𝐾𝑝𝑜𝑏𝑠 by the following equation,
𝐾𝑝𝑎𝑝𝑝 = 𝐾𝑝𝑜𝑏𝑠 exp �

−𝑍𝐷 𝐹Φ0
�
𝑅𝑇
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𝐸𝑞 3.5

where 𝑍𝐷 is the signed charge number of the drug.

pH Dependence of the Partition Coefficient (for Dex-P)
The apparent partition coefficient of Dex-P obtained at each pH value can be related to
the concentrations of species 𝐷 (unionized), 𝐷 − (monoanion) and 𝐷2− (dianion) (Figure

3.1) in the membrane and aqueous phases as follows,
𝐾𝑝𝑎𝑝𝑝 =

𝐾𝑝𝑎𝑝𝑝

−
2−
𝐷𝑚 + 𝐷𝑚
+ 𝐷𝑚
𝐷𝑤 + 𝐷𝑤− + 𝐷𝑤2−

𝐸𝑞 3.6

𝐾𝑝1 + 𝐾𝑝2 𝐾𝑎1 ⁄𝐻 + + 𝐾𝑝3 𝐾𝑎1 𝐾𝑎2 ⁄(𝐻 + )2
=
1 + 𝐾𝑎1 ⁄𝐻 + + 𝐾𝑎1 𝐾𝑎2 ⁄(𝐻 + )2

𝐸𝑞 3.7

where the subscripts m and w refer to the membrane and aqueous phases, respectively,
𝐾𝑎1 and 𝐾𝑎2 are the two ionization constants of Dex-P; and 𝐾𝑝1 , 𝐾𝑝2 and 𝐾𝑝3 are the

intrinsic partition coefficients of the three species 𝐷 , 𝐷− and 𝐷2− , respectively. Over the
pH range of interest in this study (pH 1.5-8) the properties of the DMPC bilayer itself

were assumed to be independent of pH because the intrinsic pKa of the
phosphatidylcholine head group of 0.8 (140) is still well below pH 1.5.
Bilayer Surface Density/ Free Surface Area
The normalized surface density is a parameter related to relative acyl chain ordering in
the bilayer. It is defined as 𝜎 = 𝐴0 /𝐴, where 𝐴 is the area occupied per phospholipid
molecule and 𝐴0 is its area in the crystal (40.8 Å2) (55, 121, 131). The normalized surface

density varies from 0-1 with the value of 1 representing a completely ordered crystalline
state. In the present study, the surface density values for the various liposome
compositions were taken from a single compilation in the literature (131) and
quantitatively related to the generated partitioning data.
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Xiang and Anderson (131) related the surface density to the free surface area 𝑎𝑓𝑟𝑒𝑒 of the
bilayer by the following equation:

𝑎𝑓𝑟𝑒𝑒 = 𝐴 − 𝐴0 = 𝐴0 (1⁄𝜎 − 1)

𝐸𝑞 3.8

They showed that the free surface area (𝐴0 /𝑎𝑓𝑟𝑒𝑒 = 𝜎/(1 − 𝜎)) served as a unified

fundamental molecular packing parameter in lipid bilayers for describing the
permeability of solutes across both liquid crystalline and gel phases of the bilayer. An
observed dependence of the lipid bilayer permeability coefficient on the inverse of free
surface area was attributed, at least in part, to the sensitivity of solute partitioning into the
interior hydrocarbon barrier domain of the bilayer to chain ordering as expressed by the
following equation (131):
𝐾𝑝 = 𝐾0 exp(− 𝑎∗ ⁄𝑎𝑓𝑟𝑒𝑒 )

𝐸𝑞 3.9

𝐾𝑝 in Eq. 3.9 refers to the barrier domain/water partition coefficient, not the overall

bilayer/water partition coefficient that is of interest in this study, and K0 is the partition
coefficient for the same solute in a bulk solvent (e.g., a hydrocarbon) that was found to
most closely mimick the chemical selectivity of the bilayer barrier domain and water.
Xiang and Anderson (130) later examined the lipid bilayer permeability coefficients of a
series of mono-carboxylic acids varying in the size of their alkyl portion to probe the
dependence of bilayer transport on molecular size. When relative bilayer permeability
coefficient measurements were ascribed to relative changes in apparent partitioning of the
permeant into the barrier domain with increasing solute size, the quantity 𝑎∗ in Eq. 3.9

was demonstrated to be proportional to the minimum cross-sectional area of the solute.
Thus, sensitivity of lipid bilayer permeability coefficients to free surface area of the
bilayer is a function of the permeant size.
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A few previous studies of small molecule partitioning into lipid bilayers have revealed
correlations between partition coefficients and the normalized surface density (55, 121,
122). However, the solutes employed in previous studies (i.e., hexane, benzene, and
acetic acid) are hardly representative of typical drug molecules either in terms of their
size or complexity. Herein, whether or not a dependence of the partition coefficient on
bilayer free surface area is a more general phenomenon applicable to a broader array of
drug molecules was examined.
RESULTS
Liposome Characterization
Blank liposomes of DMPC, DPPC and DSPC, prepared for partitioning studies, had the
particle size in the range of 85-100 nm, with a polydispersity index in the range of 0.050.09, indicating monodisperse formulations. The extrusion procedure employed in this
study was previously shown by 31P-NMR to produce unilamellar vesicles (141).
A simple analytical method using gradient HPLC and ELSD for evaluation of lipid
concentration was developed for three different lipids DMPC, DPPC and DSPC. Figure
3.2 shows the chromatograms of the three lipids with retention times for DSPC, DPPC
and DMPC being 7.9, 8.0 and 8.2 min, respectively. Lipid concentrations were
determined from log-log plots of peak area versus concentration which were linear over
the concentration ranges of 150-800 µM for DMPC, 100-400 µM for DPPC, and 150-400
µM for DSPC.
Lipid concentrations in the liposomal samples were analyzed prior to equilibrium dialysis
and used for calculation of volume based partition coefficients. The analyzed lipid
concentrations were typically 25-35% lower than the theoretical concentrations indicating
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Figure 3.2 Representative chromatograms of DPPC, DMPC and DSPC obtained by
HPLC with ELSD (Evaporative Light Scattering Detection) detection.
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some lipid loss during the extrusion process. This highlights the necessity for analyzing
the lipid concentration in order to obtain reliable partition coefficient values rather than
just assuming no lipid loss. In order to assess lipid stability during the time required for
equilibration (48 hr), lipid concentrations were analyzed versus time for up to 72 hr in
representative experiments in DMPC liposomes (Dex-P) at pH 1.5 and 6 (Figure 3.3). No
significant change was observed in lipid concentration as judged by the 95% confidence
interval of the slope from a first-order fit at pH 6. However, some degradation of the lipid
was detected at pH 1.5, with a first-order rate constant of 0.006±0.0003 h-1 corresponding
to a half-life of 115 ± 5 hr, consistent with previous evidence that phospholipid
hydrolysis is acid catalyzed (142, 143). Importantly, no change in partition coefficients
was discernible with time after equilibration indicating that a small percentage of lipid
hydrolysis did not alter the lipid volume within the liposomes or the membrane affinity
for the solute.
Membrane-Water Partition Coefficients
Dexamethasone
The membrane-water partition coefficient of Dex in DMPC, DPPC and DSPC liposomes
at 25 °C was determined at varying lipid concentrations by two different methods –
equilibrium dialysis and equilibrium solubility. In the equilibrium dialysis experiments,
the total drug concentrations were kept low and approximately constant with increasing
lipid concentration (drug to lipid ratios varied from 0.0006 to 0.0052) to determine the
partition coefficient in the linear region of binding isotherm (Figure 3.4). The bound drug
to lipid ratios increased linearly with increasing unbound drug concentration (Figure 3.4
inset) and the partition coefficients (705 ± 24 in DMPC, 106 ± 11 in DPPC and 58 ± 9 in
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Figure 3.3 Fraction of DMPC remaining vs. time during equilibrium dialysis experiments
at pH 1.5 and 6. Each data point is the average of five different concentrations and the
error bars are the standard deviations.
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Figure 3.4 DMPC, DPPC and DSPC membrane-water partition coefficients of Dex in
PBS buffer at pH 7.4 as a function of lipid concentration determined by equilibrium
dialysis at 25 °C. Inset shows the corresponding binding isotherms.
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DSPC liposomes) were constant in the lipid concentration range studied. In the
equilibrium solubility method, excess solid Dex was equilibrated with liposomes
resulting in linear increases in solubility as a function of lipid concentration for DMPC,
DPPC and DSPC liposomes (Figure 3.5). The membrane-water partition coefficients
determined from the equilibrium solubility method were also independent of the lipid
concentration (Figure 3.5 inset).
Partition coefficients of Dex in all three lipid systems determined by the equilibrium
dialysis and solubility methods were combined in Figure 3.6 to examine the effect of
drug-to-lipid ratio on the partition coefficient, since the drug-to-lipid ratios at equilibrium
were significantly higher in the equilibrium solubility method relative to the equilibrium
dialysis method. In DPPC and DSPC liposomes, no significant differences in partition
coefficients were observed at low vs high drug/lipid ratios as judged by the overlap of
95% confidence intervals for the average values from two methods. However, the drugto-lipid ratios for Dex in DMPC liposomes were substantially higher for the equilibrium
solubility method (~0.07) than those employed in equilibrium dialysis (<0.01), and in this
case the partition coefficients differed significantly between the two methods.
The dependence of the partition coefficients on temperature was determined in DPPC
liposomes using the equilibrium dialysis method, as shown in Figure 3.7. Partition
coefficients increased with temperature, varying from 106 ± 11 at 25 °C to 478 ± 20 at 45
°C (Figure 3.7A). Linear binding isotherms were observed (Figure 3.7A inset) in all
cases, indicating that the partition coefficients represent the infinitely dilute region. The
slope of a linear least squares fit of the van’t Hoff plot shown in Figure 3.7B yielded the
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Figure 3.5 Relationship between total equilibrium solubility of Dex and the lipid
concentration in DMPC, DPPC, and DSPC liposomes at 25 °C. Inset shows the effect of
lipid concentration on the partition coefficients.
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Figure 3.6 DMPC, DPPC and DSPC liposomal membrane-water partition coefficients of
Dex at 25 °C vs. the bound drug-to-lipid ratios. The partition coefficients at bound
Dex/lipid ratios below 0.01 were obtained by equilibrium dialysis and those above 0.01
were obtained by equilibrium solubility.
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molar enthalpy (ΔH°=58.6 kJ/mol) and entropy of transfer (ΔS°=235.1 J/mol.K) of Dex
from water to DPPC liposomes.
Dexamethasone Phosphate
The 21-phosphate prodrug of Dex is ionizable and therefore partition coefficients of DexP were generated in DMPC liposomes at 25 °C as a function of aqueous solution pH from
1.5-8.0 to study the species dependence of its partitioning behavior. The partition
coefficients generated at a fixed concentration of Dex-P and at various pH values are
plotted versus lipid concentration in Figure 3.8. At pH 1.5 and 2, systemic increases in
the partition coefficients with increasing lipid concentration are evident. In this pH
region, neutral Dex-P is the predominant bound species present because, although the
first pKa of Dex-P is 1.9 (133), preferential binding of the neutral species relative to the
monoanion results in a pKa shift for the membrane bound drug of approximately one
unit. The binding isotherms (drug/lipid (mol/mol) ratio versus unbound drug
concentration) for the data at pH 1.5 and 2 displayed in the inset to Figure 3.8 suggest
that membrane saturation may have been responsible for the decreasing partition
coefficients with increasing unbound drug concentrations that accompany a decrease in
liposome concentration. The solid lines in Figure 3.8 (inset) represent fits of the data at
pH 1.5 and 2 to Eq. 3.3. 𝐾𝑝𝑎𝑝𝑝 , respresenting the partition coefficient at infinite dilution
at the solution pH of interest, could be obtained from the linear portion of these fitted
lines.
The partition coefficients at pH 4-6 are nearly constant with increases in lipid
concentration (Figure 3.8), though a slight upward drift is discernible at pH 4. In this pH
region, the predominant membrane bound species is Dex-P monoanion. This conclusion
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Figure 3.7 (A) Influence of lipid concentration on the DPPC membrane-water partition
coefficients of Dex at different temperatures. Inset shows the corresponding binding
isotherms. (B) Van`t Hoff plot of the DPPC membrane-water partition coefficients for
Dex.
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Figure 3.8 Effect of lipid concentration on the apparent DMPC membrane-water partition
coefficients of Dex-P at different pH values (25 °C). Inset shows the binding isotherms
(bound drug/lipid ratio versus unbound aqueous drug conc.) for data at pH 1.5, 2, 4, 5 and
6. The solid curves at pH 1.5 and 2 represent non-linear least-squares fits of the data to
Eq. 3. Data at pH 4, 5 and 6 were corrected using the Gouy-Chapman equation (Eq. 5).
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is based on the experimentally determined pKa2 value for Dex-P of 6.27 ± 0.13 (pH
solubility method, our unpublished data) in aqueous solution combined with the
observation in Figure 3.8 that the partition coefficient for Dex-P at pH 8 is not
significantly different from zero indicating that the concentration of Dex-P dianion in the
membrane between pH 4-6 should be negligible. Anion partitioning to neutral
phospholipid membranes imparts a negative charge to the membrane that increases with
the bound drug/lipid ratio. Typically, the Gouy-Chapman theory can be employed to
correct for the effects of charge repulsion on the activity coefficient of the membrane
bound anion in order to obtain a partition coefficient at infinite dilution (134-139). Such a
correction, as described in Eqs. 4 & 5, was applied to the monoanion partitioning data at
pH 4-6 resulting in the plots of drug/lipid ratio versus unbound drug concentration shown
in the Figure 3.8 inset.
After the appropriate corrections, 𝐾𝑝𝑎𝑝𝑝 values for each pH applicable at infinite dilution
were obtained and plotted in Figure 3.9. These data were fit to Eq. 3.7 by nonlinear
regression to generate the solid curve shown. For this analysis, pKa1 and pKa2 were fixed
at their previously determined solution values of 1.9 and 6.27, respectively, and the
partition coefficient for Dex-P dianion was assumed to be equal to zero. The partition
coefficient for the neutral species was estimated to be 241 ± 38 (95% C.I.) and for the
monoanion, it was 48 ± 9 (95% C.I).
Membrane water partition coefficients of Dex-P (at pH 4) were determined in DMPC,
DPPC and DSPC liposomes as a function of lipid concentration by equilibrium dialysis
(25 °C) as shown in Figure 3.10. The highest partitioning was observed in DMPC
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Figure 3.9 Effect of pH on apparent partition coefficients of Dex-P in DMPC liposomes.
The solid curve represents the best fit of Eq. 7 to the data by nonlinear least-squares
regression analysis.
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Figure 3.10 DMPC, DPPC and DSPC liposomal membrane-water partition coefficients of
Dex-P at pH 4 and 25 °C determined by equilibrium dialysis versus lipid concentration.
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liposomes (62 ± 8 in DMPC (after Gouy-Chapman correction) while the values were
dramatically lower in DPPC (2 ± 4) and DSPC liposomes (6 ± 2).
Effect of Bilayer Free Surface Area on Membrane-Water Partition Coefficients
The membrane water partition coefficients were significantly higher in DMPC liposomes
as compared to DPPC and DSPC liposomes for both Dex and Dex-P (at pH 4). At 25 °C
DMPC, with a gel->liquid crystalline phase transition, Tm, of 23 °C is liquid crystalline
while both DPPC (Tm=41 °C) and DSPC (Tm=55 °C) are in their gel states. Therefore,
the acyl chain region in DPPC and DSPC bilayers is more highly ordered at 25 °C in
comparison to those in DMPC. To quantitatively probe the dependence of the partition
coefficient on the degree of bilayer chain ordering, the natural logarithms of the partition
coefficients (Kp) are plotted versus the inverse of free surface area as suggested by Eq.
3.9. For Dex, a linear relationship was observed between 𝑙𝑛(𝐾𝑝 ) and free surface area of

the bilayer ( 1⁄𝑎𝑓𝑟𝑒𝑒 = 𝜎/(1 − 𝜎) ) as illustrated in Figure 3.11. In one of the

partitioning system (Dex in DPPC liposomes), the free surface area of the bilayer was

altered by varying the temperature from 25 °C to 45 °C, through phase transition
temperature (41 °C) of DPPC. Figure 3.11 shows the combined data for Dex partition
coefficients when free surface area was varied either by varying phospholipid chain
length (DMPC, DPPC, and DSPC) or varying temperature (DPPC, 25-45 °C). The Dex-P
partition coefficients at pH 4 appear to show a similar trend though the number of data
points and poor precision of the values in DPPC and DSPC do not allow one to assess
linearity. There are numerous studies in the literature that have reported lipid
bilayer/water partition coefficients of various solutes in similar fully saturated
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Figure 3.11 Natural logarithms of the liposomal membrane-water partition coefficients of
Dex and Dex-P versus the inverse of the bilayer free surface area, a measure of chain
ordering as altered by phospholipid chain length and temperature.

49

phospholipids as a function of either phospholipid chain length or temperature. Some
representative examples taken from the literature (55, 141, 144-146) conducted in
liposomal systems for which surface density data were available from the same source
used in the present study (131) are plotted in Figure 3.12 along with the partition
coefficients generated for Dex and Dex-P in the present study versus the inverse of free
surface area. In all cases explored, a similar trend of decreasing partition coefficient
versus the inverse of bilayer free surface area was found with slopes in the plots of ln
(Kp) vs.1/afree (see Figure 3.12 legend) varying over a narrow range of approximately -0.2
to -0.3.
DISCUSSION
Liposomal partitioning studies appear to offer clear advantages in predicting the
biodistribution of drugs because ordered lipid bilayers more accurately mimic biological
membranes than bulk solvents. These advantages are particularly apparent for ionizable
compounds (111, 112, 114). Additionally, a quantitative understanding of liposomal
partitioning is essential for designing liposomal drug delivery systems with predictable
loading and tunable release characteristics (126, 127, 132, 147). However, the interfacial
nature of lipid bilayers adds complexity both in terms of generating reliable experimental
data and in interpreting the values obtained. Proper correction for surface charge effects
on binding of ionized species (134) and saturation phenomena for neutral species (138,
148) may be necessary with increasing drug concentration. For ionizable drug molecules,
quantitative mathematical models describing the contributions of neutral and ionized drug
species are needed to account for the pH dependence of membrane partitioning. Finally,
the experimental partitioning system employed in terms of liposome composition (e.g.,
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Figure 3.12 Natural logarithms of membrane-partition coefficients for various solutes
versus the inverse of free surface area (1/afree).
Key: hexane (55) (○,slope=-0.28); 17-β-estradiol (149) (◊,slope=-0.34); Dex (♦,slope=0.22); hydrocortisone acetate (145) (✳,slope=-0.21); sulfamethoxazole (144) (◍,slope=0.21); Dex-P (●,slope=-0.24); sulfathiazole (144) (∆,slope=-0.17); and acetic acid (122)
(□,slope=-0.26). (The partition coefficient values are in mole fraction for hexane and in
molarity for the other solutes).
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head group, acyl chain length, degree of unsaturation, presence of cholesterol, etc.), size
and lamellarity, temperature, and the like can be significant factors in determining the
results obtained. Presently, a different LFER equation is required for each lipid system
(146), highlighting the need for unifying relationships that could quantitatively predict
membrane-water partitioning from a knowledge of drug structure, membrane
composition, and the environmental conditions.
Some of the pioneering work on bilayer/water partitioning has revealed that factors such
as decreasing the temperature below the phase transition temperature, inclusion of
cholesterol in the bilayer, or elongating the phospholipid chain length cause decreases in
partition coefficients that can be correlated with order parameters such as surface density
of the bilayer chains (55, 121) or free surface area of the bilayer (122). The solutes
typically employed in these studies have been simple, small molecules such as benzene,
hexane, and acetic acid. Whether or not such relationships exist for larger and more
structurally complex drug molecules has not been established. The present study of the
partitioning behavior of Dex and Dex-P provides an opportunity to begin to explore the
hypothesis that the bilayer free surface area is a “universal” variable useful in relating
membrane-water partition coefficients to bilayer composition.
Factors Governing the Membrane-Water Partition Coefficient
Drug Concentration & Drug-to-Lipid Ratio
An important factor in the determination of reliable membrane-water partition
coefficients is the bound drug-to-lipid ratio at equilibrium. As noted by De Young and
Dill, it is very important to extrapolate partitioning data to infinite dilution for their
proper interpretation. Unlike adsorption to solids that might be construed as having a
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fixed number of binding sites, solute binding to bilayer membranes may involve partial or
complete insertion into the membrane with accompanying changes in both bilayer surface
area and the chemical nature of the surface, with an increase in the bound drug/lipid ratio.
These alterations with increasing solute uptake may lead to either increases or decreases
in the apparent partition coefficient with drug concentration (121, 136, 150, 151).
Alternatively, self-association of drug molecules with each other at high aqueous drug
concentrations may reduce the activity of the free available drug for the partitioning
(152).
The importance of determining partition coefficients at concentrations approaching
infinite dilution is evident from the difference in the partition coefficients obtained for
Dex from the two different methods employed in this study. In the equilibrium dialysis
method, the drug-to-lipid ratio could be varied with values approaching infinite dilution
(~0.001) (Figure 3.4 inset) whereas in the equilibrium solubility method, the drug to lipid
ratio in DMPC was constant at 0.07 (±0.004) even with varying lipid concentration as
dictated by the equilibrium solubility of Dex and the DMPC-water partition coefficient.
The equilibrium solubility method could not be used to probe DMPC partitioning in a
concentration region approaching infinite dilution and therefore the values obtained using
this method differed from those obtained by equilibrium dialysis (Figure 3.6). This was
not the case for Dex partitioning in DPPC and DSPC where the drug-to-lipid ratios at
equilibrium were <0.02 using the solubility method. For DPPC and DSPC, the partition
coefficients were the same by either method.
While generally higher drug-to-lipid ratios are possible for neutral molecules in
comparison to ionized compounds before deviations from linearity in sorption isotherms
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become apparent, the borderline appears to vary with the compound and lipid. Escher
found no deviations from linearity in neutral compound sorption isotherms up to drug-tolipid ratios of 0.1 (116) while Austin et al. suggested that the ratio of lipid to bound
neutral compound should be greater than 60 (111) which would translate to a drug-tolipid ratio of <0.017. As noted above, a significant deviation was found in the partition
coefficient for Dex at a drug-to-lipid ratio of 0.07 but using equilibrium dialysis at drugto-lipid ratios <0.007 the partition coefficients were independent of drug-to-lipid ratio
(Figure 3.4 & 3.7 insets).
Deviations in the sorption isotherms for Dex-P at pH conditions where the bound drug is
neutral were clearly evident at drug-to-lipid ratios above 0.04. Eq. 3.3 was therefore used
to extrapolate these results to infinite dilution. Langmuir-type adsorption models are
commonly employed to account for saturation effects in membrane partitioning of drug
molecules (153, 154). While the assumption of a fixed number of binding sites may not
accurately reflect the nature of the binding of molecules to flexible bilayer membranes, it
might be justifiable for drugs that bind predominantly at the membrane surface (137).
Changes in partitioning at high drug concentration are more likely due to changes in the
membrane or in the affinity of the drug molecule for the modified membrane surface
rather than a depletion of binding sites (136). However, at infinite dilution, partitioning
and association models are equivalent.
Sorption isotherms for ionized molecules become non-linear mainly because of the
repulsive forces between the charged species upon membrane binding (134, 135, 137139, 148). Austin et al suggested that for ions also, a ratio of lipid to bound ion >60
should be sufficient to render surface charge effects insignificant (111), although the
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Gouy-Chapman theory can be used to correct for surface charge effects at higher drug
concentrations (Figure 3.8 inset) (109, 116, 134, 135, 137, 138, 148, 155, 156).
Temperature Dependence of Partition Coefficients
The fundamental driving force for transfer of nonpolar solutes from water to a lipid
environment is generally assumed to be the hydrophobic effect but specific solute
interactions with the ordered bilayer structure modulate the overall thermodynamics of
the process (157, 158). The dependence of the membrane-water partition coefficient of
Dex was measured in DPPC liposomes as a function of temperature from 25-45 °C, a
range that crosses the gel->liquid crystalline transition temperature of 41 °C. These
results are displayed in the van’t Hoff plot in Figure 3.7B. The standard free energy
change (∆G°) upon transfer of Dex from water to DMPC liposomes was negative at all
temperatures indicating an energetically favorable process, driven by a positive entropy
(ΔH°=58.6 kJ/mol and ΔS°=235.1 J/mol.K). The thermodynamic parameters for the
transfer of Dex compare reasonably well qualitatively with values reported elsewhere for
corticosteroid transfer into DMPC bilayers both above and below its Tm, supporting the
observations of an entropy driven process for the partitioning of steroids into saturated
phospholipids (145, 159). One contribution to the positive entropy is that associated with
the removal of the steroids from water (57, 159, 160).
Kwon et al obtained the enthalpy and entropy changes for partitioning of several
endocrine disruptors between water and liposomes formed from DOPC, POPC, DMPC,
DPPC, and DSPC at temperatures ranging from 11 – 37°C (149). Over this temperature
range DOPC and POPC liposomes are liquid crystalline and DPPC and DSPC liposomes
are in a gel phase. DMPC undergoes a phase transition within the middle of this

55

temperature range at 23 °C. Generally, they found negative enthalpies of solute transfer
from water to liquid crystalline bilayers consisting of unsaturated lipids and positive
enthalpies for the transfer of solutes from water to gel phase membranes composed of
saturated phospholipids. Others have reported similar findings (161, 162). Such
disparities illustrate the greater complexity of the membrane binding process relative to
that for solute partitioning from water to bulk solvents.
Xiang and Anderson (131) determined that apparent energies of activation for acetic acid
permeability across liquid crystalline bilayer membranes increase in a dramatic fashion
with increases in chain ordering, with an Ea value of only 13 kcal/mol in DLPC
containing 20% cholesterol increasing to 20 kcal/mol in DMPC, and 37 kcal/mol in
DPPC. The enthalpy of transfer of acetic acid from water to decane, a bulk solvent that
mimics the chemical selectivity of phospholipid bilayers toward permeants, is only 4.8
kcal/mol (122). Thus, the elevated apparent energies of activation for acetic acid transport
were attributed largely to an increase in enthalpy for acetic acid insertion into the bilayer
barrier domain (i.e., the ordered acyl chain bilayer interior) with increases in chain
ordering. This unfavorable enthalpic contribution should be less important for solute
partitioning in comparison to transbilayer permeation because most drug molecules are
likely to be only partially inserted into the ordered chain region of the bilayer at
equilibrium, but this factor may nevertheless contribute to the positive enthalpies
generally observed for solute transfer from water into gel phase bilayers as observed by
Kwon et al. and others (144, 149, 163). On the other hand, the liquid crystalline bilayers
such as the DOPC and POPC systems explored by Kwon et al are highly disordered. For
such systems, the enthalpy associated with partial solute insertion into the acyl chain
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region likely consists of a small positive hydrophobic contribution that is often more than
compensated for by the negative enthalpic contribution accompanying hydrogen bonding
interactions or other electrostatic interactions between polar functional groups within the
solute and polar phospholipid head groups.
The thermodynamic driving force for the interaction may vary depending on the location
of binding, nature and structure of the solute and physical state of the bilayer (149, 163).
Removal of a hydrophobic solute from water and partitioning presumably into the
hydrophobic core of the membranes is entropically driven. Whereas, if a drug is
preferentially bound to the interface due to electrostatic interactions between the charged
drug and phospholipid headgroups, favorable enthalpy may dominate over the entropy,
example, cationic drugs have exothermic partitioning as compared to neutral (114). Thus,
the relative contribution of entropy driven hydrophobic effect and enthalpy driven
hydrophobic and electrostatic interaction between drug and membranes to the overall free
energy of transfer will really determine the thermodynamic driving force.
Structure-Partitioning Relationships – 21-Phosphate Group Contribution & Ionization
As reported in Table 3.1, the Kp value for Dex at 25 °C varies from 705 ± 24 in liquid
crystalline DMPC to 106 ± 11 in DPPC and 58 ± 9 in DSPC bilayers, both of which are
in their gel state at room temperature. These results illustrate the dramatic effect that
simply changing the chain length of the phospholipid can have on the partition
coefficient. Given such differences, it is understandable that a different LFER equation is
required for each lipid system (146).
The contribution of the polar phosphate group at the 21-position of dexamethasone to the
free energy of transfer from water to DMPC depends on its state of ionization. Fitting the
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Kpapp vs. pH data in Figure 3.9 to the model described in Eq. 3.7 generated values of Kp
for the neutral and monoanion forms of Dex-P of 241 ± 38 (95% C.I.) and 48 ± 9 (95%
C.I.), respectively. Comparing the neutral Kp values for Dex vs. Dex-P, phosphorylation
of Dex reduces its partition coefficient by only 3-fold, giving a group contribution for the
unionized phosphate residue to the transfer free energy from water to DMPC of only
Δ(ΔG°) = 2.66 kJ/mol (0.64 kcal/mol). Monoanion formation reduces Kp by another 5fold and dianion formation leads to a further decrease such that at pH 8, Kp is close to
zero.
Several reports indicate that amphiphilic molecules orient themselves at the interphase of
bilayers such that charged or polar groups interact with lipid head groups while their nonpolar regions are embedded in the hydrocarbon region of the bilayer (119, 164-166).
Vijayan et al. (166) conducted MD simulations of the location and orientation of
cortisone, a corticosteroid similar in structure to Dex, in a model lipid bilayer. They
observed that, unlike cholesterol which aligns itself approximately parallel to the bilayer
chains, cortisone adopts an orientation that is nearly parallel to the bilayer surface such
that its polar groups are able to maximize favorable contacts in the heterogeneous bilayer
interface region. With the increase in charge and hydrogen bonding potential
accompanying 21-phosphorylation, the molecule is likely pulled further towards the
interface such that particularly the phosphate monoanion residue remains solvated by
water. The reduction in the partition coefficient reflects the greater amount of energy
needed to break the hydrogen bonds and remove the hydrophobic portions of the solute
from water (112, 167).
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Effect of Bilayer Free Surface Area
Unlike bulk solvents, lipid bilayers are interfacial phases having properties that depend
on surface density or free surface area. The acyl chain in bilayers are more highly ordered
near the headgroups and the order diminishes with distance towards the bilayer center
(61). The free surface area and the length of the phospholipid acyl chains are the principal
independent variables that determine the chain organization (55). We studied the effect of
changes in free surface area by altering the phospholipid acyl chain lengths and by
varying temperature.
In the current study, DMPC was in liquid crystalline state at 25 °C, DPPC was in gel state
at 25 and 37 °C and in liquid crystalline state at 45 °C and DSPC in a gel phase at 25 °C.
Irrespective of the ordering mechanism (temperature or lipid composition), the partition
coefficient of Dex was found to be negatively dependent on the inverse of free surface
area (Figure 3.11). A linear relationship was obtained between 𝑙𝑛(𝐾𝑝 ) and the inverse of

free surface area (1/afree = σ/(1- σ)) for Dex (slope=-0.22). Dex-P at pH 4.0 exhibited a
similar dependence on free surface area with a similar slope (=-0.24). Dex-P, the prodrug
of Dex having the same steroidal parent structure and differing only in the presence of a
phosphate at the 21-position, is predominantly monoanionic at pH 4.0. The similarity in
slopes indicates that the two molecules, one neutral and one anionic, have nearly equal
sensitivities to bilayer chain ordering as quantified by the free surface area parameter.
There are numerous reports in the literature of decreases in membrane partition
coefficients of various solutes with increases in alkyl chain length of the phospholipids,
changes in the degree of chain unsaturation, decreases in temperature, or incorporation of
cholesterol into liquid crystalline bilayers (55, 121, 122, 145, 146, 151). Yamamoto and
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Liljestrand (146) observed a 20-fold decline in the room temperature partition coefficient
of estradiol when the liposome composition was changed from POPC to DPPC. This
substantial effect of lipid composition on solute partitioning was attributed to the
influence of chain saturation on the main transition temperature. At room temperature
POPC liposomes exist as a liquid crystalline phase while DPPC is in a gel phase.
The lattice theory developed by Marqusee and Dill (108) suggests that solute partitioning
will decrease with increasing surface density due to the increasingly unfavorable entropy
associated with solute insertion as orientational ordering of the phospholipid chains is
increased. Experimentally, correlations have been observed between the partition
coefficient for small molecules (hexane, benzene and acetic acid) and surface density of
the lipid bilayer (55, 121, 122). Xiang and Anderson combined statistical mechanical
theory with molecular dynamic simulation to show that the lateral pressure in a bilayer
increases steeply with surface density and that increased lateral pressure results in higher
local order and exclusion of solutes from the interphase (110). In other words, increased
chain-chain interaction at higher chain density inhibits solute incorporation (146, 151,
152, 168).
These results suggest that solute exclusion accompanies chain ordering but the magnitude
of the effect may be solute dependent. To explore whether a general, quantitative
relationship can be found between bilayer chain ordering and membrane-water partition
coefficients, the natural logarithms of the bilayer-water partition coefficients of several
drugs from studies published by other labs against the inverse of free surface area, 1/afree
was plotted in Figure 3.12. These studies employed similar phospholipids as those in the
present study. The average of the slopes was -0.26 with a 95% confidence interval of -
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0.22 to -0.29, emphasizing the negative relationship between the partition coefficient and
inverse of free surface area of the bilayers.
Xiang and Anderson (131) previously determined both partition coefficients and
permeability coefficients for acetic acid as a function of surface density. A slope of -0.26
for the natural logarithm of the partition coefficient of acetic acid versus the inverse of
free surface area was found in Figure 3.12 which compares to a much steeper slope (0.71) when their permeability data for acetic acid are plotted in the same manner, a 2.7fold difference. This is attributed to the requirement for passage of the solute across the
bilayer barrier region for permeation whereas partitioning involves only partial insertion
into the interfacial region of the bilayer for acetic acid (122, 131). In all cases, there is a
dependence of the partitioning on the available free surface area, as demonstrated by
Figure 3.12 for several different solutes varying in size and chemical properties.
Generally, drug molecules having both polar and hydrophobic residues may bind in the
interfacial region of bilayers with only portions of their structures embedded into the
ordered alkyl chain region depending on their lipophilicity. The similarity of the slopes
obtained for all of the representative solutes illustrated in Figure 3.12 suggests that the
dependence of partitioning on chain ordering is not highly sensitive to either the overall
size or chemical structure of the solute. The relatively uniform but modest dependence of
membrane binding on bilayer free surface area may reflect the availability of
hydrophobic surface area on the membrane, which is the surface property that increases
with an increase in free surface area. While the above relationship appears to be valid for
partitioning to a sub-set of bilayers composed of saturated phospholipids both above and
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below their phase transition temperatures, further studies in a more diverse set of
membranes are necessary to determine the universality of this relationship.
CONCLUSIONS
The partition coefficient of a drug in bilayer is dependent upon several factors such as the
bound drug-to-lipid ratio, pH, temperature, membrane composition, etc. Appropriate
corrections for neutral and ionized species at high concentrations are required in order to
determine a reliable partition coefficient value (at infinite dilution). The membrane-water
partition coefficient of Dex at infinite dilution was studied in liposomes of varying
composition. Increasing the negative charge of Dex-P gradually reduced the partition
coefficient, ultimately overcoming the hydrophobic contribution to membrane insertion
provided by the steroid rings. In order to explore the possible existence of a relationship
between membrane-water partition coefficients and bilayer chain ordering, the partition
coefficients were related to the inverse of bilayer free surface area. For both, Dex and
Dex-P, the natural logarithms of the partition coefficients in liposomes decreased linearly
with the inverse of free surface area in the bilayer as modulated by increasing
phospholipid chain length or decreasing temperature. Inclusion of membrane partitioning
data in saturated lipid systems for other solutes from the literature, showed a similar
dependence on the free surface area. These results may be useful in the development of
more comprehensive quantitative models relating membrane-water partition coefficients
of drug molecules to bilayer properties.
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CHAPTER FOUR
Determination of Drug Release Kinetics from Nanoparticles: Overcoming Pitfalls of
the Dynamic Dialysis Method
INTRODUCTION
Interest in nanoparticle drug delivery systems has grown dramatically in recent years due
to their manifold potential applications in solubilizing poorly soluble drug candidates,
reducing drug toxicity, prolonging circulation times, controlling drug release kinetics,
drug targeting, and monitoring drug delivery to enhance therapeutic efficacy (1-3, 169171). Nanoparticles have been particularly attractive in cancer because of their passive
targeting potential through the enhanced permeability and retention (EPR) effect (172174) and the perception that with the right size, shape, and cell surface properties,
nanoparticles can circulate systemically for a prolonged period, accumulate in tumor
tissue and release drug locally to cancer cells (20, 45, 175, 176). To maximize the
effectiveness of nanoparticle targeting, drug release from nanoparticles needs to be slow
enough to avoid substantial drug loss before the carrier reaches the site of action thereby
reducing toxicity (177, 178). After nanoparticle accumulation at the target site,
optimizing efficacy will require tunability of the drug release rate (51, 52, 126). Thus, the
kinetics of drug release from nanoparticles should be an essential feature of their design
and a property monitored for the quality control of nanoparticle formulations. Reliable
determination of in vitro release kinetics is also a prerequisite for establishing in vitro - in
vivo correlations which in turn define the formulation performance in vivo.
Dynamic dialysis is one of the most commonly used methods for the determination of
release kinetics from nanoparticles. Very recently, Zambito et al. pointed out that out of
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90 literature reports on in vitro drug release from nanoparticles surveyed in the year
2011, nearly 40 used dynamic dialysis to measure the release kinetics (70). The reason
for the popularity of dynamic dialysis over other methods (e.g., ultracentrifugation and
ultrafiltration) is that the additional step of separating nanoparticles from the free drug at
various time points during the kinetic study is eliminated. The external pressure applied
for separation in other methods can disturb the equilibrium and incomplete separation can
lead to significant measurement errors (68, 179).
In dynamic dialysis, the appearance of drug in the “sink” receiver compartment is the
result of diffusion from the nanoparticles followed by diffusion across the dialysis
membrane, though it is generally treated as a simple first-order process. Experimentally,
either disappearance of drug from the donor compartment containing the nanoparticles or
appearance in the receiver compartment can be measured. Because the apparent release
rate is the net result of drug transport across two barriers in series, the rate constant
obtained may not necessarily reflect the rate of drug release from the nanoparticles. Both,
the barrier properties of the dialysis membrane and the driving force for drug transport
across that membrane must be considered. The latter quantity, the driving force, is not the
total drug concentration in the nanoparticle dispersion but the free aqueous drug
concentration, a quantity that is of critical importance but never measured directly.
Therefore, assessment of the reliability of rate constants determined by dynamic dialysis
demands a careful consideration of the pitfalls in interpreting apparent release data.
Some authors have recognized the potential sources of error in data generated using
dynamic dialysis for the determination of release rates from nanoparticles. As mentioned
above, the inherent barrier properties of the dialysis membrane itself may impose a limit

64

on the rate constant of release from nanoparticles that can be measured (180, 181). Others
have highlighted the issue of drug partitioning between the phases present in dispersed
systems and their influence on the driving force for drug transport across the dialysis
membrane (70, 182-184). Reversible drug binding to the nanocarrier reduces the driving
force governing drug transport across the dialysis membrane which may alter the overall
apparent rate of release. Currently, there is not only a lack of general agreement on the
reliability of the dynamic dialysis method, but also uncertainty as to the lower limit of
nanoparticle release half-lives that can be accurately determined using this method.
In this paper, the practical limitations of the commonly used dynamic dialysis method for
determination of apparent release kinetics was highlighted along with the value of using
mechanism-based models both to obtain the actual rate constant for nanoparticle release
and to estimate its level of certainty. The experiments utilize liposomes as representative
nanocarriers and two model hydrophobic drugs, one of which is ionizable. A
comprehensive analysis of the interplay of the critical factors (membrane/water partition
coefficient, lipid concentration, and liposomal and dialysis membrane permeability
coefficients) that govern the apparent release kinetics illustrates the potential pitfalls
underlying this method. The mathematical models and their utility in extracting reliable
rate constants for drug release are demonstrated in cases where drug binding effects
and/or dialysis membrane transport may be partially contributing to the apparent release
kinetics. There are situations where dynamic dialysis can be safely used with simple firstorder treatment of the data and situations requiring detailed, mechanistic modeling of the
data.
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MATERIALS AND METHODS
AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) was provided by Novartis
Pharmaceuticals Corporation (East Hanover, NJ). Dexamethasone (Dex) (≥98%, powder)
was purchased from Sigma-Aldrich Co., St. Louis, MO. Lipids ( DSPC (1,2-distearoylsn-glycero-3-phosphatidylcholine, >99% purity), DPPC (1,2-dipalmitoyl-sn-glycero-3phosphocholine, >99% purity), DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine,
>99% purity), m-PEG DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N[methoxy (polyethylene glycol)-2000]), m-PEG DPPE (1,2-dipalmitoyl-sn-glycero-3phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]) and m-PEG DMPE (1,2dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene

glycol)-

2000])) were purchased as powders from Avanti Polar Lipids (Alabaster, AL).
Sephadex® pre-packed (PD-10) size exclusion columns (GE Healthcare Bio-sciences
Corporation (Piscataway, NJ)), containing about 8.3 ml of Sephadex G-25 M medium,
were used for separation of free drug from encapsulated. Dialysis tubes (Float-A-Lyzer®,
MWCO (Molecular Weight Cut Off): 100 kD) of 1 and 5 ml volumes were purchased
from Spectrum Laboratories (Rancho Dominguez, CA). HPLC grade solvents and other
chemicals were purchased from Fisher Scientific (Florence, KY). Deionized water was
used for all experiments.
Liposome Preparation
Blank and drug loaded liposomes were prepared based on a previously reported method
(127). Briefly, DMPC: mPEG DMPE, DPPC: mPEG DPPE and DSPC: mPEG-DSPE
(95:5 mol%, 120 mg) were separately dissolved in about 2 ml of chloroform. The solvent
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was evaporated under a stream of nitrogen and the resulting film was dried overnight in a
vacuum oven.
AR-67 loaded liposomes
Drug loaded DSPC: mPEG-DSPE liposomes were prepared at pH 4.2 and 9.5. Blank
liposomes at pH 4.2 were prepared by hydrating the dried lipid film in 85 mM acetate
buffer (pH 4.2). Drug loading at pH 4.2 was accomplished by adding 10 µl of an AR-67
stock solution in DMSO (~80 µM) to 2 ml of blank liposomes and incubating at 60°C for
about 2 hours. Drug loading at pH 9.5 was carried out by hydrating the dried lipid film in
2 ml of 100 mM borate buffer (pH 9.5) containing AR-67 (1.2 µM) by alternate vortexing
and heating at 60°C. In all cases, the lipid suspensions were then extruded 10 times
through two stacked 200 nm polycarbonate membranes (GE water and Process
Technologies, Trevose, PA) using an extrusion device (Liposofast®, Avestin, Canada) at
60°C to obtain unilamellar liposomes.
Dexamethasone loaded liposomes
Blank DMPC, DPPC and DSPC liposomes were prepared by hydrating the dried lipid
films in 2 ml of phosphate buffered saline (PBS, pH 7.4). Dexamethasone loaded
liposomes were prepared by hydrating the dried lipid films in 2 ml of a PBS solution of
dexamethasone (~0.05-0.06 mg/ml) to give a lipid concentration of 60 mg/ml. The
suspensions were alternately vortexed and heated in a water bath to temperatures above
the phase transition temperature of the respective lipid to uniformly suspend the lipid.
The lipid suspensions were then extruded 10 times through two stacked 100 nm
polycarbonate membranes using the extrusion device at 30°C, 50°C and 60°C for DMPC,
DPPC and DSPC, respectively, to obtain unilamellar liposomes.
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Blank and drug (AR-67 and Dex) loaded liposomes were allowed to cool to room
temperature for 3 hours and stored at 4°C until further use. Particle sizes of the liposomes
were measured by dynamic light scattering (DLS) using a Delsa™ Nano submicron
particle size analyzer (Beckman Coulter Inc., Brea, CA) at 25°C. The liposomes were
diluted in the same buffer as that used in their preparation.
Dynamic Dialysis Experiments
All drug loaded liposome suspensions were passed through a Sephadex® G25 column
pre-equilibrated in the same buffer as that used in the preparation of liposomes in an
attempt to separate free from entrapped drug. Aliquots (0.1-0.5 ml) of the drug loaded
liposome suspensions were applied to the top of a Sephadex column and eluted with the
same buffer as that used in the preparation in the increments of 1 ml. The eluent fraction
containing liposomes was collected between 2.5 to 5 and analyzed for drug and lipid
concentration. The residual extravesicular membrane bound fraction was determined
from model fitting (vide infra). The eluent fraction containing drug loaded liposomes was
diluted (if needed) in the same buffer to obtain a desired lipid concentration and
introduced into the dialysis tube.
AR-67 loaded liposome suspensions were diluted to a lipid concentration of about 0.48
mg/ml before placing in the dialysis tube. Total drug concentration in the dialysis tube
was monitored versus time for pH 4.2 drug loaded liposomes and blank liposomes spiked
with drug (~75 nM) at 37°C after immersion in 1 L of acetate buffer (85 mM, pH 4.2) to
provide sink conditions in the receiver solution. Dialysis experiments for drug loaded
liposomes at pH 9.5 were conducted similarly after immersion of the dialysis tube in 1L
of borate buffer (100 mM, pH 9.5). Aliquots (50 µl) withdrawn from inside the dialysis
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tube at different time points were diluted with cold (−25 °C) 2:1 v/v methanol:
acetonitrile and analyzed by HPLC.
Dynamic dialysis experiments for Dex loaded liposomes were conducted at high (~12-15
mg/ml) and low lipid concentrations (~4-5 mg/ml). Total drug concentration in the
dialysis tube was monitored versus time after immersed in 1 L of PBS.

Similar

experiments were conducted using blank liposomes spiked with Dex (~20 µM for low
and ~50 µM for high lipid concentration) and free Dex solution (100 µM) at 25°C.
Dedicated dialysis tube was used for drug loaded, spiked and free drug profile in a
particular lipid system in order to eliminate variability introduced by dialysis tubes.
Aliquots (10-100 µl) withdrawn from inside the dialysis tube at various time points were
diluted with an appropriate volume of methanol and analyzed by HPLC.
Drug Analyses
AR-67
Samples from release experiments were analyzed using a previously developed and
validated isocratic high performance liquid chromatography (HPLC) method with
fluorescence detection (126, 127). Both, lactone and carboxylate were monitored at pH
4.2 and 9.5. A Waters Alliance 2695 Separations Module coupled to a Waters Scanning
Fluorescence Detector (M474) was employed with excitation and emission wavelengths
at 380 and 560 nm, respectively. A Waters Symmetry® C18 column (5 µm, 3.9 X 150
mm) and guard column (3.9 X 20 mm) were used with a mobile phase composition of
48% acetonitrile and 52% (v/v) pH 5.5 triethylamine acetate (2%) buffer. Standards for
AR-67 carboxylate (0.2-2 µM) were prepared in 10 mM sodium carbonate buffer (pH
10.4) and standards for AR-67 lactone (0.5-2.5 µM) were prepared in acidified methanol.
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The retention times at an injection volume of 10 µl and a flow rate of 1 ml/min were 1.7
and 5.9 min for AR-67 carboxylate and lactone, respectively.
Dexamethasone
Samples from liposome release studies and partitioning experiments were analyzed using
an isocratic HPLC method with UV detection. Four independent standards of
dexamethasone (50-800 µM) in methanol were prepared and the relative standard
deviation for the response factor was less than 3%. A Waters Alliance 2695 Separations
Module coupled to a UV detector (Waters 996, Photodiode Array Detector) was
employed at a wavelength of 240 nm. A Waters Symmetry® C18 column (5 µm, 3.9 X
150 mm) and guard column (3.9 X 20 mm) were used with a mobile phase composition
of 32% acetonitrile and 68% (v/v) pH 5.5 triethylamine acetate (2%) buffer. The
retention time for Dex at an injection volume of 10 µl and a flow rate of 1 ml/min was
about ~6.4 min.
Lipid Analysis
Lipid concentrations in blank and drug loaded liposome dispersions were analyzed by
HPLC using ELSD (Evaporative Light Scattering Detector), as reported previously (126).
Briefly, an Allsphere™ Silica Column (Grace Davison Discovery Sciences, Deerfield,
IL) (5 µ, 4.6X150 mm) and guard column (5µ, 7.5 X 4.6mm) were employed with a
linear gradient method starting with 100% (v/v) mobile phase A (80% chloroform:19.5%
methanol:0.5% (v/v) ammonium hydroxide solution (30%) and changing to 80% mobile
phase A:20% mobile phase B (80% methanol:19.5% water:0.5% (v/v) ammonium
hydroxide solution (30%)) over 3 min. Standards were made in mobile phase A and
linearity was observed between log concentration and log area of the peak over the
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concentration ranges of 150-800 µM for DMPC, 100-400 µM for DPPC, and 150-400
µM for DPPC. Aliquots of blank and drug loaded liposomes (10-20 µl) were transferred
to test tubes, dried under nitrogen and stored at -20°C until further analysis. For analysis,
the dried lipid films were re-constituted in mobile phase A.
MATHEMATICAL MODELING AND SIMULATIONS
Data fitting and simulations were done based on previously developed mathematical
models (126, 127, 132). The models take into account the inner and outer aqueous
volumes, the volumes of the inner and outer bilayer leaflets in the liposome suspension,
and the membrane-water partition coefficient of drug to determine the fractions bound
inside and outside the liposomes. The rate of bilayer transport of the encapsulated drug is
determined by the concentration gradient of the unbound neutral drug concentration. The
extravesicular unbound concentration is dictated by the partition coefficient and the rate
of drug transport across the dialysis membrane into a large volume of the reservoir
solution to provide sink conditions. Thus,
𝑑(𝐷𝑖 )
= −𝑘𝑚 (𝐷𝑖𝑤 − 𝐷𝑜𝑤 )
𝑑𝑡

𝑑(𝐷𝑖 )
= −𝑘𝑚 (𝛼𝑖 𝐷𝑖 − 𝛼𝑜 𝐷𝑜 )
𝑑𝑡

(4.1)
(4.2)

𝑑(𝐷𝑜 ) 𝑘𝑚 𝑤
𝑉𝑜
(𝐷𝑖 − 𝐷𝑜𝑤 ) − 𝑘𝑑 (𝐷𝑜𝑤 ) … … 𝑥 =
=
𝑑𝑡
𝑥
𝑉𝑖
𝑑(𝐷𝑜 ) 𝑘𝑚
(𝛼𝑖 𝐷𝑖 − 𝛼𝑜 𝐷𝑜 )−𝑘𝑑 (𝛼𝑜 𝐷𝑜 )
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𝑑𝑡
𝑥
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(4.3)
(4.4)
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𝑉𝑜
𝑉𝑜
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𝑏 + 𝑎𝐾𝑝
𝑑 + 𝑐𝐾𝑝
𝑉𝑖
𝑉𝑖
𝑉𝑜
𝑉𝑜

where, Di and Do are the total intravesicular and extravesicular (within the dialysis tube)
drug concentrations respectively; a and b are volume ratios to account for the differences
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in aqueous and membrane volumes with respect to the total intravesicular volume; c and
d are volume ratios to account for the differences in aqueous and membrane volume with
respect to the total extravesicular volume in the dialysis tube. Vi is the total liposomally
entrapped aqueous volume plus the lipid volume in the inner bilayer leaflet of liposomes
in the suspension, Viw and Vim are the volumes of the inner aqueous compartment and
inner monolayer in each vesicle, respectively. Vo is the extravesicular aqueous volume
along with the volume of lipid in the outer bilayer leaflet of suspended liposomes in the
dialysis tube; Vom is the volume of the outer monolayer in each vesicle and Vow is the
volume of the extravesicular aqueous compartment in the dialysis tube. Kp is the
membrane-water partition coefficient, αi and αo are the factors that account for the
binding of drug to lipid membrane and convert total intravesicular and extravesicular
concentrations to the aqueous free concentrations, respectively; km and kd are the rate
constants for drug transport across the lipid bilayer and dialysis membrane respectively
and x is the ratio of extravesicular to intravesicular volume in the dialysis tube.
To account for non-instantaneous drug binding to the dialysis membrane, modifications
to the model were made to account for release profiles of Dex,
𝑑(𝐷𝑜 ) 𝑘𝑚
𝑘𝑜𝑛
(𝛼𝑖 𝐷𝑖 − 𝛼𝑜 𝐷𝑜 ) − (𝑘𝑜𝑛 + 𝑘𝑑 )𝛼𝑜 𝐷𝑜 +
=
𝐷
𝑑𝑡
𝑥
𝐾 𝑚
𝑑(𝐷𝑚 )
𝑘𝑜𝑛
= 𝑘𝑜𝑛 𝛼𝑜 𝐷𝑜 −
𝐷
𝑑𝑡
𝐾 𝑚

�𝐾 =
(4.6)

𝑘𝑜𝑛
�
𝑘𝑜𝑓𝑓

(4.5)

where, Dm is the drug concentration bound to the dialysis membrane and kon and koff are
the association and dissociation constants, respectively, for binding of drug to the dialysis
membrane.

72

Simulations were conducted to evaluate the impact of variations in the membrane-water
partition coefficients of the drug and the lipid concentration inside the dialysis tube on the
overall release profiles from liposomes at various km values. To determine the region of
the variable space in which reliable rate constants for drug release could be obtained (in
the absence of experimental variability), simulations were performed using the above
detailed mathematical model assuming an intrinsic rate constant and then the simulated
data were fit using a simple first order rate equation. For an assumed higher intrinsic rate
constant, the apparent kinetics (kapp) can be slower at high partition coefficient because
kapp=km*αi where αi is the factor that accounts for intravesicular binding. The effective
rate constant was deemed to be determinable by dynamic dialysis and a first-order
treatment if the fitted rate constant from first order model was within ± 20% of the input
or assumed value.
RESULTS AND DISCUSSION
Liposome Characterization
The particle sizes of blank and AR-67 loaded DSPC liposomes (pH 4.2 and 9.5) were
180±15 nm, with polydispersity indices in the range of 0.04-0.07. Blank and Dex loaded
DMPC, DPPC and DSPC liposome particle sizes were in the range of 90±20 nm, with
polydispersity indices between 0.05-0.08, indicating monodisperse formulations. The
extrusion procedure employed in this study was previously shown by
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P-NMR to

produce unilamellar vesicles (141).
In order to assess the impact of lipid concentration on the apparent release kinetics, it was
important to analyze the actual lipid concentrations in blank and drug loaded liposomal
suspensions used in release studies. Lipid concentrations were analyzed prior to release

73

experiments by gradient HPLC with evaporative light scattering detection and were
typically 25-35% lower than the theoretical concentrations indicating some lipid loss
during the extrusion process. The retention times of DMPC, DPPC and DSPC were 8.2,
8.0 and 7.9 min, respectively.
Determination of the particle size and actual lipid concentration of liposomal suspensions
was critical for mathematical modeling of the release data as the calculation of αi and αo
in Eqs. 4.2, 4.4, and 4.5 requires this information. The parameters a and b (internal
volume ratios) needed to determine αi are directly dependent on particle size while the
parameters c and d (external volume ratios) necessary for the determination of αo are
dependent on both particle size and lipid concentration.
Factors Governing the Apparent Release Rate Constants using Dynamic Dialysis
As depicted for liposomal release in Figure 4.1, four major factors govern the
determination of reliable release rate constants from nanoparticles by dynamic dialysis:
1) the effective drug concentration within the nanoparticle provides the driving force for
release from the particle (i.e., Diw in Figure 4.1); 2) the rate constant (km) for nanoparticle
release reflects the properties of the barrier domain within the carrier (i.e., for liposomes
this is the ordered chain region of the bilayer); 3) drug binding/partitioning to the
nanoparticles and the dialysis membrane influences Dow, the effective drug concentration
within the dialysis tube that serves as the driving force for drug transport across the
dialysis membrane once the drug is released from the nanoparticle; and 4) the dialysis
membrane itself constitutes a second transport

barrier as represented by kd.

The

effective liposomal drug concentration, Diw, is the unbound intravesicular aqueous
concentration of the permeable drug species. Referring to Eqns. 1-6, Diw = αiDi where
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Di is the total intravesicular drug concentration and αi accounts for the binding of drug to
the inner leaflet of the bilayer. The mathematical model treatment, developed based on
the equilibrium and transport processes and described by Eqns. 4.1-4.6, is applicable to
nonionizable drugs. For an ionizable drug where the neutral species is the permeant, Diw
would be reduced by both membrane binding and ionization as demonstrated in previous
work (126).
The rate of neutral drug release from nanoparticles that would be expected under true
sink conditions, as would likely prevail in the systemic circulation in vivo, is reflected in
the first term of Eqn. 4.2, 𝑑(𝐷𝑖 )⁄𝑑𝑡 = −𝑘𝑚 𝛼𝑖 𝐷𝑖 . Thus, the first two factors outlined

above govern drug release under sink conditions while factors (3) and (4) come into play
when release rates are monitored using dynamic dialysis. In dynamic dialysis all four
factors are intertwined although one process may dominate over the others, depending
upon the drug and nanoparticle properties, the nanoparticle concentration, drug loading,
and the dialysis membrane selected. Herein, we demonstrate the effect of these factors on
the determination of release rates using liposomes as representative nanoparticles, but the
general principles should be more broadly applicable.
Release Kinetics of AR-67 from DSPC Liposomes at pH 4.2 and 9.5

The release kinetics of AR-67 from liposomes at pH 4.2 and 9.5 demonstrate two
contrasting scenarios that may be encountered in determining release profiles by dynamic
dialysis. The first and most straightforward situation to be presented is that for the release
of AR-67 at a constant (intra- and extravesicular) pH of 9.5 as shown in Figure 4.2. AR67 is a camptothecin analogue having a α-hydroxy-δ-lactone moiety that undergoes pHdependent chemical hydrolysis to a ring-opened carboxylate form. In its lactone form, the
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Figure 4.1 Schematic depicting the ionization and binding equilibria along with transport
pathways representing the study of drug release kinetics from liposomes by dynamic
dialysis method.
Diw and Dim are the intravesicular aqueous and membrane bound drug concentration
respectively, Dow and Dom are the extravesicular aqueous and membrane bound drug
concentration respectively. Dm is the dialysis membrane bound drug concentration. km
and kd are the rate constants for permeation across the bilayer membrane and dialysis
membrane respectively. kon and koff are the apparent association and dissociation
constants for the binding of drug to the dialysis membrane.
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Figure 4.2 Fractions of initial amount of AR-67 remaining in dialysis tube versus time.
(A) First order fits of release profiles of AR-67 loaded DSPC liposomes at pH 4.2
(lactone) and pH 9.5 (carboxylate). (B) Simultaneous model fitting of the AR-67 loaded
(pH 4.2). DL stands for drug loaded liposomes.
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predominant species at pH 4.2, this compound is highly hydrophobic with a
cLogP=5.4±1.3. The aqueous solubility of the lactone form is extremely low at 0.11
µg/ml (127, 185). However, at pH 9.5, AR-67 exists predominantly in its membrane
impermeable carboxylate form and the overall release rate is very slow due primarily to
the small fraction of lactone present at that pH (126). In this case, the liposomal release is
clearly rate-determining and a first-order fit of the observed concentration versus time
profile generated in a dynamic dialysis experiment can reliably be used to obtain the
effective release rate constant that would also be expected under true sink conditions at
the same pH. The first-order rate constant for AR-67 transport from DSPC liposomes at
9.5 estimated from Figure 4.2A is 0.0034 h-1 corresponding to a half-life of 204 hr. (It
should be noted that the actual release half-life achieved in plasma for the above pH 9.5
liposomes was dramatically reduced due to CO2 mediated dissipation of the internalexternal pH gradient (126). Such considerations have not been taken into account in the
present analysis.)
At pH 4.2, however, the rate of AR-67 release from DSPC liposomes is much faster, with
an apparent first-order rate constant of 0.123 h-1 corresponding to a half-life of 5.6 hr.
Given the hydrophobic nature of this drug in its lactone form and its substantial binding
affinity toward liposome membranes (132) the question arises as to whether or not this
apparent half-life truly reflects the rate constant for nanoparticle release.
In order to explore the potential confounding effects of extravesicular membrane binding
and dialysis membrane transport in the pH 4.2 release experiment, blank liposomes at pH
4.2 were spiked with AR-67 solution at the same concentration as that present in the
drug-loaded liposomal suspensions and subjected to the same dialysis procedure, as
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shown in Figure 4.2B. Eqns. 4.2 & 4.4 were then employed to simultaneously fit the two
release profiles in Figure 4.2B. The intrinsic rate constant km obtained for nanoparticle
AR-67 release at pH 4.2 was 44 ± 18 h-1 (km.αi = 0.22 h-1) corresponding to a half- life of
3.1 ± 0.9 hr, in close agreement with the value of 2.8 ± 0.3 hr reported previously when a
similar simultaneous fit of spiked and loaded liposomes was conducted (132). The
intrinsic rate constant for free drug transport across the dialysis membrane (kd) obtained
from the simultaneous model fitting in Figure 4.2B was 1.2 ± 0.2 h-1 corresponding to a
half-life of 0.52 ± 0.07 hr. In the presence of liposomes, the half-life for AR-67
disappearance in a spiked experiment increased to 0.73 hr due to the effect of
extravesicular drug binding to the outer leaflet of the liposome bilayers (i.e., reduction in
αo). This example illustrates the importance of probing for drug binding to nanoparticles
after release. It also highlights the potential value of conducting a spiking experiment at
the same nanoparticle concentration in conjunction with simultaneously fitting the two
release profiles to obtain a more reliable estimate of the true rate constant for drug release
from the nanoparticles.
The Unencapsulated Initial Drug Concentration
In simultaneously fitting Equations 2 and 4 to drug loaded and spiked liposome release
data such as those shown in Figure 4.2B, the fraction of unencapsulated drug present in
drug-loaded liposomes at t=0 must be considered. In practice, a liposome/drug system is
never completely free of unencapsulated drug (186). For blank liposomes, the term D0
representing the extravesicular drug concentration can be assumed to represent 100% of
the drug added at t=0 but for drug loaded liposomes, D0 is unlikely to be zero despite
attempts to separate free from entrapped drug by Sephadex column chromatography or
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other techniques. In part, this is due to drug release from nanoparticles after the
separation has been completed but prior to the start of a dialysis experiment. Another
likely factor is that, depending on its binding affinity, drug bound reversibly to the
nanoparticle may not be completely removed by separation on a Sephadex column.
Shown in Figure 4.3A is an elution profile for the separation of liposome associated from
free AR-67 on passage through a mini-Sephadex G-25 column such as that typically
employed for separating free from encapsulated drug. The relatively small free drug peak
(after 20 ml) compared to the drug peak in the liposome fraction eluting within 5 ml
suggests that nearly all of the drug eluted in the liposome fraction. However, the passive
loading technique used to prepare these liposomes should have led to no more than about
50% entrapment for a highly membrane bound drug, because approximately 50% of the
bound drug should reside on the outer bilayer leaflet. Indeed, simultaneous fitting of the
release data in Figure 4.2B indicated an initial unentrapped percentage in the drug-loaded
liposomal suspension of 30 ± 14 %.
The efficiency of separation of free from encapsulated or membrane bound drug in a
Sephadex column will be determined by several factors including the membrane/water
partition coefficient, the sample load applied to the column, and the number of theoretical
plates. Previously, Joguparthi et al obtained a value of 𝐾𝑝 =2440 ± 230 for the partition
coefficient of AR-67 with DSPC liposomes (187). To explore the possibility that external
liposome binding may reduce separation efficiency, we conducted a spiking experiment
using dexamethasone and DPPC liposomes. The partition coefficient for dexamethasone
binding to DPPC liposomes is 𝐾𝑝 =106 (188), much lower than that for AR-67 with

DSPC liposomes. Blank DPPC liposomes were spiked with Dex solution and 0.5 ml of
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this suspension was immediately added to a Sephadex column and eluted with PBS (pH
7.4). Figure 4.3B shows that about 40% of the added drug was associated with the
liposome (first 5 ml) while the remaining drug continued to elute from the column over
the next 15-20 min. Given that, as shown in the next sections, the half-life for Dex release
from DPPC liposomes is ~ 4 hr, it is most likely that the high apparent concentration for
entrapped Dex in this spiking experiment is due to binding to the outer leaflet of DPPC
liposomes. These results justify the need to include a parameter to allow for an initial
concentration of unencapsulated drug in fitting release data even after a Sephadex
treatment.
Determination of Release Kinetics of Dex from DMPC liposomes
Dexamethasone is a non-ionizable corticosteroid having a log P= 2.03 and an aqueous
solubility of 0.035 mg/ml (ACD/Labs V11.02). Initially, release kinetics of Dex
encapsulated in DMPC liposomes were evaluated by dynamic dialysis in a manner
similar to that described previously for AR-67 at pH 4.2. That is, drug loaded liposomal
release was compared to that for blank liposomes spiked with Dex.

A parallel

experiment with an aqueous Dex solution was also included (Figure 4.4A). Unlike AR67, the release profiles of Dex from loaded and spiked liposomes were virtually
indistinguishable at a lipid concentration of ~13.9 mg/ml. A possible explanation for the
similarity between drug loaded and spiked profiles was that entrapped drug release is
relatively rapid. Simultaneously, the significant deviation of the spiked from free drug
profile suggests that Dex binding to the liposomal bilayer reduces the driving force for
Dex transport across the dialysis membrane.
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Figure 4.3 (A) Elution profiles of free and liposomal entrapped AR-67 (Kp=2440) as
determined by HPLC after passing 0.1 ml through Sephadex G25 and eluted with acetate
buffer (85 mM, pH 4.2). (B) Elution profile of blank liposome spiked with Dex (Kp=106)
after passing 0.5 ml through Sephadex G25 and eluted with PBS (pH 7.4).
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The influence of liposomal membrane binding on the apparent release kinetics can be
minimized by reducing the lipid concentration. To probe this, release experiments were
repeated at lower lipid concentrations (~4.6 mg/ml) in Figure 4.4B. This caused a
significant increase in the apparent rates of drug release from both drug loaded and
spiked liposomes. Also noteworthy, the concentration vs. time profiles for spiked
liposomes and free drug solution nearly overlap with virtually identical terminal slopes.
This suggests that the effect of drug binding to liposomes on the driving force for dialysis
membrane transport has been minimized and nearly eliminated at this lower lipid
concentration. Nevertheless, it is unclear from a visual examination of Figure 4.4B
whether or not there is sufficient information content to enable a reliable estimation of the
effective rate constant for liposomally entrapped drug release.
Before attempting to apply more sophisticated modeling to data such as those displayed
in Figure 4.4, the rate constant for Dex transport across the dialysis membrane, kd, was
examined by determining the disappearance of free Dex from solution in six independent
experiments with different dialysis tubes having a molecular weight cut-off of 100 kD
(Figure 4.5). The observed biphasic profile obtained suggests non-instantaneous
reversible binding or partitioning of the drug in the dialysis membrane, which was
incorporated into the mathematical model by replacing Eqn. 4.4 with Eqns. 4.5 & 4.6.
The data in Figure 4.5 highlight the potential importance of monitoring free drug
disappearance over a sufficient time frame to capture the relevant contribution of the
dialysis membrane transport and binding to the overall release processes of interest.
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Figure 4.4 Release profiles of Dex in DMPC liposomes at 25°C using dynamic dialysis
method. (A) Release profiles of drug loaded and blank liposomes spiked with Dex at high
lipid concentration (~13.9 mg/ml) along with free drug profile (B) Release profiles of
drug loaded and blank liposomes spiked with Dex at low lipid concentration (~4.6
mg/ml) along with free drug profile. DL stands for drug loaded liposomes. HL and LL
represents high and low lipid concentrations respectively.
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Comparison of Dex Binding and Release from DMPC, DPPC, and DSPC liposomes
While the impact of drug binding to the nanoparticle on the apparent release kinetics can
be probed by the studies described above, the actual quantitative determination of binding
constants might be best obtained separately to avoid introduction of another fitted
parameter in the transport models described in Eqs. 4.1-4.6.

To better understand and

quantify the role of membrane binding in modulating the apparent release kinetics, the
partition coefficients of Dex in DMPC, DPPC and DSPC liposomes was determined. The
values obtained by equilibrium dialysis at 25°C were 705±24 in DMPC, 106±11 in DPPC
and 57±9 in DSPC liposomes (188) as displayed graphically in Figure 4.6.
Further, the range of release rates from liposomes that can be reliably determined by
dynamic dialysis was determined by including studies employing DPPC and DSPC to
take advantage of the expected reduction in release rates accompanying the higher acyl
chain ordering present in these longer chain lipids as detailed in the barrier domain model
for lipid bilayer permeability previously (131, 189). Release profiles at 25°C generated
by dynamic dialysis of Dex loaded liposomes and blank liposomes spiked with Dex at
low (~4-5 mg/ml) and high lipid concentrations (~12-15 mg/ml) are compared with those
from free Dex solution in Figure 4.7. The upper panel of Figure 4.7 shows the
comparison of drug loaded liposomal release profiles at low and high lipid concentrations
while the lower panel compares spiked profiles at low and high lipid concentrations in
DMPC, DPPC and DSPC, respectively, along with the free drug profile.
Evident from Figure 4.7 (upper panel) is that differences between the release profiles
from drug loaded liposomes at low and high lipid concentrations (i.e., low vs high
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Figure 4.5 Release profile of free Dex solution across the dialysis membrane (MWCO:
100kD) at 25°C. Average of six independent profiles across six different tubes, error bars
are the standard deviations.
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Figure 4.6 Liposome-water partition coefficient of Dex in DMPC, DPPC and DSPC
liposomes determined by equilibrium dialysis at 25°C.
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Figure 4.7 Release profiles of Dex loaded liposomes, blank liposomes spiked with Dex
and free Dex solution at 25°C. The upper panel compares the release profiles of drug
loaded (DL) DMPC, DPPC and DSPC liposomes at low and high lipid concentration.
The lower panel compares the release profiles of free Dex solution in the absence and
presence of low and high concentrations of liposomes. DL stands for drug loaded
liposomes. HL stands for high lipid concentration (~12-15 mg/ml) and LL stands for low
lipid concentration (~4-5 mg/ml) inside the dialysis tube.
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nanoparticle concentrations) can be related to the partition coefficients observed in these
systems. The largest partition coefficients prevalent in DMPC liposomes resulted in the
greatest difference between the profiles at low and high lipid concentration, in both drug
loaded and spiked liposomes. At high lipid concentrations, drug released from the DMPC
liposomes undergoes relatively extensive external membrane binding inside the dialysis
tube leading to a slower apparent release that is rate-limited by transport across the
dialysis tube. Thus, a dynamic dialysis experiment performed at the highest DMPC
concentration displayed in the upper left panel of Figure 4.7 would erroneously suggest a
liposomal release half-life of ~ 10 hr when in fact it is at least 3-fold less than that. With
a substantial decrease in partition coefficient, the apparent release kinetics become less
sensitive to lipid concentration and in DSPC at a low lipid concentration no influence of
lipid binding can be discerned. Particularly noteworthy, there is no influence of liposome
concentration on the Dex release profiles from drug loaded DSPC liposomes (upper right
panel, Figure 4.7) and the slopes are significantly smaller than those obtained from free
drug solution or from spiked DSPC liposomes (lower right panel, Figure 4.7). These
combined observations provide confidence that a reliable rate constant for Dex release
from DSPC liposomes can be generated by dynamic dialysis.
The value of establishing the free drug permeation across the dialysis membrane in order
to assess its contribution to the kinetic profiles obtained from drug loaded nanoparticles
during dynamic dialysis has been well documented (66, 182, 190, 191) but this may not
be a sufficient control. Although it has also been understood for decades that the rate of
diffusion of small molecules through a dialysis membrane is proportional to the
concentration of the unbound species (192, 193) systematic studies are seldom conducted
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to account for both drug binding to the nanocarrier and its influence on dialysis
membrane transport. The effect can be dramatic for the drugs having high affinity for the
formulation and can be probed by varying the concentration of the carrier particles.
The release profiles from Dex loaded DMPC, DPPC and DSPC liposomes at low and
high lipid concentration were fit simultaneously to the mathematical model represented
by Figure 4.1 and Eqs. 4.2 & 4.5-4.6. The DPPC and DSPC results are shown in Figure
4.8. As discussed earlier, the percentage of unencapsulated drug at time t=0 was included
as a fitted parameter for each system in the model fitting. The values obtained were 31 %
and 53 % at high and low DPPC concentrations, respectively, and 15 % and 20 % at high
and low DSPC concentrations, respectively. To test the reproducibility of the release
profiles generated by dynamic dialysis and to confirm that the variation observed in
release profiles with changes in lipid concentration was not due to variability of the
method, the release profiles from Dex loaded DPPC liposomes were determined in
triplicate, at both low and high lipid concentrations along with free drug. Six drug loaded
profiles in DPPC when fitted simultaneously gave an intrinsic rate constant (km) of 2.13 ±
0.43 h-1 (95% confidence interval) while that obtained from simultaneous fitting of
average profiles at high and low lipid concentrations was 2.08 ± 0.36 h-1. The effective
rate constant for liposomal release that takes into account the effect of intravesicular
binding on the driving force (kmαi) was 0.17 h-1 corresponding to the half-life of 4.2 hrs
for release from DPPC liposomes. Similarly, the intrinsic rate constant obtained from
simultaneous fitting of profiles of Dex loaded DSPC liposomes was 0.43 ± 0.08 h-1 and
kmαi was 0.05 h-1, yielding a half-life of 13.6 hrs. While the same modeling approach
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Figure 4.8 Release profiles of Dex across DPPC (A) and DSPC (B) liposomes at high and
low lipid concentrations along with the free drug profile determined using dynamic
dialysis method. Each of the three profiles in (A) is the average of three independent
experiment and the error bars represent the standard deviation. DL stands for drug loaded
liposomes. HL and LL represents high and low lipid concentrations respectively.
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also fit the DMPC data, the 95% confidence limits for km in DMPC were too large (8.2 ±
12 h-1) to allow a reliable estimate of km in that system.
Determination of the Intrinsic Permeability Coefficient using Dynamic Dialysis Method
A significant advantage of mathematical modeling of dynamic dialysis data is that it
enables the determination of the true apparent release half-life from the nanocarrier – the
value that is expected under true sink conditions. Another advantage of the approach for
liposomal systems is that when combined with measured liposome/water partition
coefficients it enables the calculation of the intrinsic permeability coefficient of the drug
from the intrinsic rate constant, km. This is possible because both the intra- and
extravesicular unbound species concentrations are determined. These are the quantities
that constitute the driving force for permeation across the bilayer. Accordingly, the
intrinsic permeability coefficient of AR-67 across DSPC bilayers was calculated from the
fitted km of 44.3 hr-1 value at pH 4.2 (Figure 4.2B) to be 3.7 x 10-8 cm/sec, using the
following relation:
𝑘𝑚 =

𝑃𝑚 𝐴 3𝑃𝑚
≅
𝑉𝑖
𝑅

where km is the intrinsic first-order rate constant for drug release from liposomes, A and
R are the area and radius of the liposome, respectively, and Vi is the total intravesicular
volume. Permeability coefficients calculated from the fitted km values of 2.0 hr-1 and 0.43
hr-1, for the release of Dex from DPPC and DSPC liposomes are 1.8 x 10-10 cm/s and 8.9
x 10-10 cm/s, respectively.

92

Exploration of the Variable Space - Simulations
Effect of Lipid Concentration: Extravesicular Binding
Model simulations were conducted to show the effect of lipid (i.e., liposome)
concentration on the observed release kinetics for drugs with varying binding affinity and
a constant intrinsic permeability (Figure 4.9). For these simulations, a constant km of 32
hr-1 was assumed, corresponding to a situation where, in the absence of significant
intravesicular binding, the drug release rate from liposomes would be too fast to measure
(recall that kd for dialysis membrane transport in the experiments discussed previously in
this paper was on the order of 1 hr-1). Thus, for Kp=60 (Figure 4.9, left panel), the overall
drug release is dialysis membrane rate-limited regardless of lipid concentration and no
information regarding the release rate from the nanoparticles can be obtained by dynamic
dialysis under these conditions. With higher Kp values (700 and 2440, corresponding to
values for Dex in DMPC and AR-67 in DSPC liposomes, respectively), the effect of lipid
concentration is more dramatic. This can be attributed to the substantial amount of
extravesicular membrane bound drug inside the dialysis tube and the reduction in driving
force across the dialysis membrane that accompanies this binding. Figure 4.10A provides
estimates of the increases in extravesicular bound fraction accompanying increases in
lipid concentration in the dialysis tube for drugs with different partition coefficients. For
example, for a drug with moderate binding affinity (Kp=700), almost 70% drug is bound
extravesicularly at a lipid concentration of 10 mg/ml. Both Figure 4.9 (center and right
panels) and Figure 4.10A illustrate the importance of using low nanoparticle
concentrations when the drug binding affinity is high. For example, Figure 4.9 shows
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that lipid concentrations <0.5 mg/ml are necessary to minimize the confounding influence
of nanoparticle binding within the dialysis tube when the binding affinity is high.
Effect of Intravesicular Binding
Liposomes differ from other matrix type nanoparticles (e.g., solid lipid nanoparticles,
polymer micelles, etc.) in that there is an aqueous core. The aqueous core concentration
of the membrane permeable species, which provides the driving force for drug release,
may be substantially reduced by intravesicular membrane binding. Drugs having a high
liposome/water partition coefficient (Kp) may be mostly bound to the intravesicular
membrane due to the high membrane surface to aqueous core volume ratio. Figure 4.10B
illustrates the decrease in intravesicular free drug fraction with an increase in partition
coefficient. Notably, this quantity is not affected by the liposome concentration but the
free drug fraction for a given Kp does decrease with a decrease in size of the liposome
(132). Intravesicular membrane binding as reflected in the value of αi reduces the
effective rate constant (km·αi) across the bilayer (Eq. 4.2).
Simulations at a low lipid concentration (0.5 mg/ml) to minimize the impact of
extravesicular binding and varying intrinsic rate constants (km) are shown in Figure 4.11
at three values of Kp. Consider the curve representing the release profile maximally
separated from that of a solution of the free drug in each panel. With an increase in Kp,
there is a corresponding systematic increase in the intrinsic rate constant, km, or bilayer
permeability that can be clearly differentiated from the free drug profile. . In other words,
for a drug with low partition coefficient (Kp=52), an apparent half-life of approximately 7
hours is obtained when the intrinsic rate constant (km) is about 1 h-1; for a drug with Kp of
700, a similar half-life is obtained with km of 10 h-1 while for a drug with very high Kp
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Figure 4.9 Simulations showing the effect of the liposome/water partition coefficient on
the observed release kinetics from 90 nm liposomes at varying lipid concentrations
(km=32).
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Figure 4.10 Simulations for extravesicular bound and intravesicular free fractions with
increasing lipid concentration and different membrane-water partition coefficients in 90
nm liposomes.
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Figure 4.11 Simulations showing the effect of the liposome/water partition coefficient on
the observed release kinetics from 90 nm liposomes at varying intrinsic rate constants
(Lipid concentration=0.5 mg/ml).
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(2440), the same half-life is obtained for a km of more than 32 h-1. Thus, in the case of
liposomes, a high partition coefficient can be advantageous in slowing the transport rate
from liposomes by reducing the intravesicular driving force. If extravesicular binding
can be minimized by using a low liposome concentration, dynamic dialysis may still
provide a reliable measurement of the effective release rate constant.
The above observations can be used to rationalize why an intrinsic rate constant for
liposomal release could be determined for AR-67 in DSPC liposomes but not for Dex in
DMPC liposomes. AR-67, a highly hydrophobic compound in its lactone form (pH 4.2),
has a significantly higher Kp in DSPC compared to Dex in DMPC (> 3 times greater).
Yet, an intrinsic rate constant and permeability coefficient for AR-67 was determined
using the same dynamic dialysis method as that failed for Dex in DMPC. One principal
reason for this is the lower intravesicular driving force for AR-67 due to its high
intravesicular membrane binding. Also, a lower liposome concentration (0.48 mg/ml)
was possible for the AR-67 release study as compared to Dex in DMPC (4.6 mg/ml) due
to the higher sensitivity of the fluorescent method of analysis employed for AR-67.
Therefore, extravesicular binding effects were nearly negligible for AR-67.
The simulated effect of liposome concentration on the dynamic dialysis profiles for AR67 is shown in Figure 4.12.

A lipid concentration of 0.48 mg/ml was a suitable

concentration for optimizing the separation of the drug loaded and spiked release profiles.
Below this concentration, the profiles did not change significantly but above this
concentration slowing of the apparent kinetics was observed along with the decrease in
the gap between the drug loaded and spiked profiles
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Figure 4.12 Simulations of the effect of lipid concentration on the dynamic dialysis
profiles for AR-67 from drug loaded (DL) and blank liposomes of DSPC spiked with the
drug (Kp=2440).
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Considering the above observations, it follows that before inferring that a given drug
release profile obtained by dynamic dialysis truly reflects the rate of release from the
nanoparticle formulation and not an artifact due to rate-limiting dialysis membrane
transport, perhaps resulting from high extravesicular membrane binding of the drug, one
of the following validation experiments should be undertaken: (a) evaluate the profiles
obtained from a free drug solution and drug-spiked nanoparticle suspension at the same
nanoparticle concentration as the drug-loaded nanoparticle system. Nanoparticle binding
effects can be considered negligible at the nanoparticle concentration explored if the
kinetic profiles are the same; (b) alternatively, release profiles from drug loaded
nanoparticles should be generated at different dilutions and compared with the profile
obtained from a free drug solution. If the drug-loaded system release profiles at different
dilutions are not significantly different from each other but significantly slower than the
free drug profile, then the effect of nanoparticle binding can be ignored and a reliable
effective rate constant for nanoparticle release can be determined by application of the
appropriate model.
Effect of the Dialysis Membrane
The cellulose ester dialysis membranes employed in these studies had a molecular weight
cut-off (MWCO) of 100 kD but membranes having a MWCO up to 1000 kD are
available from the manufacturer (Spectrum Labs). Membranes having a MWCO between
12-15 kD or smaller have been commonly used in the literature (181, 194-200). MorinoBautista and Tam (181) demonstrated that the smaller the pore size (or MWCO), the
higher the resistance offered by the membrane to the diffusion of small solutes
(specifically, procaine hydrochloride). Thus, the initial rate of diffusion of procaine was 7
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times greater across a 10 kD membrane in comparison to a 2 kD MWCO membrane.
Considering that the dialysis membrane should be selected with a maximum possible
pore size to maximize the rate of diffusion of the drug molecule while serving as a barrier
to the carrier, a 1000 kD MWCO may be feasible for nanoparticles in the 100 nm size
range.
Three-Dimensional Response Surfaces: Reliability of Results from Dynamic Dialysis
As dictated by the principles of chemical kinetics, the rate determining step governs the
rate of an overall reaction. In dynamic dialysis, this principle can be relied upon to
unambiguously determine the nanoparticle release rate constant when the rate of transport
across the dialysis membrane far exceeds that for nanoparticle release. For liposomes,
this situation is most likely realized for polar or ionized drugs that have relatively low
membrane permeabilities and negligible membrane/water partition coefficients. In many
instances, there may be no single process that is so predominant that it completely
determines the rate of drug disappearance from the dialysis chamber, yet there may be
sufficient information content in the concentration versus time profile to obtain a reliable
rate constant for nanoparticle release even using a simple first-order fit.
In the above paragraphs, the effect of lipid concentration, partition coefficient and the
intrinsic rate constant on the observed release kinetics from liposomes using dynamic
dialysis was demonstrated. Figs. 4.13A and B systematically define in a 3-dimensional
plot the intrinsic liposomal release rate constants and apparent liposomal release halflives that can be reliably determined by a simple first-order kinetic treatment of dynamic
dialysis data as a function of the membrane/water partition coefficient and lipid
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Figure 4.13 Three dimensional surface plots showing the boundary intrinsic rate
constants (A) and release half-lives (B) that can be reliably determined in liposomal
systems under the given conditions of lipid concentration inside the dialysis tube and the
membrane-water partition coefficient of the drug. The values below the surface can be
determined by dynamic dialysis and simple first order fit with 80% accuracy. The
experimental error is not included and there has been no provision in the simulations for
the presence of unencapsulated drug at t=0.
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concentration employed in the experiment. The intrinsic rate constant and apparent
liposomal release half-life were deemed to be determinable by dynamic dialysis and a
first-order treatment if the fitted constant from a first-order fit was within ± 20% of the
input value.
Figure 4.13A shows the impact of intra- and extravesicular binding on what intrinsic rate
constant can be reliably estimated. If the effects of extravesicular binding can be
minimized by using the lowest possible lipid concentration, then a reliable estimate can
be obtained even for a drug having a relatively high intrinsic liposomal release rate
constant and a high membrane/water partition coefficient by a simple first order model.
Figure 4.13B shows the effect of extravesicular binding on the determination of apparent
half-lives. With an increase in partition coefficient and lipid concentration, relatively
slower apparent rate constants or longer release half-lives are required for the accurate
estimation by this method. The values of the intrinsic rate constants and half-lives that
can be determined with 80% accuracy using dynamic dialysis and a simple first order
model in the absence of experimental error are those below the response surfaces shown
in Figs. 4.13A and B. For example, for a drug with a dialysis membrane transport halflife from solution of 0.7 h, a Kp of 60, and at a liposome concentration of 0.2 mg/ml, a
minimum half-life of 3.5 hr can be determined with an 80% accuracy by dynamic dialysis
using a simple first-order fit.
The simulations shown in Figure 4.13 have not included experimental errors nor have the
effects of the presence of a certain fraction of unencapsulated drug at the start of an
experiment been taken into account. An appropriate mechanism-based mathematical
model treatment, such as that described in this study, would extend the region in which
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reliable intrinsic rate constants and apparent release half-lives could be determined from
real data. Then, the decision as to reliability should be based on the 95% confidence
limits of the parameters of interest.
CONCLUSIONS
In the early literature, dynamic dialysis became a useful and well validated technique for
studying protein binding of small molecules because the rate of transport could be
correlated to the extent of protein binding. The principle was based on the change in the
permeation rate of the small molecule across the dialysis membrane with the change in
the free fraction (or fraction bound) inside the dialysis chamber (192, 193). The
application of the dynamic dialysis method for determining release kinetics from
nanoparticles seems to have grown in popularity in part due to the willingness of
investigators to ignore such binding effects. With ever increasing research efforts in the
field of nanoparticles as drug delivery systems, it is critical to understand the limitations
of this widely adopted dynamic dialysis method for determination of release kinetics.
With experiments and simulations, the various scenarios were demonstrated where the
interpretation of release data using dialysis can be either straightforward or completely
misleading. As shown in this study, consideration of the binding affinity of the drug to
the nanoparticles, appropriate control experiments, and suitable mechanism-based
mathematical treatment of the data should aid in the judicious use of the dialysis method
for determination of the release kinetics from nanoparticles.

Copyright © Sweta Modi 2013
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CHAPTER FIVE
Enhanced Active Liposomal Loading of a Poorly Soluble Ionizable Drug Using
Supersaturated Drug Solutions
INTRODUCTION
Liposomes are attractive delivery systems in cancer therapy because of their potential to
passively target solid tumors (33, 44, 170, 201, 202). However, in order for liposomes to
be useful from a practical standpoint for antitumor therapy in patients, maximum drug
loading and optimization of drug retention and release rates are likely to be necessary
(39, 203-205). Liposomal drug loading can be achieved by either passive or active
methods. In passive loading, liposomes are formed in the presence of a solution of the
drug to be loaded; in active loading, drug internalization occurs into preformed liposomes
typically driven by a transbilayer pH gradient which in turn produces a chemical potential
gradient, of the unionized, permeable form of the drug across the bilayer. Active loading
has been proven to be more effective for achieving higher drug to lipid ratios compared
to the passive loading method (39, 44).
Several reports (47, 48, 84, 206-208) on different active loading methods have
emphasized the dependence of loading on experimental conditions such as
transmembrane pH gradient, membrane-water partitioning, internal buffering capacity,
aqueous solubility of the drug, lipid composition, etc. Zucker et al (48) developed a
decision tree by computational data mining to qualitatively predict loading efficiency
(i.e., low, medium, or high) based on loading conditions and the drug`s physicochemical
properties. As described in their model, good aqueous solubility of the drug is one of the
requirements for efficient active loading. High drug-to-lipid ratios are more difficult to
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achieve for drug candidates exhibiting poor aqueous solubility because the mass flux
across the bilayer is governed by the extra-liposomal concentration of the permeating
species as well as its permeability coefficient. Extremely low drug solubility reduces the
external driving force for liposomal uptake during active loading leading to low final
drug-to-lipid ratios.
In this paper, the use of supersaturated drug solutions to facilitate active liposomal
loading by the pH-gradient method was explored in order to overcome the
aforementioned limitations in actively loading poorly soluble drugs. A highly lipophilic
and poorly water soluble camptothecin analogue (AR-67, 7-t-butyldimethylsilyl-10hydroxycamptothecin) served as a model compound for this study. AR-67 is a novel,
blood-stable camptothecin analogue currently in phase II clinical trials in patients with
brain cancer (75, 79, 209). It possesses an α-hydroxy-δ-lactone moiety that undergoes
pH-dependent chemical hydrolysis to ring-opened carboxylate form (75, 79, 80), a
property that can be exploited for active loading. It was demonstrated that active loading
coupled with methods to create and maintain drug supersaturation can dramatically
enhance drug-to-lipid ratios for this poorly soluble drug. A mathematical model taking
into account the various intra- and extra-liposomal ionic and binding equilibria and
permeability coefficients has been developed to predict the rate and extent of active drug
loading. Quantitative comparison of the experimental results with the predictions from
this mechanism-based model should advance understanding of these complex
phenomena.
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MATERIALS AND METHODS
DSPC (1,2-distearoyl-sn-glycero-3-phosphatidylcholine, >99% purity) and m-PEG DSPE
(1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)2000] (MW=2806, >99% purity) were purchased as powders from Avanti Polar Lipids
(Alabaster, AL). AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) was obtained
from Novartis Pharmaceuticals Corporation (East Hanover, NJ). Dialysis tubes (Float-ALyzer®, MWCO: 100 kD) were purchased from Spectrum Laboratories (Rancho
Dominguez, CA). Sulfobutyl ether β-cyclodextrin sodium salt (SBE-CD, Captisol®)
having an average degree of substitution of 7- sulfobutyl ether residues per βcyclodextrin molecule was purchased from CyDex Pharmaceuticals, Inc. (Lenexa,
Kansas). All other reagents and HPLC grade solvents were purchased from Fisher
Scientific (Florence, KY). Deionized water was used for all experiments.
Passive Loading
Liposomes were prepared based on a previously reported method (132). Briefly, DSPC
and mPEG-DSPE (95:5 mol%, 32 mg) were dissolved in 2 ml of chloroform. The solvent
was evaporated under a stream of nitrogen while rotating the container and the resulting
thin film was dried overnight in a vacuum oven at 40°C. For preparation of liposomes at
pH 9.5, 2 ml of 100 mM borate buffer (pH 9.5) containing AR-67 (1-1.5 mM) was added
to the dried lipid film to give a lipid concentration of 16 mg/ml. After alternate vortexing
and heating at 60°C in a water bath to uniformly suspend the lipid, the lipid suspension
was extruded 10 times through two stacked 200 nm polycarbonate membranes (GE water
and Process Technologies, Trevose, PA) using an extrusion device (Liposofast®,
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Avestin, Canada) at 60°C to obtain large unilamellar liposomes. Drug loaded liposomes
were allowed to cool to room temperature for 3 hours and stored at 4°C until further use.
Active Loading Methods
Dried DSPC:mPEG-DSPE (95:5 mol%, 120 mg) lipid films, prepared as described
above, were hydrated with 2 ml of 0.25 M calcium acetate solution or 0.5 M sodium
acetate solution to produce a lipid concentration of 60 mg/ml. Alternate vortexing and
heating at 60°C followed by the same extrusion process described above provided
unilamellar liposomes. Following their preparation, blank vesicles were allowed to cool
to room temperature and dialyzed against 1 L of 0.9% NaCl solution at room temperature
for about 2 hours to remove the extravesicular calcium or sodium acetate and create a pH
gradient. Active loading was carried out either in the presence of excess solid AR-67 or
in the presence of supersaturated AR-67 solutions, at pH 7.5 and at two different
temperatures, 37°C and 60°C. Two methods were employed to produce and maintain
supersaturated solutions of AR-67, as described below:
Supersaturation Method I
AR-67 was solubilized by adjusting a 0.1 mg/ml suspension to a high pH (10.5-11) by
adding 1 M NaOH with continuous stirring followed by readjustment to pH 7.5 by
addition of 1 M HCl at either 37°C or 60°C to achieve supersaturation. Thereafter, on
each occurrence of precipitation (approximately every 6 hours) pH was again raised to
redissolve the precipitated drug followed by readjustment to pH 7.5.
Supersaturation Method II
Aliquots of a filtered (0.2 µm, PVDF syringe filter) 20 mg/ml AR-67 stock solution in
0.1 N NaOH were added into a 2% SBE-CD solution containing HEPES buffer (3 mM)
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in 0.9% NaCl and adjusted to pH 7.5 with dilute HCl to produce supersaturated loading
solutions at varying total drug concentrations (0.1, 0.2, 0.4 and 0.6 mg/ml). These
solutions were at varying degrees of supersaturation (𝐷𝑆 = 𝐶/𝐶𝑠): 3.8 for 0.1 mg/ml, 7.5
for 0.2 mg/ml, 15.1 for 0.4 mg/ml and 22.7 for 0.6 mg/ml where 𝐶 is the total

supersaturated solution concentration and 𝐶𝑠 is the equilibrium solubility of AR-67 in the

presence of 2% SBE-CD at pH 7.5. Degrees of supersaturation higher than that
represented by a total drug concentration of 0.6 mg/ml could not be sustained over the
desired loading period.
Liposomal suspensions (1 mL) in dialysis tubes were dialyzed for 48 hours
(supersaturation was maintained for 48 hours by method II) at 37°C in the supersaturated
drug loading solutions (200 mL). During loading, 10 µl samples were withdrawn from

inside the dialysis tube at various time points and diluted with 900 µl of cold (-25°C) 2:1
v/v methanol:acetonitrile to stop the interconversion between lactone and carboxylate.
The samples were stored at -25°C until further analysis by HPLC. Loading studies at the
lowest (0.1 mg/ml) (n=3) and highest (0.6 mg/ml) (n=4) drug concentrations in loading
solution were repeated to test the reproducibility of the loading process. The loading
study at the highest drug loading solution concentration (0.6 mg/ml) was also repeated
using 0.5 M sodium acetate (rather than calcium acetate) liposomes to assess the role of
the entrapped cation, if any, in the rate and extent of drug loading. The total drug
concentration in the liposomal suspension inside the dialysis tube was analyzed for the
loading experiments. These concentrations were then fitted to the model (derived in the
mathematical model section) to obtain intravesicular drug concentrations. The drug-tolipid ratios reported were calculated from these intravesicular drug concentrations.
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Studies of AR-67 uptake into the dialysis tubes were also carried out in the absence of
liposomes at the same pH, with and without cyclodextrin in the bulk loading solution, to
determine the rate constants for free and cyclodextrin-complexed drug transport across
the dialysis membrane. For determination of kd (rate constant for the reversible transport
of AR-67 across the dialysis membrane), dialysis tubes containing 1 ml of HEPES buffer
(3 mM) in 0.9% NaCl adjusted to pH 7.5 with dilute HCl were placed in 200 mL of AR67 solution (at 0.1, 0.05 and 0.05 mg/ml) in the same buffer solution and the AR-67
concentration inside the tube versus time was monitored. Simultaneous first-order fits of
the three experiments were conducted to generate kd. Two additional uptake experiments
(without liposomes) were conducted in the same buffers but also containing 2% SBE-CD
at AR-67 concentrations of 0.2 and 0.6 mg/ml to generate Kdcd (rate constant for the
transport of SBE-CD and SBE-CD/AR-67 complexes across the dialysis membrane).
AR-67

Equilibrium

Solubility

and

SBE-CD

Complexation

Constants

Determinations
The equilibrium solubility of AR-67 was determined at 37°C and pH 6.5, 7.0 and 7.5 in
the presence of 0, 1, 2, and 3% SBE-CD to determine the lactone and carboxylate
monoanion complexation constants with SBE-CD and to use in calculations of degree of
supersaturation achieved in loading solutions. Briefly, 2-4 mg of AR-67 was added to 4
ml of 10 mM MES buffer (pH 6.5) or HEPES buffer (pH 7.0 and 7.5) containing 0, 1, 2
and 3% SBE-CD. The vials were rotated in an incubator at 37°C. At different time points,
1 ml of sample was withdrawn using a needle and syringe and filtered through 0.45 µ
PVDF syringe filters (13 mm). A filter adsorption study was carried out and subsequently
the first 6-7 drops of filtrate were discarded before collecting filtrate for analysis. Filtrate
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was diluted with cold (-25°C) 2:1 v/v methanol: acetonitrile, when required. Three
independent samples were analyzed by HPLC at each condition and time point.
Equilibrium was considered to have been established when two subsequent time points
yielded similar values (8-12 days).
Particle Size Measurements
Particle sizes of blank and drug loaded liposomes were measured by dynamic light
scattering (DLS) using a Delsa™ Nano submicron particle size analyzer (Beckman
Coulter Inc., Brea, CA) at 25°C. The liposomes were diluted in the same buffer as that
used in their preparation.
HPLC Analyses
Samples from equilibrium solubility experiments and liposome loading experiments were
analyzed using a previously developed and validated isocratic HPLC method with
fluorescence detection (126, 132). Standards for AR-67 carboxylate (0.2-2 µM) were
prepared in 10 mM sodium carbonate buffer (pH 10.4) and standards for AR-67 lactone
(0.5-2.5 µM) were prepared in acidified methanol. A Waters Alliance 2695 Separations
Module coupled to a Waters Scanning Fluorescence Detector (M474) was employed with
excitation and emission wavelengths at 380 and 560 nm, respectively. A Waters
Symmetry® C18 column (5 µm, 3.9 X 150 mm) and guard column (3.9 X 20 mm) were
used with a mobile phase composition of 48% acetonitrile and 52% (v/v) pH 5.5
triethylamine acetate (2%) buffer. The retention times at an injection volume of 10 µl and
a flow rate of 1 ml/min were 1.7 and 5.9 min for AR-67 carboxylate and lactone,
respectively. Generally, unless otherwise specified, AR-67 concentrations reported in the
“Results” section refer to total concentrations considering all drug species.
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MATHEMATICAL MODEL
A mathematical model was developed for AR-67 uptake into calcium acetate vesicles,
taking into account the chemical equilibria inside and outside the vesicle, mass balance,
charge balance, and the transport kinetics of various permeable species across both the
dialysis membrane and the liposome bilayer. Built into the model were the concentrations
of various components, ionization constants, the different solution complexes present and
their association/dissociation constants, binding constants for each species of AR-67 with
the lipid bilayer, and permeability coefficients for the transport of permeable species
across the dialysis membrane (including all AR-67 species, SBE-CD and AR-67/SBECD complexes) and the lipid bilayer (i.e., AR-67 lactone and acetic acid).
AR-67 may exist in a combination of four different species at any given pH (Figure
5.1A). While the lactone (I) is considered to be the therapeutically active form, it exists in
reversible equilibrium with its ring-opened carboxylate form under physiological
conditions (76, 210). The fraction of the unionized ring-opened (carboxylic acid, II)
species has been shown to be negligible in solution (211) and therefore an effective pKa
for simultaneous ring-opening and ionization, denoted by 𝐾𝑎 (𝐾𝑎 = 𝐾 ∗ 𝐾𝑎1 ) of the E-

ring lactone, can be employed. The various equilibria (ionization, complexation,
membrane partitioning, etc.) and transport processes governing liposome uptake from the
aqueous solution inside the dialysis tube are shown in Figure 5.1B. The concentrations of
the various species in the extravesicular solution inside the dialysis tube are also
governed by their reversible transport across the dialysis membrane separating the
contents within the dialysis tube from the external loading solution. These processes
were also built into the mathematical model. The assumptions of the present model are:
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(a) the lipid bilayer permeabilities of ionized species are negligible while both neutral and
charged drug species cross the dialysis membrane with equal permeability coefficients;
(b) SBE-CD and its complexes with AR-67 undergo transport across the dialysis
membrane with identical permeability coefficients but liposomal uptake of these species
is negligible; and c) an instantaneous equilibrium exists between the various species
inside the vesicle during the loading process (126, 132, 187). All of the ionization
constants and equilibrium constants for membrane binding of AR-67 were taken from
previously published results (126, 132, 187, 212, 213). The permeability value for AR-67
lactone across the liposome was determined from model fitting of experimental data
under various loading conditions. The rate constants for free and bound drug transport
across dialysis tube were also determined experimentally.
Establishment of the pH gradient
During dialysis of calcium acetate (or sodium acetate) containing vesicles, some of the
entrapped acetate is released due to the diffusion of unionized acetic acid across the
liposome bilayer, resulting in an increase in the intraliposomal pH. AR-67 uptake is
accompanied by efflux of additional acetic acid, resulting in the maintenance of a high
intraliposomal pH as a function of time during drug loading.
The changes in acetate concentration in the intra- and extravesicular compartments due to
the reversible transport of unionized acetic acid can be described by the following rate
equations:
𝑑𝐶𝑖 3𝑃𝑚𝑎
(𝑓 𝐶 − 𝑓𝑖 𝐶𝑖 )
=
𝑑𝑡
𝑅 𝑜 𝑜

𝑑𝐶𝑜 3𝑃𝑚𝑎
(𝑓 𝐶 − 𝑓𝑜 𝐶𝑜 )
=
𝑑𝑡
𝑥𝑅 𝑖 𝑖
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(5.1𝑎)
(5.1𝑏)

𝐻𝑖+ 𝐾2
𝑓𝑖 = +
𝐻𝑖 𝐾2 + 𝐾𝑎𝑎𝑐 𝐾2 + 𝐾𝑎𝑎𝑐 𝐶𝑎𝑖+2
𝑓𝑜 =

𝐻𝑜+
𝐻𝑜+ + 𝐾𝑎𝑎𝑐

(5.1𝑐)

(5.1𝑑)

where 𝐶𝑖 and 𝐶𝑜 are the intra- and extravesicular concentrations of total acetate; 𝑓𝑖 and 𝑓𝑜

are the intra- and extravesicular fractions of the neutral acetic acid species; 𝐻𝑖+ and 𝐻𝑜+ are

the intra- and extravesicular proton concentrations; 𝐾2 is the dissociation constant of the
calcium acetate complex; 𝐾𝑎𝑎𝑐 (1.78 x 10-5) is the ionization constant of acetic acid; 𝐶𝑎𝑖+2

is the intravesicular calcium concentration; 𝑥 is the ratio of extravesicular volume (𝑉𝑜 ) to

the total intravesicular volume (𝑉𝑖 ) within the dialysis tube; 𝑃𝑚𝑎 is the permeability
coefficient of the neutral acetic acid species; and 𝑅 is the radius of the vesicles.

Various calcium complexes were considered in the intraliposomal aqueous compartment.
The intravesicular concentrations of calcium and its complexes with acetate and
hydroxide are given as follows:
𝐶𝑎(𝐴𝑐)+
𝑖

𝐶𝑎𝑖2+ 𝐴𝑐𝑖−
=
𝐾2

𝐶𝑎(𝑂𝐻)+
𝑖 =

𝐶𝑎𝑖2+ =
𝐴𝑐𝑖− =

𝐶𝑎𝑖2+ 𝑂𝐻𝑖−
𝐾1

(5.1𝑒)
(5.1𝑓)

𝐾1 𝐾2
𝐶𝑖 0
−
−
((𝐾1 𝐾2 ) + (𝐾2 𝑂𝐻𝑖 ) + (𝐾1 𝐴𝑐𝑖 )) 2

𝐾𝑎𝑎𝑐 𝐾2 𝐶𝑖
((𝐻𝑖+ 𝐾2 ) + (𝐾𝑎𝑎𝑐 𝐾2 ) + (𝐾𝑎𝑎𝑐 𝐶𝑎𝑖2+ ))
𝐴𝑐𝑜−

𝐾𝑎𝑎𝑐 𝐶𝑜
= +
𝐻𝑜 + 𝐾𝑎𝑎𝑐
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(5.1𝑖)

(5.1𝑔)
(5.1ℎ)

+
where 𝐶𝑎(𝐴𝑐)+
𝑖 and 𝐶𝑎(𝑂𝐻)𝑖 are intravesicular complexes of calcium with acetate and

hydroxide ions respectively; 𝑂𝐻𝑖− is the intravesicular hydroxide ion concentration; 𝐴𝑐𝑖−

and 𝐴𝑐𝑜− are the intravesicular and extravesicular acetate ion concentrations; and 𝐾1 is the
dissociation constant of the calcium hydroxide solution complex. The extravesicular
calcium concentration is considered to be negligible.
Substituting Eq. (5.1g) into (5.1h) and simplifying it to the quadratic form,

where

𝐴𝑐𝑖− =

(−𝐵 ± (√𝐵 2 − 4𝐴𝐶)
2𝐴

𝐴 = 2𝐾1 𝐾2 (𝐻𝑖+ + 𝐾𝑎𝑎𝑐 )

(5.1𝑗)
(5.1𝑗 − 𝑖)

𝐵 = 2𝐻𝑖+ 𝐾1 �𝐾2 2 � + 2𝐻𝑖+ 𝑂𝐻𝑖− �𝐾2 2 � + 2𝐾𝑎𝑎𝑐 𝐾1 �𝐾2 2 � + 2𝐾𝑎𝑎𝑐 𝑂𝐻𝑖− �𝐾2 2 � + 𝐾𝑎𝑎𝑐 𝐾1 𝐾2 𝐶𝑖 0
− 2𝐾𝑎𝑎𝑐 𝐾1 𝐾2 𝐶𝑖

𝐶 = −2𝐾𝑎𝑎𝑐 𝐾2 2 𝐶𝑖 (𝐾1 + 𝑂𝐻𝑖− )

(5.1𝑗 − 𝑖𝑖)

(5.1𝑗 − 𝑖𝑖𝑖)

Solving Eqs. (5.1a)-(5.1j) combined with the appropriate charge balance equation for the
intravesicular compartment using Scientist (Micromath Inc.), the change in intravesicular
pH as a function of time due to release of acetic acid can be estimated.
Active Drug Loading Step
Sink conditions inside the liposomes were created by the high intraliposomal pH (which
results in conversion of AR-67 lactone to its ring-opened carboxylate mono- and di-anion
species) and maintained by acetic acid exchange for the lactone entering the liposome.
Intraliposomal membrane binding of AR-67 further contributed to the maintenance of a
chemical potential gradient for the lactone. Thus, when liposomes were exposed to a
supersaturated AR-67 solution at pH 7.5 the unionized lactone form of the drug
permeated from the external solution into the liposomes in response to its concentration
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gradient. The mathematical model was utilized to simulate the pH and liposomal AR-67
concentration versus time for varying degrees of supersaturation of the drug loading
solution.
Details of the model development are presented below and the relevant constants used in
simulations are given in Table 5.1. The equations were solved using Scientist®
(Micromath Scientific Software, St. Louis, MO) software.
𝑑(𝐼𝑡𝑖 )
= 𝑘𝑚 (𝐼𝑜𝑤 − 𝐼𝑖𝑤 )
𝑑𝑡

(5.2𝑎)

𝑑(𝐼𝑡𝑜 ) 𝑘𝑚 𝑤
(𝐼 − 𝐼𝑜𝑤 ) + 𝑘𝑑 (𝐼𝑏 − 𝐼𝑜𝑤 ) + 𝑘𝑑 (𝐼𝐼𝐼𝑏 − 𝐼𝐼𝐼𝑜𝑤 ) + 𝑘𝑑𝑐𝑑 (𝐼𝑏 𝐶𝐷𝑏 − 𝐼𝑜 𝐶𝐷𝑜 )
=
𝑥 𝑖
𝑑𝑡
+ 𝑘𝑑𝑐𝑑 (𝐼𝐼𝐼𝑏 𝐶𝐷𝑏 − 𝐼𝐼𝐼𝑜 𝐶𝐷𝑜 )

(5.2𝑏)

𝑑(𝐶𝐷𝑡 )
= 𝑘𝑑𝑐𝑑 (𝐶𝐷𝑏 − 𝐶𝐷𝑜 ) + 𝑘𝑑𝑐𝑑 (𝐼𝑏 𝐶𝐷𝑏 − 𝐼𝑜 𝐶𝐷𝑜 )
𝑑𝑡
+ 𝑘𝑑𝑐𝑑 (𝐼𝐼𝐼𝑏 𝐶𝐷𝑏 − 𝐼𝐼𝐼𝑜 𝐶𝐷𝑜 )
𝐼𝑡 =

𝐼𝑡𝑖
+ 𝐼𝑡𝑜
𝑥

(5.2𝑑)

(5.2𝑐)

where, 𝐼𝑡𝑖 is the total intravesicular drug concentration and 𝐼𝑡𝑜 is the total extravesicular
drug concentration; 𝐼𝑖𝑤 and 𝐼𝑜𝑤 are the intravesicular and extravesicular aqueous

concentrations of the lactone form (permeable species) of the drug, respectively; 𝐼𝐼𝐼𝑜𝑤 ,

𝐼𝑜 𝐶𝐷𝑜 , 𝐼𝐼𝐼𝑜 𝐶𝐷𝑜 are the extravesicular free carboxylate, lactone/SBE-CD complex, and

carboxylate monoanion/SBE-CD complex concentrations, respectively; and 𝐼𝑏 , 𝐼𝐼𝐼𝑏 ,

𝐼𝑏 𝐶𝐷𝑏 , 𝐼𝐼𝐼𝑏𝑜 𝐶𝐷𝑏 are the free lactone, free carboxylate, lactone/SBE-CD complex, and

carboxylate monoanion/SBE-CD complex concentrations in the bulk loading solution,
respectively. 𝑘𝑚 is the rate constant for lactone transport through the given lipid bilayer

and 𝑥 is the ratio of extravesicular to intravesicular volume in the dialysis tube, as
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described before. 𝑘𝑑 and 𝑘𝑑𝑐𝑑 are the rate constants for the free drug and cyclodextrin

complexed drug (or free cyclodextrin) across the dialysis membrane, respectively. The
intrinsic permeability coefficient, 𝑃𝑚 , is related to the rate constant for lactone transport

by 𝑃𝑚 = 𝑘𝑚 ∗ 𝑉𝑖 ⁄𝐴 = 𝑘𝑚 ∗ 𝑅 ⁄3 where 𝑅 and 𝐴 are the radius and area of the liposome,
respectively.

The mass balance of total drug inside the liposomes is
𝐼𝑡𝑖 =

𝐼𝑖𝑤 + 𝐼𝐼𝐼𝑖𝑤 + 𝐼𝑉𝑖𝑤 𝐼𝑖𝑚 + 𝐼𝐼𝐼𝑖𝑚 + 𝐼𝑉𝑖𝑚
𝑉𝑖
𝑉𝑖
+
�𝑎 = 𝑤 ; 𝑏 = 𝑚 �
𝑎
𝑏
𝑉𝑖
𝑉𝑖

(5.2𝑒)

where 𝐼𝑖𝑤 , 𝐼𝐼𝐼𝑖𝑤 , 𝐼𝑉𝑖𝑤 are internal aqueous concentrations of lactone, carboxylate

monoanion and carboxylate dianion, respectively; 𝐼𝑖𝑚 , 𝐼𝐼𝐼𝑖𝑚 , 𝐼𝑉𝑖𝑚 are internal membrane
bound concentrations of lactone, carboxylate monoanion and carboxylate dianion,
respectively; 𝑎 and 𝑏 are volume ratios to account for the differences in aqueous and

membrane volumes with respect to the total intravesicular volume; 𝑉𝑖 is the total
liposomally entrapped aqueous volume plus the lipid volume in the inner bilayer leaflet

of liposomes in the suspension; 𝑉𝑖𝑤 and 𝑉𝑖𝑚 are the volumes of the inner aqueous
compartment and inner monolayer in each vesicle, respectively.

Substituting,

𝐼𝑡𝑖 =

𝐼𝑖𝑤 +

𝑤 𝑤
𝐾𝑎𝑤 𝐼𝑖𝑤 𝐾𝑎𝑤 𝐾𝑎2
𝐼𝑖
+
𝐾𝑝1 𝐼𝑖𝑤 + 𝐾𝑝2 𝐼𝐼𝐼𝑖𝑤 + 𝐾𝑝3 𝐼𝑉𝑖𝑤
𝐻𝑖+
(𝐻𝑖+ )2
+
𝑎
𝑏

(5.2𝑓)

𝑤
where 𝐾𝑎𝑤 and 𝐾𝑎2
are the ionization constants of AR-67 in the aqueous phase and

𝐾𝑝1 , 𝐾𝑝2 , 𝐾𝑝3 are the membrane/water partition coefficients of the lactone, carboxylate
monoanion and carboxylate dianion, respectively. The values of all these parameters
𝑤
(𝐾𝑎𝑤 , 𝐾𝑎2
, 𝐾𝑝1 , 𝐾𝑝2 , 𝐾𝑝3) have been determined previously (126, 132, 187, 213).
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Expressing the total intravesicular concentration in terms of free aqueous lactone
concentration,

𝐼𝑡𝑖 = 𝐼𝑖𝑤

⎧1 +
⎨
⎩

𝑤
𝑤
𝐾𝑝2 𝐾𝑎𝑤 𝐾𝑝3 𝐾𝑎𝑤 𝐾𝑎2
𝐾𝑎𝑤 𝐾𝑎𝑤 𝐾𝑎2
𝐾
+
+
+
⎫
𝑝1
𝐻𝑖+ (𝐻𝑖+ )2
𝐻𝑖+
(𝐻𝑖+ )2
+
𝑎
𝑏
⎬
⎭

⎛
𝐼𝑡𝑖 = 𝐼𝑖𝑤 {𝑎𝑖 + 𝑏𝑖 } … ⎜𝑎𝑖 =

1+

⎝

(5.2𝑔)

𝑤
𝐾𝑎𝑤 𝐾𝑎𝑤 𝐾𝑎2
+
𝐻𝑖+ (𝐻𝑖+ )2
; 𝑏𝑖
𝑎

𝑤
𝐾𝑝2 𝐾𝑎𝑤 𝐾𝑝3 𝐾𝑎𝑤 𝐾𝑎2
+
𝐾𝑝1 +
𝐻𝑖+
(𝐻𝑖+ )2 ⎞
=
⎟
𝑏

⎠

(5.2ℎ)

The intravesicular aqueous unbound concentration of lactone can be described in terms of
total intravesicular concentration;
𝐼𝑖𝑤 = 𝑢𝑏𝑖 (𝐼𝑡𝑖 ) … �𝑢𝑏𝑖 =

1
�
𝑎𝑖 + 𝑏𝑖

where 𝑢𝑏𝑖 is the intravesicular unbound fraction of the drug.

(5.2𝑖)

Now, considering the extravesicular drug equilibrium with cyclodextrin and the mass
balance of the total drug in the bulk loading solution,
𝐼𝑡𝑜 =

𝐼𝑜𝑤 + 𝐼𝐼𝐼𝑜𝑤 + 𝐼𝑜 𝐶𝐷𝑜 + 𝐼𝐼𝐼𝑜 𝐶𝐷𝑜 𝐼𝑜𝑚 + 𝐼𝐼𝐼𝑜𝑚
𝑉𝑜
𝑉𝑜
+
�𝑐 = 𝑤 ; 𝑑 = 𝑚 �
𝑐
𝑑
𝑉𝑜
𝑉𝑜

(5.3𝑎)

where, 𝐼𝑡𝑜 is the total extravesicular drug concentration, 𝐼𝑜𝑤 and 𝐼𝐼𝐼𝑜𝑤 are unbound
extravesicular aqueous concentrations of lactone and carboxylate monoanion,
respectively; 𝐼𝑜 𝐶𝐷𝑜 and 𝐼𝐼𝐼𝑜 𝐶𝐷𝑜 are the aqueous concentrations of lactone and

carboxylate monoanion complexes with SBE-CD; 𝐼𝑜𝑚 and 𝐼𝐼𝐼𝑜𝑚 are the membrane bound
extravesicular drug concentrations, respectively; c and d are volume ratios to account for
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the differences in aqueous and membrane volume with respect to the total extravesicular
volume in the dialysis tube; 𝑉𝑜 is the extravesicular aqueous volume along with the
volume of lipid in the outer bilayer leaflet of suspended liposomes in the dialysis tube;

𝑉𝑜𝑚 is the volume of the outer monolayer in each vesicle and 𝑉𝑜𝑤 is the volume of the

extravesicular aqueous compartment in the dialysis tube.

Note: In the mass balance of extravesicular drug concentrations, only lactone and
carboxylate monoanion species are considered because the extravesicular pH was
maintained at pH 7.5 where the concentration of carboxylate dianion species is assumed
to be negligible ( 𝑝𝑘𝑎2𝑤 =8.67).
𝐾𝑐𝑑1

𝐼𝑜𝑤 + 𝐶𝐷𝑜 �⎯� 𝐼𝑜 𝐶𝐷𝑜 … �𝐼𝑜 𝐶𝐷𝑜 = 𝐾𝑐𝑑1 (𝐼𝑜𝑤 )(𝐶𝐷𝑜 )�
𝐾𝑐𝑑2

𝐼𝐼𝐼𝑜𝑤 + 𝐶𝐷𝑜 �⎯� 𝐼𝐼𝐼𝑜 𝐶𝐷𝑜 … �𝐼𝐼𝐼𝑜 𝐶𝐷𝑜 = 𝐾𝑐𝑑2 (𝐼𝐼𝐼𝑜𝑤 )(𝐶𝐷𝑜 )�

(5.3𝑏)

(5.3𝑐)

where, 𝐶𝐷𝑜 is the free extravesicular concentration of SBE-CD and 𝐾𝑐𝑑1 and 𝐾𝑐𝑑2 are the

complexation constants of AR-67 lactone and carboxylate monoanion with SBE-CD,
respectively (experimentally determined in this study).
Substituting Eqs. (5.3b and 5.3c) into Eq. (5.3a),

𝐼𝑡𝑜
𝐼𝑡𝑜 =

𝐼𝑜𝑤 + 𝐼𝐼𝐼𝑜𝑤 + 𝐾𝑐𝑑1 (𝐼𝑜𝑤 )(𝐶𝐷𝑜 ) + 𝐾𝑐𝑑2 (𝐼𝐼𝐼𝑜𝑤 )(𝐶𝐷𝑜 ) 𝐼𝑜𝑚 + 𝐼𝐼𝐼𝑜𝑚
=
+
𝑐
𝑑
𝐼𝑜𝑤 +

𝐾𝑎𝑤 𝐼𝑜𝑤
𝐾𝑐𝑑2 𝐾𝑎𝑤 𝐼𝑜𝑤 𝐶𝐷𝑜
𝐾 𝑤 𝐼𝑤
𝑤
𝐾𝑝1 𝐼𝑜𝑤 + 𝐾𝑝2 𝑎 +𝑜
+ + 𝐾𝑐𝑑1 (𝐼𝑜 )(𝐶𝐷𝑜 ) +
+
𝐻𝑜
𝐻𝑜
𝐻𝑜
+
𝑐
𝑑

𝐼𝑡𝑜 = 𝐼𝑜𝑤 �

1+

𝐾𝑎𝑤
𝐾𝑐𝑑2 𝐾𝑎𝑤 𝐶𝐷𝑜
𝐾𝑎𝑤
+
𝐾
(𝐶𝐷
)
+
𝐾
+
𝐾
𝑐𝑑1
𝑜
𝑝1
𝑝2 +
𝐻𝑜+
𝐻𝑜+
𝐻𝑜
+
�
𝑐
𝑑
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(5.3𝑑)
(5.3𝑒)
(5.3𝑓)

𝐼𝑡𝑜 = 𝐼𝑜𝑤 �

�1 +

𝐾𝑎𝑤
𝐾𝑐𝑑2 𝐾𝑎𝑤
𝐾𝑤
𝐾𝑝1 + 𝐾𝑝2 𝑎+
+ � + 𝐶𝐷𝑜 (𝐾𝑐𝑑1 +
+ )
𝐻𝑜
𝐻𝑜
𝐻𝑜
+
�
𝑐
𝑑

(5.3𝑔)

Considering the mass balance of extravesicular total cyclodextrin,
𝐶𝐷𝑡 = 𝐶𝐷𝑜 + 𝐼𝑜 𝐶𝐷𝑜 + 𝐼𝐼𝐼𝑜 𝐶𝐷𝑜

(5.3ℎ)

where 𝐶𝐷𝑡 is the total concentration of extravesicular cyclodextrin.
𝐶𝐷𝑡 = 𝐶𝐷𝑜 + 𝐾𝑐𝑑1 (𝐼𝑜𝑤 )(𝐶𝐷𝑜 ) + 𝐾𝑐𝑑2
𝐶𝐷𝑜 =

1

𝐶𝐷𝑡

+ 𝐾𝑐𝑑1 (𝐼𝑜𝑤 )

Substituting eq. 5.3j into 5.3g,

𝐾𝑎𝑤 𝑤
(𝐼 )(𝐶𝐷𝑜 )
𝐻𝑜+ 𝑜

𝐾𝑤
+ 𝐾𝑐𝑑2 𝑎+ (𝐼𝑜𝑤 )
𝐻𝑜

(5.3𝑖)

(5.3𝑗)

𝐾𝑎𝑤
𝐶𝐷𝑡
𝐾𝑐𝑑2 𝐾𝑎𝑤
�1
+
�
+
(𝐾
+
)
⎧
𝑐𝑑1
𝐾𝑎𝑤 𝑤
𝐻𝑜+
𝐻𝑜+
𝑤)
(𝐼
(𝐼
)
+
𝐾
1
+
𝐾
⎪
𝑐𝑑1 𝑜
𝑐𝑑2 + 𝑜
𝐻𝑜
𝐼𝑡𝑜 = 𝐼𝑜𝑤
𝑐
⎨
⎪
⎩
+

𝐾𝑝1 + 𝐾𝑝2
𝑑

𝐾𝑎𝑤 ⎫
⎪
𝐻𝑜+

(5.3𝑘)

⎬
⎪
⎭

Rearranging and simplifying it to the quadratic form,
𝐼𝑜𝑤

(−𝐵1 ± (�𝐵1 2 − 4𝐴1 𝐶1 )
=
2𝐴1
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(5.3𝑙)

where,

𝐴1 = �1 +

𝐾𝑎𝑤
�𝐾
𝐻𝑜+ 𝑐𝑑1
+

𝐵1 = �1 +

+ �1 +

𝐾𝑝1 + (𝐾𝑝2
𝑑

𝐾𝑎𝑤 𝐾𝑐𝑑2 𝐾𝑎𝑤
��
�
𝐻𝑜+
𝐻𝑜+

𝐾𝑎𝑤
)
𝐻𝑜+

+

𝐾𝑝1 + (𝐾𝑝2
𝑑

𝐾𝑐𝑑2 𝐾𝑎𝑤
𝑐�
�
𝐻𝑜+

𝐾𝑎𝑤
𝐾𝑐𝑑2 𝐾𝑎𝑤
�
+
�𝐾
+
� 𝐶𝐷𝑡 +
𝑐𝑑1
𝐻𝑜+
𝐻𝑜+
𝐾𝑐𝑑2 𝐾𝑎𝑤
�
− 𝐼𝑡𝑜 𝑐 �
𝐻𝑜+

𝐶1 = −𝐼𝑡𝑜 𝑐

𝐾𝑐𝑑1 𝑐

(5.3𝑙 − 𝑖)

𝐾𝑝1 + (𝐾𝑝2

(5.3𝑙 − 𝑖𝑖)

𝐾𝑎𝑤
)
𝐻𝑜+

𝑑

𝐾𝑎𝑤
)
𝐻𝑜+

𝑐 − 𝐼𝑡𝑜 𝐾𝑐𝑑1 𝑐

(5.3𝑙 − 𝑖𝑖𝑖)

Similarly, considering the mass balance in the bulk loading solution,
𝐼𝑡𝑏 = 𝐼𝑏 + 𝐼𝐼𝐼𝑏 + 𝐼𝑏 𝐶𝐷𝑏 + 𝐼𝐼𝐼𝑏 𝐶𝐷𝑏

(5.4𝑎)

where, 𝐼𝑡𝑏 is the total drug concentration in the bulk loading solution, 𝐼𝑏 and 𝐼𝐼𝐼𝑏 are

unbound bulk aqueous concentrations of lactone and carboxylate monoanion,
respectively; 𝐼𝑏 𝐶𝐷𝑏 and 𝐼𝐼𝐼𝑏 𝐶𝐷𝑏 are the aqueous concentrations of lactone and
carboxylate monoanion complexes with SBE-CD in the bulk.
𝐼𝑡𝑏 = 𝐼𝑏 +

𝐾𝑎𝑤 𝐼𝑏
𝐾𝑎𝑤 𝐼𝑏
(𝐼
)(𝐶𝐷
+
𝐾
)
+
𝐾
�
� (𝐶𝐷𝑏 )
𝑐𝑑1 𝑏
𝑏
𝑐𝑑2
𝐻𝑜+
𝐻𝑜+

𝐼𝑡𝑏 = 𝐼𝑏 �(1 +

𝐾𝑎𝑤
𝐾𝑐𝑑2 𝐾𝑎𝑤
)
+
𝐶𝐷
(𝐾
+
)�
𝑏
𝑐𝑑1
𝐻𝑜+
𝐻𝑜+

(5.4𝑏)
(5.4𝑐)

Considering the mass balance of total cyclodextrin in the bulk loading solution,
𝐶𝐷𝑡𝑏 = 𝐶𝐷𝑏 + 𝐼𝑏 𝐶𝐷𝑏 + 𝐼𝐼𝐼𝑏 𝐶𝐷𝑏
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(5.4𝑑)

where, 𝐶𝐷𝑡𝑏 is the total cyclodextrin concentration in the bulk loading solution.
𝐶𝐷𝑡𝑏 = 𝐶𝐷𝑏 + 𝐾𝑐𝑑1 (𝐼𝑏 )(𝐶𝐷𝑏 ) + 𝐾𝑐𝑑2
𝐶𝐷𝑏 =

𝐶𝐷𝑡𝑏

𝐾𝑎𝑤
(𝐼 )(𝐶𝐷𝑏 )
𝐻𝑜+ 𝑏

𝐾𝑤
1 + 𝐾𝑐𝑑1 (𝐼𝑏 ) + 𝐾𝑐𝑑2 𝑎+ (𝐼𝑏 )
𝐻𝑜

(5.4𝑒)

(5.4𝑓)

Substituting eq. 5.4f into 5.4c,

𝐼𝑡𝑏 = 𝐼𝑏 ��1 +

𝐾𝑎𝑤
�+(
𝐻𝑜+

𝐶𝐷𝑡𝑏

𝐾𝑤
1 + 𝐾𝑐𝑑1 (𝐼𝑏 ) + 𝐾𝑐𝑑2 𝑎+ (𝐼𝑏 )
𝐻𝑜

)(𝐾𝑐𝑑1 +

𝐾𝑐𝑑2 𝐾𝑎𝑤
�
𝐻𝑜+

(5.4𝑔)

Rearranging and simplifying it to the quadratic form,
(−𝐵2 ± (�𝐵2 2 − 4𝐴2 𝐶2 )
𝐼𝑏 =
2𝐴2

where,

𝐾𝑎𝑤
𝐾𝑎𝑤 𝐾𝑐𝑑2 𝐾𝑎𝑤
𝐴2 = �1 + + � 𝐾𝑐𝑑1 + �1 + + � �
�
𝐻𝑜
𝐻𝑜
𝐻𝑜+

(5.4ℎ)

(5.4ℎ − 𝑖)

𝐾𝑎𝑤
𝐾𝑐𝑑2 𝐾𝑎𝑤
𝐾𝑐𝑑2 𝐾𝑎𝑤
𝑏
𝑏
� 𝐶𝐷𝑡𝑏 − 𝐼𝑡 𝐾𝑐𝑑1 − 𝐼𝑡 �
�
𝐵2 = �1 + + � + �𝐾𝑐𝑑1 +
𝐻𝑜
𝐻𝑜+
𝐻𝑜+
Charge Balance

𝐶2 = −𝐼𝑡𝑏

(5.4ℎ − 𝑖𝑖𝑖)

𝐻 + + 2𝐶𝑎2+ + 𝐶𝑎(𝑂𝐻)+ + 𝐶𝑎(𝐴𝑐)+ −𝐴𝑐 − − 𝑂𝐻 −
− 𝐼𝐼𝐼 − − 2𝐼𝑉 2− = 0
𝑎

(5.4ℎ − 𝑖𝑖)

(5.4𝑖)

Eqs. (5.1a)-(5.1j), (5.2a-5.2i) (5.3a)-(5.3l) and (5.4a)-(5.4i) constitute the comprehensive
set of equations used to model active drug loading into calcium acetate-containing
liposomes. (Eqs. (5.1a)-(5.1j) describe the establishment of the pH gradient due to acetic
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acid transport and Eqs. (5.2a-5.2i, 5.3a-5.3l and 5.4a-5.4i) account for active drug loading
as a function of time.
Experimentally, the pH gradient was established in a separate step where 1 ml of
liposome was dialyzed against 1000 ml of 0.9% NaCl solution. The drug loading step
was then carried out in 200 ml of supersaturated drug solution following the pH gradient
step. However, for the purposes of modeling, the equations governing the pH gradient
were solved simultaneously with drug loading equations.
Sodium Acetate Vesicles
Similarly, while using the sodium acetate-containing vesicles instead of calcium acetatecontaining vesicles, the equations remain the same except that the equilibria involving
calcium are absent. Sodium acetate (NaAc) dissociates completely in water.
𝑁𝑎𝐴𝑐 → 𝑁𝑎 + + 𝐴𝑐 −

(5.5𝑎)

𝑁𝑎+ = 𝐶𝑖 0

(5.5𝑏)

𝐻𝑖+
𝑓𝑖 = +
𝐻𝑖 + 𝐾𝑎𝑎𝑐

(5.5𝑐)

where 𝐶𝑖 0 is the total initial acetate concentration (t=0).

and 𝑓𝑖 is the fraction of unionized acetic acid.
Charge Balance

𝐻 + + 𝑁𝑎 + −𝐴𝑐 − − 𝑂𝐻 −
− 𝐼𝐼𝐼 − − 2𝐼𝑉 2− = 0
𝑎
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(5.5𝑑)

Table 5.1 Values of the constants used in the model simulation

Parameter Values
a
b
c
d
x
Kaw
Ka2w
Kp1
Kp2
Kp3

#

1.08
12.86 #
1.0272 #
39.15 #
3.2118 #
3.4E-7 M $
2.7E-9 M $
2443 $
141 $
73 $

Parameter Values
Kcd1
Kcd2
K1
K2
Kaac
k
km
kd
kdcd

#

9788 (±820) M-1 &
1385 (±170) M-1 &
0.05 M *
0.066 M *
1.78E-5 M *
1.77E5 hr-1 $
287 (±43) hr-1 ¥
0.71(±0.06) hr-1 ¥
0.33(±0.04) hr-1 ¥

From the calculations described in the mathematical model section; $ from references
(126, 131, 132, 187, 212, 213), & Avg. ± 95% CI (determined in this study); *calculated
using Chemist® (Microsoft Scientific Software), ¥ from model fitting of experimental data
in this study (Avg. ± 95% CI).
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RESULTS
Liposome Characterization
The particle size of blank liposomes was in the range of 180-190 nm, with a
polydispersity index in the range of 0.075-0.087, indicating monodisperse formulations.
Passive and active loading of liposomes with AR-67 did not alter the particle size
significantly as drug loaded liposomes exhibited particle sizes within the range of 175185 nm, polydispersity index of 0.080-0.091. The extrusion procedure employed in this
study was previously shown by 31P-NMR to produce unilamellar vesicles (141).
Passive Loading
Based on the pH-solubility profile of AR-67 (Figure 5.2), passive loading could not be
successfully carried out with the lactone form of the drug due to its extremely poor
aqueous solubility at pH 4.2 (1.11x 10-4 mg/ml). In order to overcome the limitations of
low solubility at pH 4.2, passive loading at pH 9.5 was carried out. Despite an
improvement in solubility of about four orders of magnitude, the drug-to-lipid ratio
achieved was only 3x10-5. The low drug-to-lipid ratio achieved by passive loading led to
consideration of the active loading method.
Preliminary Active Loading Studies
At high intravesicular pH, lactone (I) undergoes ring-opening and ionization to give
carboxylate monoanion (III) and dianion forms (IV), providing sink conditions for
uptake. Preliminary active loading of AR-67 into calcium acetate vesicles in the presence
of excess solid at 37°C resulted in a drug-to-lipid ratio of only 0.0016 even after 70 hours
(Figure 5.3A). Model simulations also predicted a very slow uptake under these
conditions due to the low solubility of AR-67 at this temperature. In order to expedite the
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Figure 5.1 (A) Equilibria between AR-67 lactone (I), AR-67 carboxylic acid (II), AR-67
carboxylate monoanion (III) and dianion (IV). (B) Possible chemical equilibria inside and
outside the liposomes and transport processes during active drug loading in calcium
acetate liposomes.
Kaac is the dissociation constant for acetic acid; k is the rate constant for acetic acid transport; K1 and K2 are
the dissociation constants of calcium hydroxide and calcium acetate complexes respectively. M is calcium
metal ion, Iiw, IIIiw, IViw refer to intravesicular lactone, monoanion and dianion form of AR-67 respectively;
Iim, IIIim, IVim are corresponding intravesicular membrane bound species. Kaw and Ka2w are ionization
constants of AR-67 in water and Kam and Ka2m are ionization constants of membrane bound AR-67. Kp1,
Kp2 and Kp3 are bilayer water partition coefficients for lactone, monoanion and dianion form of AR-67
respectively, km is release rate constant of AR-67 through bilayer. Iow and IIIow are extravesicular lactone
and monoanion form of AR-67 respectively; I-CD and III-CD are their corresponding cyclodextrin
complexes in the extravesicular supersaturated drug solution. Kcd1 and Kcd2 are the binding constants of
lactone and monoanion AR-67 with SBE-CD. The subscripts i and o denote intravesicular and
extravesicular, respectively; superscripts w and m refer to water and membrane phases, respectively. Note:
Dialysis tube is not shown in the figure but was considered in the development of the mathematical model.
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Figure 5.2 pH-solubility profile of AR-67 in aqueous solution at 25°C (●) from ref [27]
and solubility data generated in this study at 37°C and pH 6.5, 7.0 and 7.5 at 0% SBECD
(□) and at 2% SBECD (▲). Solubility data at 37°C are averages of three independent
determinations; the error bars are buried in the symbol itself.
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uptake process, active loading in the presence of excess solid was also carried out at 60°C
(i.e., above the gel→liquid crystalline phase transition temperature of DSPC of 55°C) as
shown in Figure 5.3B. The intraliposomal pH-gradient stability was compromised at this
high temperature, as evident from the significant increase in the fraction of intraliposomal
lactone as a function of time (Figure 5.3B inset). The pH gradient was much more stable
at 37°C, as shown by the inset in Figure 5.3A, although some drift in the fraction of
lactone was apparent over the 70 hour time frame of these studies.
To overcome the low solubility problems and subsequent low loading encountered using
the active loading method even in the presence of excess solid, supersaturated solutions
were produced by the pH adjustment method (Method I) and liposome uptake was
monitored from these solutions at either 37°C or 60°C. Loading from supersaturated
solutions increased dramatically compared to the results obtained in the presence of
excess solid without supersaturation, as shown by the results in both Figures. 3A and B.
Interestingly, the rate and extent of loading from the supersaturated drug solution was
lower at 60°C (Figure 5.3B) compared to 37°C (Figure 5.3A) and at 60°C, the fraction of
lactone increased rapidly as a function of time, exceeding 0.5 after 5 hrs (Figure 5.3B).
Liposomal concentrations of AR-67 also peaked at 5 hours at 60°C and gradually
declined thereafter, consistent with the evidence of instability in the pH gradient as
monitored by the fraction of intraliposomal lactone. At 37°C, the fraction of lactone
remained relatively stable and below 0.2 over at least 96 hours (Figure 5.3A inset),
indicating that the high intraliposomal pH was maintained. Consistent with this result,
the liposomal uptake of AR-67 from the supersaturated solution at 37°C continued to
increase over the entire 120 hr duration of the loading experiment (Figure 5.3A).
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Figure 5.3 Active loading in 0.25 M calcium acetate liposomes at pH 7.5 and 37°C (A) or
60°C (B) in the presence of excess solid and from supersaturated AR-67solutions
(Method I). Inset shows intraliposomal % lactone during loading. a and b denotes
replicates for the experiments at 37ºC.
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Maintenance of Supersaturation
The solubility profiles of AR-67 at pH 6.5, 7.0 and 7.5 with increasing concentrations of
the cyclodextrin ([CD]) are shown in Figure 5.4. The linear solubility profiles indicate
that 1:1 complexes predominate. Assuming [CD]>> 𝑆𝑜 and carboxylate dianion is
negligible in the pH 6.5-7.5 region, complex formation constants for the neutral lactone

(Kcd1) and carboxylate monoanion (Kcd2) were calculated from the following equation
(185):
𝑆 = 𝑆𝑜 (1 + 𝐾𝑎 10𝑝𝐻 + 𝐾𝑐𝑑1 𝐶𝐷 + 𝐾𝑐𝑑2 𝐶𝐷𝐾𝑎 10𝑝𝐻 )

(5.6)

where 𝑆𝑜 is the intrinsic solubility of lactone. A linear least-squares fit of the data in

Figure 5.4 to the above equation yielded Kcd1 =9788 (±820) M-1 and Kcd2 =1385 (±170)
M-1 (the values in the bracket are ± 95% S-plane confidence intervals).

Creating a supersaturated drug solution significantly increased the drug loading
achievable but to maintain the supersaturation achieved by the pH adjustment method
(Method I), frequent re-dissolution of precipitates formed over time by raising and then
lowering the pH was required - a tedious and poorly reproducible process. Incorporation
of a low (2%) concentration of SBE-CD into the pH 7.5 supersaturated solutions
produced by the pH adjustment method was found to dramatically inhibit drug
precipitation. The equilibrium solubility of AR-67 at pH 7.5 in the presence and absence
of 2% SBE-CD was determined to account for the increase in the equilibrium solubility
that would result from the complexation of AR-67 with SBE-CD and to assess the degree
of supersaturation that could be achieved in loading solutions containing 2% SBE-CD.
The equilibrium solubilities of AR-67 (± SD) were experimentally determined to be 1.35
± 0.07 μg/ml and 26.5 ± 0.2 μg/ml in the absence and presence of 2% SBE-CD,

130

Figure 5.4 Plots of equilibrium solubility of AR-67 at 37°C as a function of SBE-CD
concentration in buffered aqueous solutions at pH 6.5, 7.0 and 7.5. Each value is the
average of three independent determinations; error bars are the standard deviations.
Straight lines are least squares fits using Eq. 5.6.
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respectively, at a pH of 7.5 at 37°C. Total supersaturated solution concentrations
achieved by pH adjustment and maintained in the presence of 2% SBE-CD ranged from
0.1-0.6 mg/ml. Figure 5.5 depicts the degree of supersaturation achieved in different
loading solutions after normalizing to the appropriate equilibrium solubility value. The
equilibrium solubilities of AR-67 at pH 7.5 with and without 2% SBE-CD were
significantly different (p<0.05). Dramatic increases in concentrations of the permeable,
free lactone were possible using this method (Method II).
Active Loading from Drug Solutions Varying in Degree of Supersaturation
Active loading of AR-67 in liposomes using an acetate pH gradient method was carried
out in supersaturated loading solutions containing different drug concentrations (0.1, 0.2,
0.4 and 0.6 mg/ml). Evidently, an increase in total drug concentration and a
corresponding increase in lactone concentration in the loading solution resulted in
increased intravesicular loading (Figure 5.6).
Furthermore, a linear relationship was observed between the extent of loading and
loading time with slopes that increased linearly with the drug concentration in the loading
solution. This linearity is demonstrated in Figure 5.7, where liposome suspension
concentration at 48 hr are plotted versus the drug concentration in the loading solution.
The highest intraliposomal drug-to-lipid ratio of 0.17 was achieved when the drug
concentration of 0.6 mg/ml was used in the external loading solution. Furthermore, the
intraliposomal carboxylate fraction was found to remain above 0.86 in all cases (Figure
5.8), indicating that the high intraliposomal pH was stable over the entire time frame of
the loading experiments. Studies at the lowest (0.1 mg/ml) (n=3) and highest (0.6 mg/ml)
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Figure 5.5 Enhancement of the total drug solubility and corresponding lactone
concentration at pH 7.5 in the presence of 2% SBE-CD at equilibrium and in
supersaturated solutions of varying degree. (Degree of supersaturation was calculated
with respect to equilibrium solubility in 2% SBE-CD). * denotes the two values are
significantly different from each other (p<0.05).
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Figure 5.6 Liposome suspension concentrations of AR-67 versus time during active
loading in calcium acetate-containing liposomes in supersaturated loading solutions
(Method II) at different drug concentrations (0.1, 0.2, 0.4 and 0.6 mg/ml) at 37°C. Solid
lines are the least-squares fits using the active loading model (Eqns. 5.2a-5.2d).
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Figure 5.7 Experimental and predicted relationship between liposome drug loading upto
48 hours and 37°C and total drug concentration in the external supersaturated loading
solution.
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(n=4) loading solution concentrations were repeated and the results were found to be
reproducible.
Drug-to-lipid ratios obtained in all drug loading experiments described above are
summarized in Table 5.2.
Effect of counter ions on loading
The active loading experiments reported above were carried out in liposomes prepared
from 0.25 M calcium acetate. Active loading of AR-67 was also carried out in liposomes
prepared in 0.5 M sodium acetate using supersaturation Method II at the highest solution
concentration of drug (0.6 mg/ml) to determine the role of the entrapped counter ion on
loading. No significant difference was found in either the rate or extent of loading in
sodium acetate vs. calcium acetate containing vesicles at various time points up to 48
hours (Figure 5.9).
Model Predictions
Dialysis experiments in the absence of liposomes were necessary to obtain the reversible
first-order rate constants for the transport of AR-67 in either its lactone and carboxylate
forms (kd) and SBE-CD or SBE-CD/AR-67 complexes (kdcd) across the dialysis
membrane. The values found for kd and kdcd are shown in Table 5.1 with their 95%
confidence limits generated from a total of five independent concentration versus time
profiles as described in the methods section. The values obtained for kd and kdcd in the
absence of liposomes within the dialysis tube were assumed to be the same when
liposomes were present.
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Table 5.2 Drug/Lipid ratios for liposome formulations of AR-67 under passive and active
loading conditions
Initial
extravesicular
Loading type/Conditions
solution drug
conc. (mg/ml)
0.8
Passive/ pH 9.5
0.00135
Active/Excess Solid
0.1*
Active/ Supersaturated
0.2
Active/ Supersaturated
0.4
Active/ Supersaturated
0.6*
Active/ Supersaturated

Lipid
Conc#
(mM)
18.0
67.4
67.4
67.4
67.4
67.4

AR-67 conc.
(mM) in the
liposome
suspension
5.3E-4
0.11
1.91±0.44
4.26
6.58
11.95±0.99

Drug/Lipid
ratio
3.0E-5
0.0016
0.027±0.006
0.060
0.089
0.170±0.015

# For calculation of lipid concentration, normalized molecular weight of lipid was used,
DSPC: mPEG-DSPE 95:5 mol%, Mol. Wt.= (0.95*Mol. Wt. of DSPC)+(0.05*Mol. Wt.
of mPEG-DSPE)
* Replicate experiments were conducted under these two extreme loading conditions to
test the reproducibility of the loading method. Averages of three (at 0.1 mg/ml) and four
(at 0.6 mg/ml) loading experiments are reported along with standard deviations.
Drug/lipid ratios were calculated based on intravesicular drug concentrations.
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The permeability coefficient for AR-67 lactone (permeable species) was determined from
model fitting at different loading conditions (total external drug concentration of 0.1, 0.2,
0.4 and 0.6 mg/ml) to be 2.13x10-7 ± 0.38 cm/s (95% confidence interval). Simulations
can be performed, using the determined permeability value, to predict the loading as a
function of the degree of supersaturation. While some of the constants and parameters
(aqueous and membrane bound ionization constants of the drug, membrane partition
coefficients of each species) employed in these model simulations were from previously
published experimental studies from our lab (126, 132, 187), the permeability coefficient
of the lactone was the only fitted parameter generated from the liposome loading data, as
the rate constants for free and bound drug across the dialysis membrane were determined
from separate experiments. Figure 5.6 shows the model fitting of the experimental data
demonstrating the linear increase in intravesicular drug concentrations with time. The
slopes of the fits increased linearly with drug concentration consistent with the model
prediction indicated by the dashed line in Figure 5.7. The model simulations also gave
identical results with sodium and calcium acetate liposomes for the liposomal
concentration vs. time (Figure 5.9) indicating that the nature of the intraliposomal cation
(i.e., Na+ vs. Ca++) was inconsequential for loading.
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Figure 5.8 Liposomal suspension fraction of carboxylate and lactone versus time during
active loading in calcium acetate-containing liposomes in supersaturated loading
solutions (Method II) at different total drug concentrations (0.1, 0.2, 0.4 and 0.6 mg/ml)
at 37°C. The points are the experimental data and the lines are the model simulations.
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Figure 5.9 Comparison of active loading in 0.5 M sodium acetate and 0.25 M calcium
acetate-containing liposomes in the presence of supersaturated solutions (Method II)
containing 0.6 mg/ml AR-67 concentration at 37°C.

140

DISCUSSION
Liposomal delivery of antitumor agents is highly desirable to passively target these drugs
to tumor tissues and minimize unwanted side effects (214). Achieving high liposomal
loading may be particularly challenging for new, highly lipophilic antitumor agents
exhibiting very low water solubility. AR-67, a novel camptothecin analogue that is
currently in clinical studies, serves as an example and was therefore chosen as a model
drug for this study.
Passive Loading
The intraliposomal drug concentrations achieved by passive loading, the conventional
method of drug loading into liposomes, depends on entrapped aqueous volume, lipid
concentration, and the solubility and partition coefficient of the drug (48). For the lipid
concentration (16 mg/ml) employed in this study, the entrapped aqueous volume can be
estimated to be ~ 6.4%. Passively loading liposomes using AR-67 solutions at a low pH
of 4.2 was not feasible due to the poor drug solubility at this pH. An attempt to improve
drug uptake by carrying out passive loading at a higher pH of 9.5, where an aqueous
solubility of 0.8 mg/mL could be achieved (Table 5.2), resulted in a very low drug to
lipid ratio (D/L=3x10-5). Theoretically, based on the solubility at pH 9.5 and the aqueous
entrapped volume, a D/L of ~3x10-3 can be estimated with no contribution of
intraliposomal membrane binding. The much lower loading ratio achieved may reflect
poor permeation of the hydrophilic dianionic species which predominates at pH 9.5
through the lipid film layers during the hydration step prior to vesicle formation.
Moreover, based on the profile for AR-67 membrane binding versus pH (126) and its pHsolubility profile (185), there exists an interplay between solubility and membrane
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Figure 5.10 Model simulations for different intraliposomal and extraliposomal species.
(A) Loss of intraliposomal acetic acid and corresponding intraliposomal AR-67 gain
during active loading along with comparison of acetic acid loss in the absence of drug;
(B) Intravesicular and extravesicular pH during active loading of drug in 0.25 M calcium
acetate liposomes at 37°C.
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partitioning with changes in pH. While the solubility of AR-67 increases from 1.11x10-4
mg/ml at pH 4.2 to 0.8 mg/ml at pH 9.5, the bilayer/water partition coefficient decreases
from 2443 ± 230 at pH 4.1 to 57 ± 5 at pH 9.5 (212). Thus, in terms of passive loading,
the advantage of increased solubility at high pH is offset in part by decreased membrane
binding.
Active Loading
Active loading is primarily driven by a chemical potential gradient across the bilayer as
given by Eq. 5.7.
𝑜𝑢𝑡
𝑖𝑛
𝐹𝑙𝑢𝑥 𝛼 𝑃𝑚 (𝐶𝑓𝑟𝑒𝑒
− 𝐶𝑓𝑟𝑒𝑒
)

(5.7)

𝑜𝑢𝑡
where 𝑃𝑚 is the intrinsic permeability coefficient for the unionized species, 𝐶𝑓𝑟𝑒𝑒
is the

𝑖𝑛
is the free
free concentration of the unionized species in the external medium and 𝐶𝑓𝑟𝑒𝑒

intraliposomal concentration of the same species assuming that only the unionized
species is permeable.
Enhancement of the External Driving Force for Active Loading
To enhance liposome loading of AR-67, a pH-gradient active loading approach was
explored in which a high intraliposomal pH was created by preparing liposomes in the
presence of high concentrations of either calcium acetate or sodium acetate. As indicated
in Eq. 5.7, the driving force for active loading of AR-67 is the external to internal free
lactone concentration gradient. Partial release of acetic acid creates a high intraliposomal
𝑖𝑛
pH resulting in a reduction in 𝐶𝑓𝑟𝑒𝑒
, providing sink conditions for liposomal uptake of

AR-67. Eq. 5.7 also indicates that the rate of uptake (flux) can be increased by enhancing
the trans-membrane permeability of the drug, for example, by increasing temperature.
𝑜𝑢𝑡
Under conditions in which 𝐶𝑓𝑟𝑒𝑒
is limited by the equilibrium solubility of AR-67, it was
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reasoned that maintaining this concentration by conducting drug loading in the presence
of excess solid would be beneficial. Therefore, active loading studies were initially
conducted in the presence of excess solid drug at 37°C, although model predictions
suggested that this approach would have limited success due to the very low equilibrium
solubility of the drug. Slow uptake was indeed observed at 37°C, as shown by the data in
Figure 5.3A. To increase Pm (and perhaps AR-67 solubility) loading experiments were
also conducted at 60°C, as above the phase transition temperature for DSPC (55°C), the
liposome bilayer is in a more permeable liquid crystalline form (131). This resulted in a
modest increase in uptake rate (Figure 5.3B) but as illustrated by the inset in Figure 5.3B,
the fraction of the intraliposomal lactone species which is dominant only at a lower pH
increased dramatically with time at 60°C indicating that within 5-10 hrs the pH gradient
had dissipated. Previous reports (215, 216) have confirmed losses in pH gradients during
active loading in cholesterol free liposomes above the phase transition temperature
attributed to membrane destabilization, leading to a decline in loading with time.
Dissipation of pH gradients above the phase transition temperature may be attributable to
increased permeability of hydrochloric acid, hydrogen ions, or ion pairs, etc. (215, 217220). Liposomes containing 40-50% cholesterol may be more resistant to these effects
due to stabilization of bilayers by cholesterol above the phase transition (206, 221, 222).
In an attempt to overcome the limitations in liposomal uptake imposed by the low
aqueous solubility of AR-67, which results in a low driving force (cf., Eq. 5.7),
supersaturated drug solutions of AR-67 was created, first simply by pH adjustment
(Method I). Supersaturation increased the aqueous concentration of the drug, including
free lactone, and dramatically enhanced liposomal uptake rates at both 37°C (Figure
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5.3A) and 60°C (Figure 5.3B), although the aforementioned dissipation in pH gradient
and a resulting decline in drug loading now became clearly evident at 60°C. Because
Method I was ineffective in maintaining supersaturation over a prolonged period, the use
of SBE-CD to inhibit nucleation and crystal growth was evaluated. Previously, 20%
SBE-CD had been shown to inhibit the crystallization of 2 mg/ml supersaturated
solutions of AR-67 after reconstitution from lyophiles for at least three days (185). Here,
2% solution concentrations of SBE-CD were employed to minimize the fraction of
lactone present in inclusion complexes while maintaining high supersaturated
concentrations. As demonstrated in Table 5.2 and Figure 5.5, supersaturated solution
concentrations as high as 0.6 mg/ml were maintained using this approach, resulting in
substantial increases in drug loading at 37°C, with D/L ratios as high as 0.17 (Table 5.2)
and with no apparent dissipation in the pH gradient (Figure 5.8).
Mechanism-Based Mathematical Model Development
A mathematical model was developed to explore intraliposomal properties that may be
important both for loading and drug release and to predict drug loading under various
conditions. A key assumption in the model is that the driving force for drug uptake is the
transbilayer concentration gradient of the free lactone. The model incorporates the
experimentally determined ionization and membrane binding constants of each species of
the drug along with equilibrium constants for the formation of cyclodextrin complexes of
AR-67 lactone and its ring-opened monoanion. The incorporation of the permeability
coefficients enables the prediction of rates of drug uptake, representing an important
advance in comparison to previous models (223-225).
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Experimental data generated at various loading concentrations (0.1, 0.2, 0.4 and 0.6
mg/ml) were fitted to the developed model to determine the permeability coefficient of
the lactone under active loading conditions. The intrinsic permeability value for AR-67
lactone obtained in this study from km (see Table 5.1) is 2.13x10-7 ± 0.38 cm/s, which lies
between a previously reported experimental value determined from liposomal release
studies by Joguparthi et al (212) and a predicted value using the “barrier-domain”
solubility diffusion model (130, 212).
While one would expect the permeability coefficient to be the same for both uptake and
release the determination of the driving forces (lactone concentration gradient) governing
drug uptake or release rates is not trivial. If the driving force is not determined accurately,
the permeability coefficient obtained by experiment will also be inaccurate. Estimating
the driving force governing drug release requires determination of the aqueous
concentration of free lactone inside the liposome, which depends on the intraliposomal
pH and membrane binding of each AR-67 species inside the liposome. AR-67 is
extensively bound intraliposomally due to its high membrane binding coefficients and the
high membrane surface to volume ratio inside the liposomes [19, 20]. The driving force
for drug uptake is somewhat easier to determine, although one must either analyze the
free lactone concentration or use a mathematical model that includes transport across the
dialysis membrane to obtain the steady-state extravesicular lactone concentration inside
the dialysis tube. In the present study, the dialysis membrane did partially contribute to
the overall barrier for drug-loading but reliable estimation of the intrinsic permeability
coefficient of AR-67 was still possible. The extravesicular free lactone concentration at
steady-state was 2.4 times lower than the free lactone concentration in the bulk solution
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outside the dialysis tube due to the resistance of the dialysis membrane barrier. In the
absence of this barrier, a maximum increase of ~2.5 fold in the rate of loading might have
been achievable. It can be expected that using a dialysis membrane of higher molecular
weight cut-off would have had some benefit, but much less than this maximum.
Differences in the uptake rate and extent of AR-67 loading up to 48 hours into calcium
acetate-containing liposomes under various loading conditions can be accurately
predicted by the mathematical model using the permeability value determined for AR-67
(Eqs. 5.2a-5.2d) as illustrated in Figures 5.6 and 5.7. Simulations using the same model
were conducted to further explore the role of intraliposomal acetate in establishing the pH
gradient. A high intraliposomal pH is produced by the transbilayer concentration gradient
of acetic acid, which is a highly permeable weak acid (𝑃𝑚𝑎 =1.6 (± 0.2)x10-4 cm/s across
DSPC bilayers (131)). Figure 5.10B shows the simulated increase in intraliposomal pH
during the initial dialysis step to remove unentrapped buffer (Eqs. 5.1a-5.1j). This high
intraliposomal pH is maintained by the continuous transport of acetic acid from inside the
vesicles in exchange for incoming lactone. Figure 5.10A shows the direct relationship
between acetate loss and intraliposomal drug loading. For each molecule of lactone
internalized, two molecules of acetic acid are lost due to the predominance of the AR-67
dianion at this intraliposomal pH. Model predictions of the fractions of lactone and
carboxylate in the liposome suspension during the course of loading compare favorably
to the experimental observations except at the initial time points. In the initial stages of
loading, the contribution of the extravesicular drug concentration to the total suspension
concentration is relatively high and the discrepancy in this early region may be
attributable to the fact the solution initially introduced into the dialysis tube is a poorly
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buffered dilute calcium acetate solution in 0.9% NaCl that may have a higher initial pH
than the bulk loading solution. The model assumes a constant extravesicular and bulk pH
of 7.5. Also, there may be some error associated with quenching the carboxylate to
lactone conversion during sample preparation and prior to HPLC analysis. In their
validation of an analytical method for the determination of the lactone and carboxylate
concentrations in mouse plasma, Horn et al. reported a carboxylate to lactone conversion
of about 3.7% prior to sample analysis [44]. Nevertheless, experimental analysis of both
lactone and carboxylate fractions during drug loading under different conditions revealed
relatively stable, high intraliposomal carboxylate fractions, indicative of a high
intraliposomal pH.
The high intraliposomal pH demonstrated in both simulations and experimentally in this
study results in a low intravesicular fraction of free lactone (I), caused by base-catalyzed
ring-opening of the lactone to its carboxylate form (III and IV) at the high intraliposomal
pH. Internal membrane binding further reduces the intraliposomal lactone concentration,
creating intraliposomal sink conditions. The uptake rate during active loading is therefore
primarily governed by the extravesicular driving force (i.e., free lactone concentration
enhanced by supersaturation to varying degrees). These increases in drug loading with
higher lactone concentrations in the supersaturated loading solutions are illustrated in
Figures. 5.5 and 5.6. Experimentally, the maximum drug-to-lipid ratio demonstrated
within 48 hours was 0.17. However, as mentioned previously, the rate of loading may
have been modestly enhanced by using a dialysis membrane of higher molecular weight
cut-off to increase dialysis membrane transport rates. Model simulations predict that a
very high extent of loading (D/L of 0.8) could be achieved at equilibrium, provided
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supersaturation could be maintained for a prolonged period of time. Also, loading may be
further enhanced by intraliposomal precipitation of the calcium salt of AR-67, as
governed by its solubility product (226). While the model developed herein does not
consider possible intraliposomal salt precipitation, the rates of uptake and extent of
loading within 48 hrs would not have been affected by this possibility because
intraliposomal sink conditions were maintained throughout this time frame even in the
absence of salt precipitation. No significant difference could be detected between the rate
and extent of loading at 48 hours from 0.6 mg/ml supersaturated drug concentrations
when liposomes prepared in 0.5 M sodium acetate were employed rather than those
containing 0.25 M calcium acetate (Figure 5.9). This further suggests that the enhanced
active loading is mainly dependent upon establishment and maintenance of the pH
gradient leading to intraliposomal sink conditions and increases in the external driving
force by supersaturation.
Active loading in response to a transmembrane chemical gradient is dependent upon the
properties of the individual drug (208). Zucker et al. suggested an aqueous solubility of
1.9 mM to be a reasonable solubility for active drug loading (48). While the aqueous
solubility of a drug is important, it is the concentration of the unionized permeable
species that provides the driving force for active loading (cf., Eq. 5.7). A detailed analysis
of the factors responsible for the maximum liposome loading achieved by others (39, 41,
44, 46-48, 84, 206, 208, 227) using the active loading technique is difficult, but the
evidence suggests that reasonable loading required either a moderate solubility of the
unionized species, or, in some cases, the authors may have unknowingly created
supersaturated solutions during loading. In the present study, achieving the high drug to
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lipid ratio of 0.17 clearly required a combination of the transmembrane pH gradient
approach and supersaturation.
CONCLUSIONS
A novel method of active loading was developed for a poorly soluble model compound,
AR-67, a third generation potent camptothecin analogue, using supersaturated drug
solutions along with a high intraliposomal pH produced by a transmembrane acetate
gradient. Maintenance of supersaturation was aided by use of a cyclodextrin (SBE-CD) to
inhibit

drug

crystallization

during

loading.

Furthermore,

a

mechanism-based

mathematical model was developed to understand the loading process, assuming that the
driving force for drug uptake across the membrane is the concentration gradient of the
free unionized species. Loading was mainly driven by the establishment of a pH gradient
(high pH inside) produced by the loss of acetic acid, intraliposomal drug ionization, and
internal membrane binding of the drug leading to near intraliposomal sink conditions.
Improved liposome loading of AR-67 was achieved by developing a novel method for
creating and maintaining supersaturation of this hydrophobic, water insoluble drug during
the active loading process. The model was successful in fitting the rates of drug-loading
(up to 48 hours, period of time supersaturation was maintained using SBE-CD) at several
degrees of supersaturation to obtain a single intrinsic membrane permeability coefficient.
The developed model can be used to further predict the rate and extent of loading under
different loading conditions. This proposed loading methodology may be useful in
meeting the formulation challenges presented by the increasing number of poorly soluble
anticancer agents emerging from drug discovery.
Copyright © Sweta Modi 2013
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CHAPTER SIX
Optimization of Liposome Release Kinetics of a Corticosteroid Phosphate Based on
pH and Lipid Composition
INTRODUCTION
Dexamethasone (Dex) acts as an anti-inflammatory and immunosuppressive agent by
inhibiting the production of pro-inflammatory cytokines. Since inflammatory responses
play an important role in tumor progression and metastasis, dexamethasone was shown to
enhance the anti-tumor efficacy of certain chemotherapeutic agents. Wang et al. found in
pre-clinical studies that pre-treatment with Dex significantly enhanced the antitumor
activity of carboplatin and gemcitabine and increased their tumor accumulation (90-92).
These observations were further supported by phase II randomized clinical studies (228)
and Dex has been proposed as an adjuvant (chemoprotectant and/or chemosensitizer) in
cancer chemotherapy to reduce some of the associated side effects (nausea,
hematotoxicity) and increase the efficacy of antitumor drugs. Although Dex has
numerous therapeutic applications, its use is limited by the side-effects such as
immunosuppression, hyperglycemia etc. (229, 230). In addition, due to its rapid clearance
from the body, frequent high doses are required to achieve efficacy which in turn causes
serious side effects (84). This leads to the demand for a targeted and sustained delivery of
dexamethasone to maximize its therapeutic potential and minimize the side effects. It was
in fact demonstrated that a sustained delivery over 3-4 days was more effective compared
to the 1-day pre-treatment in reducing the carboplatin induced hematologic toxicity (231233).
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Liposomal drug delivery systems play an important role in targeted delivery of anti-tumor
agents (20). The steady-state drug concentration at the site of action is a function of the
local input and elimination rates. Thus, the rate of drug release from the formulation is an
important factor governing the availability of drug at the target site (52). There may be a
need to modulate drug release rates based on the tumor type and size in order to provide
safe and efficacious concentrations at the tumor site. As a result, it would be highly
desirable to design formulations with tunable and predictable drug release rates that can
be tailored according to the therapeutic requirement. Generally, drug release half-lives of
approximately 24 hours or more are needed so that liposomes retain a majority of their
drug payload prior to reaching their maximum accumulation at the tumor site (234-236).
Previously, half-lives of dexamethasone (Dex) in liposomes varying in lipid composition
were determined.

The longest half-life obtained was in DSPC, a densely packed

phospholipid that is in its gel state at 37C and therefore more highly resistant to
permeability than shorter chain lipids, but the half-life was only 14 hours..
Due to the higher permeability and poor solubility of dexamethasone, the water soluble
21-phosphate prodrug was considered. Along with the advantage of enhanced solubility,
the phosphate prodrug of Dex is ionizable, thus allowing the exploration of pH as a
formulation variable to tailor its release kinetics. As reported in chapter five for AR-67
and in previous publications from this laboratory (189, 237), lipid bilayer permeabilities
of neutral drug species are often orders-of-magnitude higher than their ionized species.
Therefore, the release kinetics of liposome encapsulated ionizable drugs can potentially
be controlled by modulating the intravesicular pH, providing that the intravesicular pH
can be maintained at the desired value. Previous studies have shown that maintaining
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intravesicular pH in the alkaline region can be challenging due to the dissipation of the
pH gradient due to CO2 uptake into liposomes under physiological conditions (126).
However, phosphate prodrugs possess the advantage of having a low first pKa (~2) and
consequently do not require an alkaline pH for ionization (133).
In addition to pH control, the barrier properties of the bilayer can be altered by varying
the lipid composition. The effect of bilayer chain density on permeability has been taken
into account in the barrier domain model (131, 189). The decrement in permeability due
to chain ordering in this model depends exponentially on the ratio of solute size to bilayer
free surface area. The relationship between trans-bilayer transport and bilayer free surface
area has been tested for small solutes (61, 62, 122, 131, 189, 237, 238) while the present
study offers the opportunity to test the applicability of the theory to larger drug-like
molecules.
A fundamental understanding of the physicochemical factors governing drug transport
across lipid bilayers is essential to predict the release kinetics from liposome
formulations. The key for both tunability and predictability is the development of
quantitative mathematical models that will take into account the physicochemical
properties of the drug and the bilayer membrane along with the intraliposomal and
external local environments.
The goal of the present study was to develop a mechanism-based mathematical model of
drug release kinetics to account for the physicochemical properties of the drug (e.g., ionic
equilibria, membrane binding, etc.), the barrier properties of the bilayer membrane, and
the intraliposomal pH microenvironment. The hypothesis was that liposomal release rates
could be prolonged significantly by modulating the intravesicular pH and entrapping the
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drug in the membrane impermeable ionized form. In addition, changes in the free surface
area of the bilayer brought about by changing the lipid composition were expected to
further affect the trans-bilayer solute permeability. This study explores liposomal
delivery systems of a corticosteroid phosphate, dexamethasone phosphate (Dex-P), that
provide a range of release half-lives. Such information will also be useful in extending
previously developed quantitative relationships between lipid bilayer permeability and
factors such as intravesicular pH, lipid composition, and permeant size to larger
molecules having a size more typical of most drugs.
MATERIALS AND METHODS
Dexamethasone sodium phosphate USP (Dex-P)

was purchased from Spectrum

Chemical Mfg. Corp, New Brunswick, NJ and dexamethasone (Dex) (≥98%, powder)
was purchased from Sigma-Aldrich Co., St. Louis, MO. Lipids (DSPC (1,2-distearoyl-snglycero-3-phosphatidylcholine, >99% purity), DPPC (1,2-dipalmitoyl-sn-glycero-3phosphocholine, >99% purity), DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine,
>99% purity), m-PEG DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N[methoxy (polyethylene glycol)-2000]), m-PEG DPPE (1,2-dipalmitoyl-sn-glycero-3phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]) and m-PEG DMPE (1,2dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene

glycol)-

2000])) were purchased as powders from Avanti Polar Lipids (Alabaster, AL). Dialysis
tubes (Float-A-Lyzer®, MWCO: 100 kD) were purchased from Spectrum Laboratories
(Rancho Dominguez, CA). HPLC grade solvents and other chemicals were purchased
from Fisher Scientific (Florence, KY).
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Determination of ionization constant
The second ionization constant of Dex-P was determined at room temperature by the pHtitration method. Dexamethasone sodium phosphate USP (Dex-P) solution (4 ml) at about
4 mM in deionized water was titrated with 8 mM HCl solution under continuous stirring
and pH was monitored after each addition. Plots of pH versus volume of titrant added
were fitted to the following implicit equation.
𝐻+ +

𝐶𝑑𝑟𝑢𝑔 𝑉𝑜 𝑃 𝐶𝐻𝐶𝑙 𝑉𝑎 𝐾𝑤
𝐶𝑑𝑟𝑢𝑔 𝑉𝑜 𝑃
𝐾𝑎2
=
+ ++
𝐾𝑎2 + 𝐻 + 𝑉𝑜 + 𝑉𝑎
𝑉𝑜 + 𝑉𝑎
𝑉𝑜 + 𝑉𝑎 𝐻

(6.1)

where 𝑉𝑜 is the initial volume of Dex-P solution and 𝑉𝑜 is the volume at each titration

point. 𝐾𝑤 is the ion product of water and 𝐾𝑎 is the second ionization constant of Dex-P. P
is the purity of the drug. The data was also analyzed by plotting the change in pH/ml of
acid added Vs volume of titrant added.
Determination of Critical Aggregation Concentration (CAC)
Fluorescence Method
CAC of dexamethasone sodium phosphate USP (Dex-P) was determined by the

fluorescence method using pyrene (Sigma) as a probe molecule and a Varian Cary
Eclipse spectrofluorometer with a 10 mm path length quartz cuvette. Excitation was at a
wavelength of 335 nm and the emission spectrum was recorded from 350-500 nm. The
excitation slid width was maintained at 5 nm and emission slit width at 1.5 nm, at a slow
setting. Pyrene was dissolved in acetone to give 0.1mg/ml concentration, 65-100µl of this
solution was added to blank test tubes and acetone was then evaporated under nitrogen.
To these test tubes, 2 ml of different concentrations (0-85 mM) of Dex-P solution was
added and vortexed. Data were acquired using Cary Eclipse software from Varian at
25°C.
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Solubility Method
Dexamethasone sodium phosphate USP (Dex-P) solutions were made from 0.01-0.5M
concentration range. Excess Dex was added to each solution and equilibrated at 25°C for
48 hours. After equilibration, the suspensions were filtered using 13 mm 0.45µ PVDF
syringe filters (Fisherbrand) and the first 10 drops were discarded to minimize possible
effects of filter adsorption. Successive 10 drop fractions were collected and compared to
ensure that filter adsorption had no effect on the results. The filtrates were diluted with
mobile phase (32:68 acetonitrile:aqueous buffer containing 2% triethylamine acetate)
before analysis by HPLC.
Liposome Preparation
Dex-P loaded liposomes for transport experiments were prepared based on a previously
reported method (127). Briefly, DMPC: mPEG DMPE, DPPC: mPEG DPPE or DSPC:
mPEG-DSPE (95:5 mol%, 80 mg) were separately dissolved in about 2 ml of chloroform.
The solvent was evaporated under a stream of nitrogen and the resulting film was dried
overnight in a vacuum oven. The lipid film (DMPC, DPPC and DSPC) was hydrated with
2 ml of buffer (50 mM glycine buffer at pH 2 or 50 mM citrate buffers at pH 3, 4, 5 and
6)) containing dexamethasone sodium phosphate (Dex-P) (2-3 mM) to give a lipid
concentration of 40 mg/ml. The pH of the drug solutions were adjusted back to the
desired pH after Dex-P addition before hydrating the lipid films. After alternate vortexing
and heating in a water bath at a temperature above the phase transition temperature of the
respective lipids to uniformly suspend the lipid, the suspension was extruded 10 times
through two stacked 100 nm polycarbonate membranes using an extruder at 30°C, 50°C
and 60°C for DMPC, DPPC and DSPC, respectively, to obtain unilamellar liposomes
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(141). Liposomes were allowed to cool to room temperature for 3 hours and used for
release studies. Particle sizes of Dex-P loaded liposomes were measured at 25°C by
dynamic light scattering (DLS) using a Delsa™ Nano submicron particle size analyzer
(Beckman Coulter Inc., Brea, CA). The liposomes were diluted in the same buffer as that
used in their preparation.
Determination of Liposomal Drug Release Kinetics
Dex-P loaded liposomes were separated from free drug by passing through a Sephadex®
G25 column pre-equilibrated in the same buffer as that used in the preparation of
liposomes. Drug loaded liposome suspensions (0.1-0.5 ml) were added to the Sephadex
column, eluted with 2-5 ml of buffer, and eluting fractions were analyzed for drug and
lipid concentration.
The liposome containing eluent fractions were diluted in the same buffer (if needed),
introduced into a dialysis tube (Float-a-lyzer, MWCO (Molecular Weight Cut Off) 100
kD, Spectrum Laboratories), immersed into a 1000 ml of aqueous reservoir (sink
conditions) containing the same pH buffer as that used for the liposome preparation and
dialyzed at 37°C. Since some of the release studies were monitored for several days,
0.05% sodium azide was added to the buffers to inhibit microbial growth. Total drug
concentration in the tube was monitored versus time by HPLC by withdrawing 50-100 µl
samples from inside the dialysis tube at various time points and diluting with an
appropriate volume of methanol. The kinetics of disappearance of free Dex-P from
solution (800 µM) from the dialysis tube was also studied in a similar fashion.
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HPLC Analysis of Dex and Dex-P
Samples from solubility studies (for pKa2 determination) and liposome release studies
were analyzed using an isocratic HPLC method with UV detection. A Waters Alliance
2695 Separations Module coupled to a UV detector (Waters 996, Photodiode Array
Detector) was employed with wavelength of maximum absorption at 240 nm. A Waters
Symmetry® C18 column (5 µm, 3.9 X 150 mm) and guard column (3.9 X 20 mm) were
used with a mobile phase composition of 32% acetonitrile and 68% (v/v) pH 5.5
triethylamine acetate (2%) buffer. The retention times at an injection volume of 10 µl and
a flow rate of 1 ml/min were about 2.3 and 6.4 min for Dex-P and Dex, respectively. Four
independent standards for Dex-P (100-800 µM) in water and Dex (100-800 µM) in
methanol were prepared. The relative standard deviation for the response factor was less
than 3%.
Lipid Analysis
Lipids were analyzed using HPLC and ELSD (Evaporative Light Scattering Detector) as
reported previously (126). Briefly, separation was done using an Allsphere™ silica
column (Grace Davison Discovery Sciences, Deerfield, IL) (5 µ, 4.6X150 mm) with a
guard column (Allsphere silica, 5µ, 7.5 X 4.6mm). A linear gradient method was used;
mobile phase A was 80% chloroform: 19.5% methanol: 0.5% (v/v) ammonium hydroxide
solution (28-30%) and mobile phase B consisted of 80% methanol: 19.5% water and
0.5% (v/v) ammonium hydroxide. Each run began with 100% (v/v) mobile phase A,
changing to 80% mobile phase A: 20% mobile phase B at 3 min, maintaining the
composition (80%A: 20%B) until 7 min and changing back to 100% mobile phase A at
14 min. The total run time was 15 min at a flow rate of 1 ml/min with the following
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ELSD settings:

gain, 8; pressure, 3.4 bar; and temperature, 40°C. The sample

compartment temperature was maintained at 4°C and the column was at ambient
temperature. Standards were in mobile phase A and log-log plots of peak area versus
concentration were linear. Aliquots of drug loaded liposomes (10-20 µl) for lipid analysis
were transferred to test tubes, dried under nitrogen, and stored at -20°C until further
analysis. For analysis, the dried lipid films were re-constituted in mobile phase A. Lipid
concentration was evaluated versus time during the course of transport studies in
representative DPPC liposomes at various pH values.
DATA ANALYSES
Equilibrium pH-Permeability Model
Dex-P is n amphiphilic, ionizable drug that can exist as three different species depending
on the pH (Figure 6.1). A mathematical model to explain the pH dependent permeability
of a solute across the liposome and its evaluation by dynamic dialysis method was
developed in chapter five and in previous publications from this laboratory (126, 132). A
similar model with some modifications has been adopted and explained here. The model
takes into account the ionization, membrane binding, and transport of possible permeable
species. Instantaneous equilibrium between the various species is assumed both within
and outside the liposomes. The model considers the internal and external volume in the
liposomal suspension along with the volume occupied by the aqueous (inner and outer)
and membrane phases (inner and outer leaflets of the bilayer), the membrane/water
partition coefficients of the various drug species and the fractions bound inside and
outside the liposomes. The kinetics of release of the encapsulated drug from the
liposomes and the transport of free drug across the dialysis membrane into a sufficiently
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large volume of dialysate to ensure sink conditions in the reservoir are incorporated into
the rate equations. Samples taken from inside the dialysis tube at various time points
were analyzed for the total Dex-P remaining.
Two types of models were considered in the pH-permeability studies of Dex-P (Figure
6.2). The membrane-water partition coefficient of the monoanionic species was found to
be either small (DMPC) or negligible (DPPC and DSPC) in the lipid systems used for
release studies (Chapter three). Therefore, initially, the following mathematical model
(Model I) that ignored binding of the drug to the liposomal membrane was employed.
Model I
𝐼𝑖𝑡 = 𝐼𝑖 + 𝐼𝐼𝑖 + 𝐼𝐼𝐼𝑖
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(6.8)

where, 𝐼𝑡𝑖 and 𝐼𝑡𝑜 are the total intravesicular and extravesicular drug concentrations (in

molar); 𝑘𝑚 and 𝑘𝑑 are the rate constants for drug transport across the lipid bilayer and
dialysis membrane, respectively, and 𝑥 is the ratio of extravesicular to intravesicular
volume in the dialysis tube. 𝐼𝑖 , 𝐼𝐼𝑖 , 𝐼𝐼𝐼𝑖 and 𝐼𝑜 , 𝐼𝐼𝑜 , 𝐼𝐼𝐼𝑜 are the intravesicular and

extravesicular neutral, monoanion and dianion concentrations, respectively. 𝐷𝑚 is the
drug concentration bound to the dialysis membrane; 𝑘𝑜𝑛 and 𝑘𝑜𝑓𝑓 are the association and

dissociation constants for binding of drug to the dialysis membrane �𝐾 = 𝑘𝑜𝑛 ⁄𝑘𝑜𝑓𝑓 �.
Model II

Model I was inadequate for explaining the release data obtained in DPPC and DSPC
liposomes for Dex-P. As a result, a more elaborate model (Model II) that took into
account the binding of different species to the liposome membrane was considered.
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where 𝑎 and 𝑏 are volume ratios to account for the differences in aqueous and membrane
volumes with respect to the total intravesicular volume
Similarly,
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𝐼𝑜𝑤 = 𝑢𝑏𝑜 𝐼𝑜𝑡

𝐼𝐼𝑜𝑤 = 𝑢𝑏𝑜 𝐼𝑜𝑡

(6.12)
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where 𝐾𝑎𝑤 and 𝐾𝑎2
are the ionization constants of Dex-P in the aqueous phase and

𝐾𝑝1 , 𝐾𝑝2 , 𝐾𝑝3 are the membrane/water partition coefficients of the neutral, monoanion

and dianion, respectively.
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where 𝐼𝑖𝑤 , 𝐼𝐼𝑖𝑤 , 𝐼𝐼𝐼𝑖𝑤 are the unbound aqueous intravesicular neutral, monoanion, and
dianion

concentrations, respectively, while 𝐼𝑜𝑤 , 𝐼𝐼𝑜𝑤 , 𝐼𝐼𝐼𝑜𝑤 are the unbound aqueous

extravesicular neutral, monoanion, and dianion concentrations, respectively. In the

present study, the pH was assumed to remain constant and not change due to ionization of
the drug because the buffer concentration (50 mM) was about 1000-fold higher than the
drug concentration (40-60 µM).
The apparent permeability at each pH can be expressed as:
𝐼
𝐼𝐼
𝐼𝐼𝐼
𝑃𝑎𝑝𝑝 = 𝑃𝐼 𝑓𝑢𝑏
+ 𝑃𝐼𝐼 𝑓𝑢𝑏
+ 𝑃𝐼𝐼𝐼 𝑓𝑢𝑏
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(6.16)

where PI, PII and PIII represent the permeability coefficients of the unionized, monoanion
and dianion Dex-P with fub representing the fraction unbound for each species. The
dianion was assumed to be membrane impermeable (PIII=0). Substituting the terms for
the fraction unbound of the unionized and monoanionic species from Eq. 6.11, the
apparent permeability coefficient of Dex-P can be expressed as:
𝑃𝑎𝑝𝑝
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1
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Bilayer Free Surface Area-Permeability model

Historically, passive permeability through lipid bilayers has been described by the “bulk
solubility diffusion” model that assumes the membrane to be homogenous and isotropic,
resembling a bulk hydrocarbon solvent. According to this model, permeability is given
as:
𝑃𝑜 =

𝐾𝑚/𝑤 𝐷𝑚
ℎ𝑚

(6.18)

where Po is the permeability coefficient, Km/w and Dm are the membrane/water partition
coefficient and diffusion coefficient across the membrane, respectively, and hm is the
membrane thickness. However, unlike bulk solvents, lipid bilayers are heterogeneous,
interfacial and anisotropic systems. The lipid bilayer can be roughly divided into three
regions: an ordered, polar interfacial head group region, a highly ordered hydrocarbon
chain region and a relatively disordered hydrocarbon chain region towards the center of
the bilayer (189). As permeant moves across the bilayer, it encounters variations in the
barrier environment. For very small polar molecules the transport is primarily governed
by a distinct region within the bilayer interior (i.e. the highly ordered chain region).
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Solubility diffusion theory fails to account for the effects of lipid bilayer chain order on
the permeability coefficient of a permeant. Xiang and Anderson have addressed this issue
by introducing a scaling factor that must be applied to permeability prediction from
solubility-diffusion theory. The permeability coefficient for small molecules, according
to this new “barrier-domain” solubility diffusion model is
𝑃𝑚 =

𝐾𝑏𝑎𝑟𝑟𝑖𝑒𝑟⁄𝑤𝑎𝑡𝑒𝑟 ∗ 𝐷𝑏𝑎𝑟𝑟𝑖𝑒𝑟
= 𝑓 ∗ 𝑃𝑜
ℎ𝑏𝑎𝑟𝑟𝑖𝑒𝑟

(6.19)

where Kbarrier/water and Dbarrier are the partition coefficients from water into and diffusion
coefficient of the permeant within the barrier domain, respectively, and hbarrier is the
barrier thickness. Thus, Pm is the product of Po from solubility-diffusion theory and a
scaling factor f, the permeability decrement due to chain ordering effects (61, 131).
The permeability decrement factor, f can be defined in terms of the two-dimensional
packing structure of the bilayer, as characterized by the free surface area per lipid
molecule, af, and cross-sectional area of the permeant, as, as follows (61, 131):
𝑓 = 𝑓𝑜 𝑒𝑥𝑝�−𝜆𝜆 𝑎𝑠 ⁄𝑎𝑓 �

(6.20)

where fo and 𝜆𝜆 are constants independent of permeant size and bilayer packing structure.
Thus, the scaling factor that accounts for the decrease in permeability due to chain

ordering is exponentially dependent on the ratio of permeant size to the free surface area
of the membrane. It was proposed that non-spherical solutes orient their long axes along
the bilayer normal and the permeation across the bilayer occurs with the creation of a free
volume with a cross-sectional area equal to or greater than the minimum cross-sectional
area of the diffusing permeant. Alternative models have employed a power law in
permeant volume instead of the minimum cross-sectional surface area to rationalize the
molecular size dependence of membrane permeability (131, 239). Mitragotri et al. also
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analyzed the size selectivity of solute permeability in lipid bilayers using scaled-particle
theory. They evaluated the relative contributions of both partitioning and diffusion
processes across the ordered chain region and suggested the dependence of each on the
solute size and bilayer parameters (168).
RESULTS
Dex-P and Liposome Characterization
The state of ionization is important for rationalizing the pH dependent liposome
permeability of Dex-P. The accurate determination of pKa values less than about 2 by the
potentiometric method is challenging. However, Derendorf et al. calculated a pKa1 of 1.9
by studying the partition coefficient of Dex-P as a function of pH. This value was
therefore assumed in the present study. The value of pKa2 of Dex-P, as determined by
pH-titration method and fitting the data to Eq. 6.1, was 6.27 ± 0.13 (Figure 6.5), which is
in good agreement with the reported value of 6.4 (133). Although the experimental
determination of pKa2 was performed at room temperature, the temperature sensitivity
for phosphate pKa values is known to be insignificant where d(pKa)/dT for pKa1 is about
0.0044 and for pKa2, it is -0.0028 (240, 241). This suggests a change in pKa1 of 0.05 and
pKa2 of -0.03 units with change in temperature from 25 to 37°C (240, 241).
Figure 6.3 shows the change in fluorescence emission spectra of pyrene (excitation at 335
nm) in increasing concentrations of Dex-P solution (0-84 mM). The ratio of the first
vibrational band (372 nm), the highest energy vibrational band, to that of the vibrational
band at 383 nm is considered to be an index of polarity of its environment. In water the
ratio (I1/I3) is around 1.6-1.8, in ethanol about 1.1, and in hydrocarbon solvents around
0.57-0.61. Left inset shows the ratio of I1/I3 of pyrene as a function of Dex-P
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concentration. In the presence of micelle forming systems at concentrations below the
CMC, the intensity of the highest energy vibrational band normalized against the
intensity of third peak decreases. There was a sharp breakpoint at the CAC (34 mM) and
above the CAC the ratio was constant. As an additional confirmation of CAC values, the
intensity of the excimer peak (at 475 nm) relative to first peak (IE/I1) was plotted against
the Dex-P concentration and was observed to show a peak at CAC concentration (Figure
6.3 right inset).
The critical aggregation concentration (CAC) of Dex-P determination, by solubility
method (Figure 6.4) gave an apparent value of ~120 mM with no sharp deflection point
observed in the solubility curve. The inset of Figure 6.4 shows the rise in solubility of
Dex even at lower concentrations of Dex-P (<50 mM) suggesting smaller aggregate
(dimer, trimer etc.) formations prior to true aggregation.
Dex-P loaded liposomes of DMPC, DPPC and DSPC prepared at different pH values
exhibited particle sizes in the range of 87-102 nm, with polydispersity indices in the
range of 0.06-0.09, indicating monodisperse formulations. The drug and lipid
concentrations during release studies at different pH values were determined using
previously developed and validated HPLC methods. For the analysis of Dex-P, samples
were taken from inside the dialysis tube at various time points, diluted with methanol and
analyzed for both, Dex-P and its hydrolytic product, Dex. There was no degradation of
Dex-P observed during the time period of transport studies at any pH. Based on the
literature,, the half-life Dex-P at pH 4.06 and 70°C is about 4.6 days (242). Flynn and
Lamb studied solvolysis of several corticosteroid phosphates and found that the nature of
the steroid nucleus has little effect on the monoanion hydrolysis rate constant. They
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Figure 6.1 Equilibria between neutral, unionized Dex-P (I), its monoanion (II) and
dianion (III). pKa1 and pKa2 are the first and second ionization constants, respectively.
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Figure 6.2 The pH-permeability model considered to explain Dex-P liposomal release
profiles at different pH values determined by dynamic dialysis (model II).
I, II and III refer to the unionized, monoanion and dianion concentrations of Dex-P,
respectively. Subscripts i and o refer to the intravesicular and extravesicular
compartments. Superscripts m and w refer to the membrane and aqueous phases. The
binding parameters (Kp1, Kp2 and Kp3) were assumed to be negligible in model I.
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suggested that stability data for methylprednisolone-21-phosphate could be considered to
be representative of related steroid phosphates as well (242). Therefore, using the
activation energy reported for methylprednisolone-21-phosphate, the half-life for
hydrolysis of Dex-P at pH 3.32 and 37°C should be about 347 days, well beyond the time
frame of the present studies.
The lipid concentration in the dialysis tube during the transport studies was in the range
of 0.6-2.0 mg/ml. Shown in Figure 6.9 are DPPC concentration versus time profiles
during transport studies at pH 2, 3, 4, 5 and 6. Table 6.2 shows the parameters from
regression analysis at each pH along with 95% C.I for slope and intercept. The %
coefficient of variation for the determination of initial value (t=0) was 8-20% and the
slope was not significantly different from zero (P>0.05). Therefore, the total
concentration of lipid remained constant during the release studies. Additionally,
previous studies on stability of saturated phosphatidylcholines (DSPC and natural
soybean PC) have shown that the half-life of degradation is greater than 3 months at pH 9
and 40°C and more than 2 months for DMPC at pH 4 and 30°C (142, 143, 243, 244).
Although in the same order of magnitude, a small increase in hydrolysis rate constant
(Kobs) from 3.2 x 10-4 hr-1 to 4.7 x 10-4 hr-1 was reported with increase in fatty acid chain
length of liposomes from C12 (DLPC) to C18 (DSPC) at pH 4 and 30 °C (245, 246).
The membrane water partition coefficient of Dex-P monoanion was previously
determined by equilibrium dialysis for DMPC, DPPC and DSPC liposomes (pH 4) to be
62 ± 8, 2 ± 4 , 6 ± 2, respectively. In addition, the study of Dex-P binding at different pH
values in DMPC liposomes showed significant binding of the neutral form (241 ± 38)
relative to the ionized species.
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Kinetics of Drug Release from Liposomes at Different pH
The kinetics of free drug disappearance from dialysis tubes (100 kD) that were used in
the pH-permeability studies was evaluated. Previous dynamic dialysis studies for release
of Dex from liposomes indicated free drug binding to the dialysis membrane. Therefore,
the kinetics of free Dex-P disappearance from aqueous solutions during dynamic dialysis
was evaluated for a sufficient time to capture the effect of binding to the dialysis
membrane, if present. Figure 6.6 indicates that a biphasic profile was observed for Dex-P
disappearance from solution very similar to that observed for Dex. The similarity in the
biphasic profiles for free Dex and Dex-P despite the differences in their physicochemical
properties suggests membrane binding rather than partitioning into the membrane. The
rate and equilibrium constants obtained from the fitting of free drug profiles were used in
modeling the transport of Dex-P from liposomes.
The concentration versus time profiles for the release of Dex-P from DPPC and DSPC
liposomes at different pH values are shown in Figure 6.7. Concentration versus time
profiles for Dex-P release from drug loaded liposomes at all pH values (pH 2, 3, 4, 5 and
6) were simultaneously fit to equations 6-8 (Model I) to obtain the rate constants for
permeation of the neutral and monoanionic species (with the assumption that the di-anion
is impermeable) and the apparent pKa1 of Dex-P. The second ionization constant was
fixed because all the pH values explored were below pKa2. The values of pKa1 obtained
from the simultaneous fitting of the pH dependent transport data across DPPC and DSPC
were 2.8 (95% CI of 2.6-3.3) and 3.4 (95% CI of 3.3-3.6), respectively.
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Figure 6.3 Fluorescence spectra of pyrene recorded at increasing concentrations of Dex-P
and the corresponding decrease in peak intensity at 372 and 383 nm The inset shows the
breakpoint when the ratio of the I1/I3 is plotted against the Dex-P concentration and a
peak when the ratio of excimer peak (475 nm) relative to first peak is plotted against the
Dex-P concentration.
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Figure 6.4 Solubility of Dex with increasing concentrations of Dex-P at 25°C. The inset
shows the magnified view of the region between 0-100 mM Dex-P.
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Figure 6.5 Change in pH of a 4 mM Dex-P solution on addition of HCl titrant. The data
points are the experimental recording while the solid line is the model predictions on
solving Eq. 6.1. Inset shows the ratio of the change in pH per ml of acid against the
volume of HCl and the peak in the plot corresponds to the half-equivalence point.
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Figure 6.6 Fractions of initial amount of Dex-P in solution remaining in the dialysis tube
with time. Error bars are the standard deviations from the replicate experiments (n=3).
The kinetics of free Dex is also shown for comparison.
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Figure 6.7 Fraction of Dex-P remaining (mean ± S.D) in dialysis tubes containing Dex-P
loaded liposomes at pH values of 2, 3, 4, 5 and 6. Solid lines are simultaneous fits based
on the equilibrium pH-permeability model (Eqs. 6.13-6.15). Error bars are the standard
deviations from the replicate (n=2) experiments (A) DPPC (B) DSPC.
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The apparent permeability constants (calculated from apparent first order rate constants)
at each pH from transport data across DPPC and DSPC liposomes were plotted versus
pH. The pH-permeability profiles of Dex-P from DPPC and DSPC liposomes shown in
the log-linear plot in Figure 6.8 indicate an upward shift in first pKa, from 1.9 to 2.8 in
DPPC and to 3.4 in DSPC liposomes.
Since previous studies on membrane binding of Dex-P in DMPC liposomes indicated
significant binding of the neutral form, inclusion of a term for neutral species binding to
account for the apparent shift in pKa was considered. Model II including a binding
parameter was used to simultaneously fit the release data at different pH values with the
first and second ionization constants fixed at 1.9 and 6.4, respectively. Rate constants for
the transport of the neutral and monoanionic Dex-P species, kma and kmb, in DPPC were
4.2 ± 1.8 and 9 ± 3 x 10-3 hr-1 (95% C.I.) while in DSPC the values were 0.54 ± 0.14 and
8 ± 2 x 10-4 hr-1, respectively. The intrinsic permeability coefficients of the neutral Dex-P
across DPPC and DSPC were calculated to be 1.74 (±0.74) x 10-9 cm/s and 2.24 (±0.59) x
10-10 cm/s (95% C.I.), respectively. The partition coefficients of the neutral form,
obtained from the fitting were 42 ± 35 and 186 ± 68 (95% C.I.) in DPPC and DSPC
respectively.
Quantitative Relationship between Permeability and Chain Ordering (Free Surface
Area)
Transport data for Dex-P at pH 4 were available for unilamellar vesicles composed of
DMPC, DPPC and DSPC, as shown in Figure 6.10. The apparent half-lives obtained
were 1.2, 10.8 and 169 hours, respectively. These lipids varied in their acyl chain length
and bilayer chain density, which also brought about changes in phase structure (gel or
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liquid crystalline phase). At 37°C, DMPC (Tm of 23°C) is in a disordered liquidcrystalline phase, DPPC is in a gel phase but very close to its phase transition temperature
(Tm of 41°C) and DSPC is in the highly ordered gel phase (Tm of 55°C). The chain
ordering can be quantified in terms of surface density or free surface area, as
demonstrated earlier (122, 131). To test the dependence of apparent permeability of DexP on the order parameter, the log of apparent permeability was plotted versus the inverse
of free surface area and a linear dependence was observed (Figure 6.11). A least-squares
fit of the data gave a slope of -0.53 and correlation coefficient of 0.99.
Table 6.1 shows the observed half-lives for release obtained at various pH values and
different liposome compositions. The experimental half-life for Dex-P release from
liposomes ranged from 1.2 h at pH 4 in DMPC liposomes to 892 hours at pH 6 in DSPC
liposomes. The broad range of release kinetics was obtained by modulation of two
formulation variables in liposomes i.e. pH and lipid composition.
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Figure 6.8 Log of apparent permeability of Dex-P vs pH across DMPC, DPPC and DSPC
liposomes at 37°C. The solid lines for DPPC and DSPC represent the predicted values
based on model II and Eq. 6.17.
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Table 6.1 The half-life (t1/2) for liposome retention of Dex-P as a function of liposome
composition and intraliposomal pH

Liposome

pH

Retention Half-life (hrs)*

DMPC

4

1.2 ± 0.05

DPPC

2

1.9 ± 0.1

DPPC

3

2.2 ± 0.3

DPPC

4

10.8 ± 2.3

DSPC

2

32 ± 2

DSPC

3

48 ± 3

DPPC

5

58 ± 9

DPPC

6

58 ± 5

DSPC

4

169 ± 6

DSPC

5

579 ± 82

DSPC

6

892 ± 78

*The values are mean ± Std. Dev.
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Figure 6.9 Concentration-time profiles for DPPC liposomes at pH 2, 3, 4, 5 and 6 during
transport studies of Dex-P by dynamic dialysis.
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Table 6.2 Regression analyses of lipid concentration Vs time data at different pH of
release studies

P value
pH

Slope (95% C.I)

Intercept (95% C.I.)

(Is slope significantly
non-zero?)

2

-0.0041 (-0.0101 to 0.0019)

1.429 (1.131 to 1.726)

0.1368 (>0.05)

3

-0.0020 (-0.0153 to 0.0113)

1.338 (0.675 to 2.002)

0.7134 (>0.05)

4

-0.0015 (-0.0030 to 0.00005)

0.961 (0.739 to 1.184)

0.0566 (>0.05)

5

-0.0008 (-0.0017 to 0.00001)

1.245 (1.034 to 1.456)

0.0529 (>0.05)

6

-0.0003 (-0.0012 to 0.0006)

1.109 (0.8828 to 1.335)

0.4300 (>0.05)
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Figure 6.10 Fraction of Dex-P remaining in dialysis tube from DMPC, DPPC and DSPC
liposomes at pH 4. Error bars are the standard deviations from replicate experiments
(n=2).
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Figure 6.11 Dependence of the natural logarithm of apparent permeability of Dex-P on
the inverse of free surface area of the liposome bilayer. Points represent permeability
coefficients in DMPC, DPPC, and DSPC.
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DISCUSSION
Liposomes hold the promise of enhancing the therapeutic index of drugs by reducing the
toxicity and increasing drug efficacy (20). To accomplish the goal of selectively
delivering the drug to the target site, the drug needs to remain entrapped inside the
liposomes while the nanoparticles are circulating in the blood and then release once at the
target site. Even at the site of action, drug release should ideally be optimized as per the
therapeutic need. Therefore, there is a great need for the ability to tune the release
kinetics of drugs from liposomes in response to the therapeutic requirement. Depending
on the therapeutic need, half-lives ranging from a few hours to several days may be
required. To meet this end, quantitative relationships that could provide predictive
capability based on the drug and delivery vehicle properties would be highly desirable.
Such a universal quantitative model would also greatly enhance mechanistic
understanding of release kinetics from the delivery system. In this study, two simple
liposomal formulation variables, pH and phospholipid chain length were explored to
obtain a range of release kinetics. The mathematical modeling of the release data enables
an understanding of the release kinetics under different conditions and the ability to
design systems having a predetermined release rate.
CAC Determination
Hydrophobic solutes or compounds having a large surface area of exposed organic
groups or aromatic rings have a tendency to self-associate in water at higher
concentration. As opposed to molecules containing flexible chains that organize into
typical micellar structures above a particular critical concentration, organic compounds
containing rigid aromatic fused rings rather have a more diffuse concentration range
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where they associate to a different extent (247, 248). Also, such molecules do not form
the typical micellar structures but rather form aggregates due to stacking of the rigid
aromatic rings. The critical concentration for aggregate formation is often referred to as
Critical Aggregation Concentration (CAC) instead of Critical Micelle Concentration
(CMC) (249).
Pyrene is a very common fluorescent probe used in the determination of CMC of
amphiphiles owing to the dependence of its emission characteristics on the polarity of its
environment (250). As the concentration of aggregate forming agent (Dex-P) increases,
pyrene molecules experience a more hydrophobic environment than water due to
premicellar aggregates and a lowering of the intensity ratio (I1/I3) is observed (Figure 6.3
inset, below CAC). Above the CAC, with increase in Dex-P concentration there is no
increase in monomer concentration and the ratio of the pyrene intensity peaks (I1/I3) is
constant due to incorporation of pyrene into the hydrophobic region of micelles or
aggregates (250, 251).
Excited pyrene monomers form an excimer complex with a ground state pyrene monomer
and show an emission peak at 475 nm. Pyrene excimer formation is a concentration
dependent phenomenon in organic solution. Owing to the low solubility of pyrene in
water, pyrene excimer formation is not observed in pure water. Solubilization of pyrene
by micelle forming agents allows excimer formation in aqueous solution. The
measurement of excimer emission as a function of surfactant concentration allows the
determination of aggregation number of micelles (252). As the concentration of micelle
forming agent increases, IE/I1 ratio increases owing to movement of pyrene molecules
from premicellar aggregates to micelles resulting in a rise in average occupancy of
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pyrene molecules in micelles. Above the CAC, the number of micelles increases causing
the lowering of an average occupancy and thereby lowering the probability of excimer
formation and hence the decrease in IE/I1 ratio (253).
The CMC of methylprednisolone-21-phosphate has been reported by surface tension
measurements to be 0.017 M (242), which is on the same order of magnitude as the CAC
for Dex-P of 0.034 M as determined by the fluorescence method. However, Shah et al
have determined the CAC of Dex-P to be 0.0034 mol/kg at 25 °C by measuring the
electrical conductivities of increasing concentrations of the drug solution (254). The
reported value is about ten times lower than that determined for Dex-P in our study by
fluorescence method. The differences in these various techniques probably reflect the
different properties being probed where conductivity may be more sensitive to very small
aggregates. Additionally, Flynn and Lamb also used the conductivity method for the
study of CMC of methylprednisolone-21-phosphate at pH 7.5 at various temperatures
including 25 °C but did not find a sharp break point and obtained a range of 0.01 to 0.02
M between which the CMC values lies (242).
The CAC determined by the solubility method is only an apparent value because of the
curvature in the solubility curve instead of distinct discontinuity and therefore differs
significantly from the value obtained by fluorescence method. Since the solubility
method does not allow for direct calculation of the monomer concentration, the presence
of premicellar aggregates complicates the data interpretation. If the aggregates formed are
sufficiently large, containing more than 20 monomers, a simple monomer-micelle model
adequately describes the equilibria. Such systems are characterized by a distinct sharp
break point in plots of any properties versus its concentration. However, steroidal
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molecules, such as Dex-P, are known to form pre-micellar aggregates prior to true
aggregation resulting in curvature rather than a distinct break-point in the plots (255) as
seen in Figure 6.4 and the inset highlighting the increase in Dex solubility even at lower
Dex-P concentration (~50 mM).
For drugs with a smaller hydrophilic portion relative to their hydrophobic portion, a trend
of decreasing CMC or CAC values with an increase in temperature has been observed
(256). In particular, the CAC of Dex-P was found to increase with temperature and was
attributed to greater dehydration of polar head groups than those of hydrophobic groups
leading to repulsion between them and difficulty in aggregation (254). Based on this, the
CAC of Dex-P at 37°C would be expected to be higher than that determined at 25°C.
Although the CAC values at lower pH where the free acid predominates was not
investigated, the low solubility of Dex-P at low pH would preclude the determination
(242).
The present studies were conducted at concentrations well below the determined CAC
value of 34 mM or even 3.4 mM as reported by Shah et al. The Dex-P conc. range in
loading and release studies were less than 1 mM. Also, since the release studies were
conducted at 37 °C and the CAC of Dex-P is known to increase with temperature, it
further ensures the absence of aggregates in the transport experiments. Additionally, the
release studies at different pH values were conducted at much lower concentrations (<1
mM) because structural resemblance between the corticosteroid phosphates and the
surface active bile acids raises the possibility of mixed micellization and potential bilayer
disruption at higher concentrations (257, 258). This could also be a likely explanation for
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inefficient loading of Dex-P by passive loading methods despite its high water solubility,
as observed in our and other studies (259, 260).
pH Dependence of Bilayer Permeability Coefficients
The method of pH adjustment to modulate bilayer transport of ionizable drugs was
studied long back by Xiang and others, mostly for small molecules such as α and βnaphthoic acids (238), p-toluic acid and their analogues (189, 237) etc., where they also
demonstrated a quantitative relationship between pH and permeability. However, mostly
with the goals of understanding the barrier properties of the bilayers, they studied the pHpermeability relationship in an attempt to explore the pH region where the flux of the
highly permeable carboxylic acids was membrane controlled and changed several orders
of magnitude (189, 237, 238).
The pH-gradient strategy has also been explored and applied to a great extent for active
loading of weak acids and bases in liposomes but the approach of intravesicular pH
modification has not been explored as much for the retention of large-drug like molecules
for the purpose of achieving controlled or tunable release. Joguparthi et al. developed the
pH-permeability model for drug permeability in liposomes for a hydrophobic model drug,
AR-67, a camptothecin analogue (126). Since this can be a very valuable and simple
formulation approach for the modulation of release kinetics of both hydrophobic and
hydrophilic ionizable compounds, there is a need to extend the applicability of the
relationship to more drugs having structural diversity. Here, this effect was demonstrated
for a hydrophilic steroidal compound, Dex-P.
The bilayer properties were assumed to be independent of pH in the range explored in
this study (pH 2-6) based on the previous studies from this laboratory. Xiang et al.
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showed there was no change in apparent permeability with change in pH for α-D-glucose
across DHPC and DPPC bilayers and for acetamide across egg-lecithin bilayers, both
non-ionizable compounds, indicating pH-independence of the barrier properties of the
bilayers (189). Additionally, Joguparthi et al. found no change in barrier properties of
DSPC liposomes at pH 4.1 and 9.5 by comparing the permeability of 14C-thiourea to that
reported previously (126).
At a given pH, an ionizable drug exists partially in its neutral and ionized forms,
depending upon the ionization constants. The change in apparent permeability with pH
can be attributed to different permeability coefficients of the neutral and ionic species and
changes in the relative fractions of those species with pH. The bilayer permeability of the
neutral form of Dex-P could not be determined directly from experiments due to the low
pKa1 of 1.9 and the lipid stability concerns that would arise in conducting transport
studies at pH values below the pKa (142, 243, 244). However, the permeability of the
neutral species could be estimated from the simultaneous model fitting of the release
profiles at various pH values. Since the rate constant for the monoanion was more than
500 fold smaller than that for the neutral species, the permeability of the monoanion and
dianion was assumed to be negligible. Transport of ionic species across liposome bilayers
is energetically unfavorable due to the tremendous energetic penalty incurred in their
transfer from water into the non-polar hydrocarbon-like region in the bilayer (62).
Although the permeability of monoanion was about 500 fold smaller than the unionized
species, the difference is smaller compared to that obtained between neutral and ionized
species of some small carboxylic acids (189, 261). This can be attributed to the
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possibility of ion pair transport through the membrane, although the evidences for it have
not been explored here.
Model I was inadequate in satisfactorily describing the data in Figure 6.8 and therefore
model II which considers the intra and extra-vesicular membrane binding of the different
species was tested. The membrane binding of Dex-P has been described in detail in
chapter three. Although the binding of Dex-P mono-anion (at pH 4) was negligible in
DPPC and DSPC liposomes, based on the pH-partition profile in DMPC, the binding of
neutral Dex-P in DPPC and DSPC could not be neglected. Considering the binding of the
neutral species accounted for the shift in the pKa observed from the pH-permeability
profile when no binding was considered. The bilayer membrane transport is primarily
governed by the concentration gradient of the aqueous free neutral species. The
simultaneous binding and ionization deplete the free aqueous concentration of permeable,
neutral species that is the driving force for the transport of drug across the liposome.
Owing to the large intraliposomal surface-to-volume ratio, there is significant
intraliposomal binding of a drug even for low partition coefficient values. The depletion
of the free neutral drug, attributed to binding and ionization, therefore needs to be taken
into account for accurate determination of the permeability coefficient. Thus, the
retention of the weak acid drugs in liposome would depend upon the pKa of the drug,
membrane partitioning of the neutral and ionized species and the intraliposomal pH.
The fitting of the pH-permeability data of Dex-P to model II suggested the membrane
partition coefficients of the unionized neutral Dex-P to be 42 ± 35 and 186 ± 68 (95%
C.I.) in DPPC and DSPC, respectively. The predicted higher partition coefficient in
DSPC liposomes as compared to DPPC is in contrast to the expected dependence of
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membrane partition coefficients on free surface area, as reported in the literature (55, 121,
122) and chapter three. Since DPPC has a smaller acyl chain length and a lower chain
density leading to a higher free surface area as compared to DSPC, the partition
coefficient would be expected to be higher in DPPC. However, the large 95% confidence
intervals of the predicted partition coefficients are quite large, thus complicating the
interpretation of these results. One of the reasons for the wide confidence intervals is the
low pKa1 of Dex-P and the absence of permeability data at pH values below pKa1.
Considering the release profiles shown in Figure 6.7, the experimental pH values mainly
explore the pH region where the drug is predominantly in the monoanionic form.
Moreover, the profiles at pH 2 and pH 3 were not significantly different from each other
and in DPPC they very similar to the profile observed for free Dex-P. More reliable data
at low pH may require the use of a different transport method.
Quantitative Relationship between Permeability and Free Surface Area
Depending on the properties of the permeant, the rate-limiting or barrier region for
liposomal release may differ. If the polarity of solute is sufficient to establish the bilayer
membrane as rate-limiting, then it might be reasonable to expect a dependence of the
permeability coefficient on the available free surface area of the bilayer. Indeed, Xiang
and Anderson discovered using acetic acid as a model solute that the bilayer free-surface
area was a "universal" variable that quantitatively related solute permeability to chain
packing in both liquid-crystalline and gel phases (122, 131). They further demonstrated
the dependence of the permeability decrement (f=Pm/Po), a factor that accounts for the
effects of chain ordering, on the inverse of the bilayer free surface area for several shortchain monocarboxylic acids (61). Thus, it has long been demonstrated that the effects of
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bilayer packing on trans-bilayer transport can be rationalized in terms of a dependence of
permeability on the two-dimensional packing structure, as characterized by the free
surface area per lipid molecule, afree. However, there has been no systematic attempt to
test such a quantitative relationship using larger drug-like molecules. Such a quantitative
model could provide a significant contribution by enhancing the predictive capability for
drug release across liposomal delivery systems.
The effects of lipid chain packing in gel and liquid crystalline lipid bilayers on
permeability was investigated for the larger solute Dex-P by measuring its release
kinetics from DMPC, DPPC and DSPC liposomes at pH . As shown in Figure 6.11, the
natural logarithm of Papp was found to correlate linearly with the inverse of the bilayer
free surface area. The slope is the measure of the sensitivity of the apparent permeability
of Dex-P on bilayer chain density. Particularly noteworthy is the finding that the apparent
permeability coefficient for Dex-P across gel phase DSPC bilayers is 16-fold smaller than
that across co-existing gel-liquid crystalline phase DPPC bilayers, which in turn is 9-fold
smaller than that across the liquid crystalline DMPC bilayer. In other words, the apparent
permeability across highly ordered gel phase of DSPC is nearly 2 orders-of-magnitude
smaller than that across the disordered liquid crystalline bilayer of DMPC, demonstrating
a significant role of bilayer chain ordering on solute transport.
In chapter three, the concept of surface density or free surface area and its effect on
membrane partition coefficients was explained. A similar relationship was observed here
with apparent permeability of Dex-P across the liposomes. However, the degree of
changes in apparent permeability with decrease in free surface area is higher than that
observed for partitioning as demonstrated by the steeper slope of -0.5 for apparent
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permeability versus a slope of -0.2 for partitioning of Dex-P (Chapter Three). This is
attributed to the requirement for passage of solute across the bilayer for permeation as
opposed to partitioning and thereby a higher sensitivity to the chain density. In
partitioning, depending on the nature of the solute and its location and specific
interactions with the bilayer, there may be only partial insertion of the solute into the
bilayer. For permeation, the solute has to travel from one side of the bilayer to the other
and may encounter a large penalty in free energy for insertion into the highly ordered
barrier domain. Thus, the permeation process probes a different region of bilayer than
the partitioning process. Additionally, variations in free surface area have an additional
effect on solute diffusivity in lipid bilayers which does not affect solute partitioning. Both
the barrier domain/water partition coefficient and the diffusion coefficient within the
barrier domain may be functions of afree and have a combined effect on trans-bilayer
permeability.
CONCLUSIONS
A range of liposome release rates for Dex-P corresponding to half-lives from 1 hour to
892 hours were obtained by varying the lipid composition and the intravesicular pH.
Changes in bilayer free surface area by varying the lipid composition and intravesicular
pH are the simple formulation variables that can be exploited to tune drug release
kinetics. Moreover, the ability to quantitatively relate the permeability across liposomes
to physicochemical factors and bilayer barrier properties can be tremendously helpful in
tailoring the release kinetics as per the therapeutic need. Although the free surface area
was varied in this study by using lipids of different acyl chain length, it can also be
modified by changing the temperature and inclusion of different percentages of
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cholesterol in the bilayer. The prediction of permeability of a drug molecule across the
bilayer is also relevant for the mechanistic understanding of the drug absorption process.
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CHAPTER SEVEN
Conclusions and Future Directions
In the design of liposomal delivery systems, predictive strategies are needed to maximize
drug loading and optimize drug retention regardless of the physicochemical properties of
the drug. Drug candidates that are either highly hydrophobic or hydrophilic may pose
particular challenges in their formulation design and for such compounds the
optimization of both loading and release kinetics, if achieved at all, is usually done
empirically.

It would be highly beneficial to have a universal, comprehensive

mathematical model relating the drug and bilayer properties to the rate and extent of
loading and release kinetics in liposomes. In view of this objective, one of the principal
goals of this work was to explore the factors affecting the bilayer partitioning, loading
and permeability of model solutes using mechanism-based mathematical models to
predict these processes in liposomes based solely on the structure of the solute,
composition of the lipid membrane, and the local environmental conditions.
The investigation of the influence of liposome composition on membrane partitioning
behavior of two solutes differing in physicochemical properties demonstrated a
quantitative relationship between bilayer/water partitioning and the bilayer chain ordering
(free surface area). Thus, knowledge of the membrane partition coefficient of a particular
drug in a given phospholipid bilayer would enable the prediction of the same quantity in
another bilayer varying, for example, in lipid chain length solely from the difference in
bilayer free surface area. Relationships between solute structure and lipid bilayer
membrane binding, if sufficiently comprehensive, would not only be useful for
determining how much of a drug of interest would be bound to a liposomal membrane,

195

which is an essential term in understanding and modeling both drug loading and release,
but it would also be an important piece of the puzzle in understanding how drugs
distribute in vivo. However, a more comprehensive set of compounds with diverse size,
structure and properties needs to be evaluated to establish universally applicable
structure-binding relationships.
To properly design nanoparticle release kinetics, one must have the right mathematical
models to describe drug release as well as proper methods to test those models. The
analysis of the dynamic dialysis method for the determination of release kinetics from
nanoparticles as conducted in this work should greatly enhance understanding of the
central mechanisms involved in dynamic dialysis and provide the ability to evaluate the
reliability of data generated by this method. The proposed mathematical models will
enable the deconvolution of the true release rate constant from the apparent kinetics
where drug binding effects and/or dialysis membrane transport may be partially
contributing.
The novel active loading method developed in this study using supersaturated drug
solutions should be valuable in overcoming formulation challenges associated with the
liposomal delivery of poorly soluble, ionizable anticancer agents. In terms of drug release
kinetics, the a priori design of liposomal release kinetics may play an important role in
the selection of optimal systems tailored to specific tumor types. Mechanistic
understanding of the thermodynamic and kinetic factors governing the trans-bilayer
activity gradient of a drug is the key to predicting its release kinetics. It was shown that a
varying range of release kinetics from few hours to several days can be obtained by
modulation of formulation variables such as intraliposomal pH and bilayer barrier
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properties.

A

quantitative

relationship

between

membrane

permeability,

the

intraliposomal microenvironment, and bilayer chain ordering was demonstrated.
However, the connection between mechanistic models for in vitro release in aqueous
buffers and the in vivo release kinetics from the same systems in the systemic circulation
and local tumor environment has not yet been established. Mechanism-based models such
as those developed in this study should also be beneficial in understanding and
minimizing differences between in vitro and in vivo behavior of drug-loaded liposomes
when such differences emerge.
In the near term, evaluation of the in vivo performance of optimized liposomal
formulations in order to test the applicability of models based on in vitro observations to
in vivo behavior should be considered. The long term goal would be to evaluate the
applicability of such binding, loading and release models with a diverse set of compounds
varying in size and structure in order to contribute towards the ultimate vision of
establishing global, comprehensive mathematical models that can predict in vitro drug
loading and both in vitro and in vivo release kinetics of various liposomally loaded drugs.
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